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Zusammenfassung 
Rekombinante Adenoviren zählen zu den am häufigsten verwendeten Vektoren in der 
Gentherapie. Die replikationsdefizienten rekombinanten Adenoviren umfassen Vektoren der 
frühen Generation mit Deletionen von wenigen adenoviralen Genen und als modernste 
Form Gen-deletierte Adenoviren (HC-AdVs), denen alle virale Gene fehlen. Das Genom von 
HC-AdVs besitzt als virale Bestandteile lediglich die beiden invertierten 
Wiederholungssequenzen (ITRs) und das Verpackungssignal, wodurch bis zu 36 Kilobasen 
an fremder DNA eingebaut und in die Zielzelle eingeschleust werden können. Die Effizienz 
dieser Vektoren konnte in mehreren Tiermodellen gezeigt werden. So konnte nach einer 
einmaligen Injektion eines HC-AdVs bis zu drei Jahre Transgenexpression nachgewiesen 
werden. Dennoch gibt es in Bezug auf rekombinante Adenoviren inklusive den HC-AdVs 
limitierende Faktoren, die im Zuge dieser Arbeit verbessert werden sollten.  
Ein bekannter limitierender Faktor ist die ineffiziente Produktion von HC-AdVs, da sie einen 
zeitintensiven Prozess darstellt und eine fundierte, experimentelle Erfahrung voraussetzt. 
Daher wurde im Rahmen dieser Arbeit zunächst ein vereinfachtes Protokoll entwickelt, das 
die effiziente Generierung dieser Viren von Beginn der Klonierung bis hin zur Titration der 
aufgereinigten Partikel detailliert beschreibt. Als Anwendungsbeispiel dieses Protokolls 
konnte daraufhin im Rahmen dieser Studie die Fähigkeit von HC-AdVs für den Transport 
von haarnadelförmigen RNAs (shRNAs) gezeigt werden. Eine spezifische shRNA gerichtet 
gegen Hepatitis B RNA Moleküle erzielte dabei eine signifikante Verbesserung der Hepatitis 
B Infektionsparameter in vitro und in vivo. 
Derzeit basieren die meisten HC-AdVs auf dem humanen Serotypen 5 (Ad5). In 
vergangenen Studien zeigte sich jedoch, dass die verbleibenden viralen Sequenzen von 
Ad5 (ITR und Verpackungssignal) die Dauer und die Stabilität der Transgenexpression 
entscheidend beeinflussen, was für einen gentherapeutischen Ansatz von Nachteil sein 
kann. In der vorliegenden Studie ergab die Analyse der ITRs verschiedener adenoviraler 
Serotypen sowohl nach innen und außen gerichtete transkriptionelle Aktivität als auch eine 
inhibierende Funktion einiger ITRs. Zudem konnte der negative Einfluss der ITRs auf 
nahegelegene Promotoren gezeigt werden. In der Zukunft ist es daher zu empfehlen, die 
Transgenexpressionskassette im HC-AdV Genom mit insulierenden Sequenzen zu 
flankieren, um eine unerwünschte Beeinflussung der Genexpression zu verhindern. Des 
weiteren zeigte diese Arbeit, dass vor allem Adenovirus des Serotyps 7 eine mögliche 
Alternative zu Ad5 darstellt, da dieser nur moderate transkriptionelle Aktivität besitzt und 
nahegelegene Promotoren nur geringfügig beeinflusst. 
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Wie in Lebertransferstudien gezeigt wurde, beruht die Effizienz von HC-AdV vor allem auf 
der Stabilität der Vektorgenome in ruhenden Zellen. In teilenden Zellen hingegen führt eine 
stetige Reduktion der viralen DNA aufgrund fehlender Retentionsmechanismen zum Verlust 
des therapeutischen Effekts. Daher wurden virale Hybridsysteme entwickelt, die mittels 
nichtviraler Rekombinasen eine dauerhafte somatische Integration der therapeutischen DNA 
vom HC-AdV Genom in die chromosomale DNA vermitteln. Prominentester Vertreter der 
nichtviralen Integrationssysteme stellt die Sleeping Beauty (SB) Transposase dar. Obwohl 
die Funktion und Effektivität dieser Transposase mittels HC-AdV Gentransfer bereits gezeigt 
wurde, stellte sich heraus, dass nach SB vermittelter Transposition eine Inhibition der 
Transgenexpression den therapeutischen Effekt vermindert. In dieser Arbeit zeigte die 
Untersuchung der Transposition in Zellen mit unterdrücktem RNAi Weg eine verbesserte 
Transpositionsrate durch erhöhte Transgenexpression. Dies bestätigte erstmals ein Model, 
dem zufolge durch konvergente Transkription, ausgehend von dem Transposon, 
doppelsträngige RNAs (dsRNAs) und somit Substrate für den RNAi Mechanismus gebildet 
werden, die für die Inhibierung der Genexpression verantwortlich sind. Die daraus 
gewonnenen Erkenntnisse können in der Zukunft dafür genutzt werden, die Transposon 
Technologie entscheidend zu verbessern. 
Weiterhin wurde in dieser Arbeit der Einfluss des RNAi Mechanismus auf den adenoviralen 
Lebenszyklus untersucht. Es konnte dabei gezeigt werden, dass sowohl die Replikation also 
auch die Virusproduktion von Adenoviren durch ein RNAi Inhibitorprotein um das 10- bis 
100-fache verbessert werden konnte. Zudem steigerte die Bindung von doppelsträngigen 
siRNAs an dieses Inhibitorprotein die Produktion von HC-AdVs um das 6-fache. Es wurde in 
dieser Arbeit bereits begonnen den Mechanismus, der die erhöhte Replikation bedingt, zu 
untersuchen. Die vorliegenden Ergebnisse weisen darauf hin, dass vor allem die erhöhte 
Expression viraler, regulatorischer Proteine sowie die Unterdrückung kleiner adenoviraler 
RNAs (virus-assoziierte RNAs), den Effekt verursachen.  
Zusammenfassend eröffnet diese Arbeit verschiedene Optimierungsstrategien, um den 
therapeutischen Erfolg von rekombinanten Adenoviren zu verbessern. Vor allem der Einfluss 
des RNA Interferenz Signalwegs auf die Replikation von Adenoviren konnte in dieser Arbeit 
zum ersten Mal demonstriert werden. Die erworbenen Erkenntnisse können zur 
Verbesserung der Virusproduktion und der Weiterentwicklung von onkolytischen Adenoviren 
von Nutzen sein. Zudem verdeutlicht diese Arbeit mit ihren verschiedenen Angriffspunkten, 
dass eine sorgfältige biologische Charakterisierung der Gen-therapeutischen Vektoren 
notwendig ist, um das Potential der Vektoren für therapeutische Ansätze entscheidend zu 
erweitern.  
Abstract 
 
 
Abstract 
Recombinant adenoviral vectors are among the most commonly used vehicles in gene 
therapy. Replication-deficient adenoviruses include early generation adenoviruses, which 
are deleted in less than three adenoviral genes, and the high-capacity adenoviruses (HC-
AdV) as the most advanced form. HC-AdVs are deleted for all viral sequences leaving only 
the two inverted terminal repeat sequences (ITRs) and the packaging signal from the original 
viral genome. Therefore, up to 36 kilobases of foreign DNA can be packaged by HC-AdV 
particles and transduced into the desired target cell. Efficacy of these vectors was shown in 
several animal models, in which a single injected virus dose resulted in up to 3 years of 
transgene expression. However, also for recombinant adenoviruses including HC-AdVs 
limiting factors remain, which were investigated and improved in the course of this work. 
 
The production of HC-AdV represents one limiting factor because it is a labour intensive and 
sophisticated process that requires some experience. Therefore, in this study, a protocol 
was developed that simplifies the generation of these viruses starting with an improved 
cloning procedure and ending with precise titration of the purified particles. In addition, this 
improved virus production procedure was used to demonstrate the feasibility of HC-AdV to 
delivery short-hairpin RNAs, thus reducing hepatitis B RNA molecules in vitro and in vivo. 
 
The majority of HC-AdVs are currently based on the adenovirus serotype 5 (Ad5). However, 
DNA sequences inserted into the HC-AdV genome and remaining viral sequences were 
shown to influence duration and stability of transgene expression, which can negatively 
influence the outcome of a therapeutic approach. By analyzing viral ITR sequences derived 
from different adenoviral serotypes, this work demonstrated that ITR-driven transcriptional 
activity from several serotypes but also inhibiting functions occur leading to reduced 
transgene expression. Furthermore, a negative impact of ITR sequences on nearby 
promoters could be observed. The data obtained in this work suggest that it could be 
beneficial to introduce shielding sequences into the HC-AdV genome, which flank the 
transgene expression cassettes and therefore, prevent undesired side effects. Moreover, the 
results indicated, that pursuing ITRs from adenovirus serotype 7 in the context of an 
adenoviral vector could be advantageous, as it demonstrated most suitable features 
regarding transcriptional activation and influence on promoter performance. 
 
The efficiency of HC-AdV in terms of long-term expression of foreign DNA sequences is 
mainly based on the stability of vector genomes in quiescent cells. In dividing cells, however, 
a continuous reduction of the viral DNA reduces the therapeutic effect. Thus, integration 
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systems on the basis of viral hybrid vectors were developed, which result into recombinase-
mediated somatic integration of the therapeutic DNA from the HC-AdV genome into the 
chromosomal DNA. The most prominent representative of non-viral integration systems is 
the Sleeping Beauty (SB) transposase. Although function and efficacy of this transposase 
was shown in the context of an HC-AdV, it turned out, that transgene expression is 
decreased after Sleeping Beauty mediated transposition. Herein, analysis of transposition in 
cells with suppressed RNA interference pathway, showed a higher transposition rate in RNA 
interference knockdown cells compared to control cells, which was mainly based on an 
increased transgene expression. Therefore, this work shows for the first time that due to 
convergent transcription, originated from the two SB recognition sequences (IRs) flanking 
the transposon, formation of double-stranded RNAs (dsRNAs) can occur. These dsRNAs 
can be substrates for the RNAi mechanism and contribute to the silencing of gene 
expression. In the future this finding can be used to significantly improve the SB transposon 
technology. 
 
Moreover the influence of the RNAi mechanism on the adenovirus life cycle could be 
demonstrated within this project. By the suppression of the RNAi pathway using an RNAi 
suppressor protein we could improve recombinant adenovirus replication and viral particle 
production, up to 100-fold. In addition, this RNAi suppressor protein increased production of 
HC-AdV up to 6-fold. This upregulation was mainly based on the increased expression of 
viral regulatory proteins as well as the suppression of small adenoviral RNAs. 
 
In conclusion, this work provides different strategies to improve HC-AdVs for gene 
therapeutic purposes. Furthermore, it investigated mechanisms that negatively interfere with 
the therapeutic outcome, which need to be considered in future work. In particular, the 
influence of the RNA interference pathway on the replication profile of recombinant 
adenoviruses could be demonstrated for the first time essentially broadening the potential of 
these vectors with respect to viral production and design of oncolytic adenoviruses. In 
summary, this study emphasizes the importance of understanding the biology of viral vectors 
systems, which then can be translated into the development of optimized vectors for gene 
therapeutic applications. 
1 Introduction 
 
 
1 
1 Introduction 
Gene therapy is a young, emerging field of molecular medicine. It is based on the 
administration of therapeutic DNA sequences into the target cell to repair genetic defects. In 
1990 the first gene therapy treatment utilizing a viral vector was performed in a SCID 
(severe combined immunodeficiency) patient with adenosine deaminase deficiency. This 
novel approach caused worldwide attention and a boost for gene therapy. Until 1999, the 
database “Gene Therapy Clinical Trials World Wide” recorded more than 400 clinical trials 
(Wiley 2010). However, the death of Jesse Gelsinger in 1999 after being given a high dose 
of adenoviral particles meant a drawback for the popularity of gene therapy (Raper et al., 
2003). Furthermore an additional phase 2 study treating 27 SCID-X1 patients with a 
retrovirus based vector could indeed achieve a significant improvement of the disease, but 5 
patients developed leukemias after several years, which was due to insertional mutagenesis 
after provirus integration. Both studies emphasize the importance of a detailed 
characterization and continuous improvement of gene therapy vehicles to prevent negative 
side effects. Since 1990 until to date more than 1,500 clinical trials with various viral and 
non-viral vectors have been performed with adenovirus, retrovirus and plasmid DNA being 
the predominantly used vector types (Figure 1.1) and especially over the past few years, 
very promising results were obtained. The treatment of patients suffering from liver 
congenital amaurosis with an adeno-associated virus could partially restore the ability to see 
in nearly blind patients without inducing toxicity (Bainbridge et al., 2008; Cideciyan et al., 
2009; Wright et al., 2010). Furthermore a phenotypic correction of up to 30 month in two X-
linked adrenoleukodystrophie patients could be demonstrated after ex-vivo administration of 
a lentiviral vector encoding for the defective ABCD1 gene (Cartier et al., 2009). Last but not 
least in a very recent publication the phenotypic correction of a ß-thallasemia patient for 22 
month after treatment with a lentiviral vector was reported (Cavazzana-Calvo et al., 2010).  
          
Figure 1.1: Vectors used for clinical trials. Modified from the source: 
www.abedia.com/wiley/vectors.php (Wiley 2010). 
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1.1 Adenoviral Vectors 
Adenoviral vectors (AdV) are among the most commonly used vectors in gene therapy 
(Figure 1.1). The structure of their capsid, the composition of the genome and the 
replication cycle of adenoviruses provide ideal conditions for use as a gene therapeutic 
vector. Furthermore, they offer the opportunity of a wide range of possible modifications to 
improve vector properties. As most of the biological information exists from the two human 
serotypes 2 and 5 (Ad2 and Ad5), therapeutic approaches are mainly based on these two 
species. 
1.1.1 Adenovirus taxonomy and virus particle composition 
To date, there are 53 known adenoviral serotypes, which are assigned to seven subgroups 
(A, B1, B2, C, D, E, F). The classification is based on their genetic variability, the oncogenic 
potential and the tropism of each species (Table 1.1). According to the tropism Ads infect a 
wide host cell range, which defines the diversity of diseases. Therefore, Ads can cause 
acute respiratory, gastro-intestinal and ocular infections, which are usually self-limiting, 
however, in immuno-compromised patients they can cause serious illness. 
In 1991, the first intact adenoviral particle was visualized by cryo-electron microscopy, to 
which today's morphological knowledge is based on (Stewart et al., 1991). A schematic 
representation of the viral capsid is shown in Figure 1.2. 
Adenoviruses are non-enveloped, icosahedral particles with 70-100 nm in diameter. 
Dependent on the serotype, they harbour 
an 25-45 kilo basepair (kb) long double-
stranded DNA genome which, together 
with four structural proteins, build up the 
core. The viral capsid consists of 252 
subunits (240 hexons and 12 pentons) and 
seven structural proteins (II, III, IIIa, IV, VI, 
VIII, IX). In addition, in each viral capsid, 
10 copies of the adenoviral protease are 
packaged. On the viral surface and 
connected to the penton the fiber protein 
appears whose C-terminal knob domain 
mediates the contact to the cellular 
receptors.  
 
Figure 1.2: Composition of the adenoviral 
particle. Modified from 
http://nobelprize.org/nobel_prizes/medicine/laureates/
1993/illpres/genes-in-pieces.html. 
 
1 Introduction 
 
 
3 
Table 1.1: Classification and tropism of human adenoviruses. Serotypes, with 
known receptor are labeled: bcoxsackie and adenovirus-receptor (CAR); cCD46; dSialin 
acid (SA); eCD80/86; fHeparinsulfat; gDesmoglein 2 (Wang et al., 2010); hGD1a (Nilsson 
et al., 2010). Modified from Zhang and Bergelson (Zhang and Bergelson 2005). 
Subgroup Serotype Tropism 
A 12b, 18, 31b  intestinal, respiratory 
B1 3c,e,g, 7g, 16c, 21c, 50c respiratory, ocular 
B2 
11c,g, 14c,g, 34, 35c 
renal, respiratory, 
ocular 
C 1, 2b,f, 5b,f, 6   respiratory, ocular, lymphoid 
D 8d, 9, 10, 13, 15b, 17, 19pb, 19ad, 20, 22, 23, 24, 
25, 26, 27, 28, 29, 30, 32, 33, 36, 37c,d,h, 38, 39, 
42, 43, 44, 45, 46, 47, 48, 49, 51 
ocular, respiratory 
E 4b respiratory, ocular 
F 40, 41b intestinal 
 
The adenoviral DNA genome within the virion contains overlapping transcription units, which 
are located on both strands of the DNA and in case of Ad5 encode for round 38 genes and 
50 proteins (Figure 1.3). All viral coding regions are transcribed by the cellular RNA 
polymerase II. Only the two non-coding virus-associated RNAs I and II (VAI, VAII) are read 
from the RNA polymerase III. The transcription is divided into three phases, the expression 
of early genes (E1A, E1B, E2, E3, E4), the delayed transcription of proteins IX and IVA2 and 
the expression of the late transcription unit from the major late promoter (MLP). From the 
latter 5 mRNAs are generated by alternative splicing processes, which code for structural 
proteins forming the viral capsid. The packaging of the viral genome is mediated by the 
 
Figure 1.3: Composition of the adenoviral genome and location of coding regions of human 
serotype 2 from subgroup C. The double-stranded DNA genome is colored in grey, the 2 inverted 
terminal repeats (ITRs) in black. The arrows determine the transcriptional direction of the different 
early (red) and late (blue) gene coding regions. Ψ: packaging signal; VA-RNAs: Virus-associated 
RNAs. 
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packaging signal Ψ, which is located on the left end of the genome in close proximity to the 
5´inverted terminal repeat (ITR). Within the viral capsid the terminal protein (TP) is 
covalently attached to the 110-160 nt long 5´- and 3´ ITRs (the length is determined by the 
serotype) flanking the whole Ad genome. TP in concert with the adenoviral polymerase and 
cellular factors such as NFI / CTF, and NFII NFIII / OctI (nuclear factors), are essential 
proteins for viral replication (Curiel and Douglas 2002). 
1.1.2 Infection and replication cycle of adenoviruses 
The first contact of Ad2 / 5 with the host cell is mediated by the interaction of the fiber knob 
domaine with cellular receptors (Bergelson et al., 1997; Tomko et al., 1997; Freimuth et al., 
1999). Nearly all Ad serotypes, except subgroup B Ads, use the cellular coxsackie and 
adenovirus receptor (CAR) for cellular uptake of the virus (Arnberg 2009). Besides this 
specific interaction also other capsid components bind to cellular surface receptors, such as 
the fibershaft of type C Ads to heparan sulfates and penton base proteins to members of the 
integrin family. In contrast the group B Ads use CD46, CD80, CD86 and Desmoglein 2 for 
entry into the cell, thus enabling transduction of hematopoietic stem cells and also a variety 
of cancer cells (Arnberg 2009; Wang et al., 2010). Other co-receptors that are recognized by 
the surface proteins of different serotypes are shown in Table 1.1. 
CAR alone is not sufficient to mediate uptake of the viral particle. The binding of penton 
base within the capsid to the two co-receptors ανβ3 and ανβ5, both members of the integrin 
family, induces endocytosis via clathrin-coated pits and initiates the formation of the 
endosome (Wickham et al., 1993; Davison et al., 1997). In the endosome the slight acidic 
pH induces the destruction of capsid proteins and subsequently the activation of the viral 
cysteine protease. This protease then initiates the degradation of the endosome. In the 
cytoplasm, the particles are transported along the microtubules to the nucleus. The inward 
transfer of the viral DNA into the nucleus is mediated by the nuclear pore complexes and the 
replication starts (Saphire et al., 2000). The entire process, from initial contact with the 
cellular surface until viral DNA appears in the nucleus takes about 30-60 minutes. 
E1A is the first viral protein that is produced after introduction of the DNA into the nucleus. 
As a transcription factor it activates the expression of early viral genes (E1B-E4). The 
function of the early viral gene products is comprised by the manipulation of the cell cycle 
and the modification of the cellular metabolism in favor of viral replication. Two proteins 
encoded by E1A (12S and 13S) drive the host cell from the inactive G1/GO phase in the 
active S-phase by inactivation of cellular factors such as the tumor suppressor 
retinoblastoma (pRb) protein, CBP or p300. The E1B encoded products modulate the host 
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cell environment by inhibition of p53 and tumor necrosis factor induced apoptosis. Together 
with the E4Orf6 protein, E1B55K stabilizes the transport of viral mRNAs out of the nucleus, 
thus forcing the viral protein synthesis and simultaneously inhibiting the production of cellular 
proteins. In addition, other early phase proteins encoded by the E2 transcription unit are 
involved in viral replication, such as the viral polymerase or the 72 kilo Dalton (kDa) major 
DNA-binding protein (DBP), which binds to single-stranded DNA during replication, 
unwindes the DNA and protects it against degradation. The transcripts of the E3 region are 
mainly required for the modulation of the host immune response, because they prevent the 
expression of MHC class I molecules on the cellular surface, but are not essential for 
replication in vitro. In contrast, E4 is essential for replication because it was shown that a 
deletion of the complete E4 region reduced viral replication by approximately 5-log levels 
compared to wild type adenovirus. E4 encodes for six different open reading frames. The 
respective proteins have a variety of features which are important for viral replication, like 
the inhibition of apoptosis, mRNA transport and stability. However, in this context it is worth 
mentioning that only one protein either E4Orf3 or E4Orf6 is necessary to restore virus 
growth up to 10-fold of wild type. Both factors bind the DNA protein kinase, and thereby 
block DNA repair mechanisms such as the double strand break repair (DSBR). This process 
prevents the formation of long concatemers from the viral genomes that can not be 
packaged into the capsid. E4Orf6 alone binds and inhibits p53 wheras the interaction with 
the E1B55K protein mediates its proteasome-dependent degradation (Curiel and Douglas 
2002). Futhermore, the transforming properties of E4Orf6 are enhanced by E1A, probably 
also by binding to p53. 
The expression of late proteins is initiated by the MLP promoter. The activation of this 
promoter requires cellular transcription factors such as TBP / TF-IID, as well as viral proteins 
and a change in genome structure. First, a long transcript of about 30.000 nt is generated, 
which is then cut by a number of splicing processes into 5 groups. The late transcripts 
encode almost exclusively for structural proteins, such as hexon, penton and fiber proteins. 
The assembly of the capsid takes lace in the nucleus but it is not yet known in detail which 
factors initiate the subsequent lysis of the cells. 
The entire replication cycle takes about 24 hours resulting in the release of about 10 000 
viral particles per cell (Curiel and Douglas 2002). 
1.1.3 Types of recombinant adenoviral vectors and their application in gene 
therapy 
Gene therapy encompasses a wide range of applications. Historically, the term gene therapy 
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has been characterized by the use of vectors in gene-replacement therapy for the treatment 
of genetic disorders. However, in today's modern medicine, this term includes many other 
applications, as demonstrated by a statistics from “Gene Therapy Clinical Trials World Wide” 
(Wiley 2010). According to this database the vast majority of clinical trials aim at the 
treatment of tumors, followed by treatment of cardiovascular and monogenic diseases 
(Figure 1.4). In addition, viral vectors are also used for vaccination. Each of these 
indications has specific demands on the vector used, and only a few systems can be applied 
to all areas. Adenoviral vectors, however, find success in almost all fields of gene 
therapeutic applications. 
Monogenic diseases are based on the mutation or disregulation of only one protein and are 
therefore particularly accessible to gene therapy treatment. A successful gene substitution 
requires efficient transduction of specific target cells with a sufficient amount of therapeutic 
DNA without inducing toxicity.  
In the early 90s adenoviral vectors have been used mainly because of their high 
transduction efficiency. Within the adenoviral vectors of the first generation, only the E1 
region was deleted (Figure 1.5A), whereas in some cases also the E1- and E3-deleted Ads 
are refered to as first generation (Berkner 1988). This created space for therapeutic DNA of 
about 7.6 kb. In order to ensure the production of these replication-defective vectors, the 
recombinant viruses were amplified in specific producer cell lines (eg HEK293 cells, human 
embryonic kidney cells), in which the left arm of Ad5 was stably integrated into the genome. 
Because most natural adenoviral infections affecting the respiratory tract, these vectors were 
especially used for the treatment of cystic fibrosis as a monogenetic model disease (Brody 
et al., 1994). The deletion of the E1 transcription factor should prevent the expression of 
further viral genes and therefore viral replication. But it became quickly clear that even in the 
                
Figure 1.4: Indications of all gene therapeutic trials reported in 2010. Modified from the source: 
www.abedia.com/wiley/indications.php (Wiley 2010). 
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absence of the E1 proteins low- level transcription of the remaining viral genes occurred, 
resulting in activation of a rapid innate and adaptive immune response and subsequently to 
antibody-mediated destruction of the transduced cells (Yang et al., 1994; Yang et al., 1995a; 
Yang et al., 1995b; Kay et al., 2001; Thomas et al., 2003). Thus, the therapeutic effect is 
drastically reduced.  
Consequently, second-generation adenoviral vectors were developed in which E1 and E2 or 
E3 and / or the E4 region were deleted (Figure 1.5B). Although these vehicles showed a 
better toxicity profile, the administration of a high dose of an E1/E4 deleted adenovirus in the 
arterie of a young man with ornithintranscarbamylase-deficiency was responsible for the first 
death in a gene therapy trial (Gao et al., 1996; Gorziglia et al., 1996; Lusky et al., 1998; 
O'Neal et al., 1998) Due to the uncontrolled immune response triggered by viral components 
multi-organ failure was induced, which subsequently caused the death of the patient (Raper 
et al., 2003). As a consequence within the next years reduction of toxicity directed against 
adenoviral incoming particles and de novo synthesized viral proteins was an important 
research priority.  
The most advanced generation of adenoviral vectors, the so-called high-capacity adenoviral 
vectors (HC-AdV), consists of the two adenoviral ITRs and the packaging signal, but lacking 
all viral coding sequences (Figure 1.5C)(Parks et al., 1996; Palmer and Ng 2003). Thus, the 
capacity for therapeutic DNA, in contrast to earlier generations rises up to 36 kb and toxicity 
due to de novo synthesized viral proteins can be excluded. The production of these viruses 
is based on a “two-vector“ system consisting of the high-capacity adenoviral construct that 
contains the transgene expression cassette and a helper virus, providing all viral proteins for 
packaging in trans. All production protocols are based on the publication of Parks et al. in 
1996 (Parks et al., 1996). However, many labs are still restricted in generating these viruses 
due to lack of experience in this sophisticated procedure. 
The long-term therapeutic effect after systemic administration of the HC-AdV was 
demonstrated in both small and large animal models. A study in mice showed the 
expression of the human coagulation Factor IX for 54 weeks after a single injection 
(Ehrhardt and Kay 2002). This effect is independent of the species, since hemophilia B dogs 
as well as baboons demonstrated transgene expression for up to 964 days (Brunetti-Pierri et 
al., 2004; Brunetti-Pierri et al., 2005; Brunetti-Pierri et al., 2007; Brunetti-Pierri et al., 2009; 
Hausl et al., 2010). Furthermore in a rat model for the Crigler-Najjar syndrome life-long 
phenotypic correction of the bilirubin metabolism was shown (Toietta et al., 2005). 
Therefore, HC-AdVs were used for the treatment of numerous monogenic diseases such as 
Duchenne muscular dystrophy, cystic fibrosis, haemophilia A and B or 
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hypoalphalipoproteinemia (Ehrhardt and Kay 2002; Ehrhardt et al., 2003; Gilbert et al., 2003; 
Brown et al., 2004; Brunetti-Pierri et al., 2005; McCormack et al., 2006; Cerullo et al., 2007; 
Deol et al., 2007; Oka et al., 2007; Kawano et al., 2008). Nevertheless, there are also 
limitations of the HC-AdV system. The episomal status of the adenoviral genome in the 
nucleus allows the sufficient production of the transgene, but over time a constant decrease 
of the therapeutic effect could be observed (Morral et al., 1998; Ehrhardt and Kay 2002; 
Jager and Ehrhardt 2007). Also the loss of viral genomes in rapidly dividing cells remains a 
challenge to be overcome (Ehrhardt and Kay 2002; Yant et al., 2002). Moreover, the 
immune response against the incoming viral capsid or the introduced transgene must be 
considered. Further modifications for achieving stable expression of the therapeutic gene 
and reduced toxicity of the capsid are therefore the focus of prospective vector 
modifications.  
In contrast to the studies aiming at gene correction or gene-replacement therapy a high 
immunogenic potential of adenoviruses can also be advantageous for instance in tumor 
therapy. Currently several adenoviral mutants are being applied in the clinic for the treatment 
of cancer patients. In 2004, the first gene therapeutic application based on a replication 
deficient adenovirus was approved in China, which is now, in combination with conventional 
chemotherapy, routinely used for the treatment of head and neck tumors (Peng 2005; 
Garber 2006; Yu and Fang 2007). The adenoviral genome of this mutant contains the 
 
Figure 1.5: Summary of recombinant adenoviral vectors used in gene therapy. A) The genome 
of first generation adenoviral vectors. This vector is lacking the early E1 coding region or E1 in 
concert with an E3 deletion. B) Adenoviral vector genomes of the second generation. This vectors are 
deleted in several coding regions, e.g. E1,  E3 and additionaly E2 (upper panel) or E4 (middle panel) 
or only E1 and E4 (lower panel). C) High-capacity adenoviral vector genome. The vector genome is 
deleted in all viral coding sequences only the inverted terminal repeats (ITRs) and the packaging 
signal (Ψ) are left. 
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wildtype human p53 gene instead of the E1 region, thus substituting the p53 defect of most 
tumors (Peng 2005). Another approach for tumor therapy was introduced by Fueyo and his 
colleagues in 2000, who generated the first conditional replicating adenovirus (CRA) also 
called, oncolytic adenovirus (Delta24) (Fueyo et al., 2000). Compared to the replication 
deficient virus (see above), which usually infiltrate and lyse only the outer regions of tumors, 
CRA have a higher transduction rate, better penetration into the tumor tissue and could be 
classified as safe in several studies (Hemminki and Alvarez 2002; Lichtenstein and Wold 
2004). By the deletion of a 24 bp region in the E1A gene, Fueyo limited the replication of 
adenovirus specifically to tumor cells because this deletion removes the Retinoblastom 
(pRB) binding site and therefore leads to the inhibition of viral replication in normal cells by 
RB-mediated apoptosis. The productive replication of these viruses in pRB-lacking tumor 
cells thereby results in lysis of aberrant cells and subsequently to regression of the tumor 
(Sherr 1996; Hernando et al., 2004). Another CRA, Onyx-015, has a deletion in the 
E1B55KDa protein, thus it replicates only in cells with p53 deregulation and is currently 
being tested in over 15 clinical trials (Bischoff et al., 1996; Heise et al., 2000; Ries and 
Brandts 2004; Liu et al., 2007). One injection of the virus directly into the tumor in vivo 
confirmed a transient anti-tumor activity (Heise et al., 2000). Nevertheless, the low 
replication rate of these oncolytic viruses in the tumor still remains an obstacle (Pesonen et 
al., 2010). 
Another field, in which adenoviral vectors are being extensivley studied is vaccination. The 
activation of a strong immune response against the adenovirus mediated by T and B cells, 
the high transduction efficiency in mammalian cells and the ease of modifications and 
production are excellent pre-conditions for the use of adenovirus in this area. Adenoviral 
vaccination strategies in the field of HIV, HCV and malaria control are currently being 
investigated in phase I and II clinical trials (Priddy et al., 2008; Wiley 2010). 
1.1.4 Adenoviral vector modifications 
Adenoviral vectors offer many opportunities for optimization of their gene therapeutic profile. 
In general, one can distinguish between two levels of vector modifications: (1) the 
modulation on the genome level and (2) the change in the capsid composition. 
With respect to vector modifications on the genome level the introduction of HC-AdVs was 
an important milestone in vector development, as the deletion of all viral coding sequences 
could greatly reduce the immunogenic potential and simultaneously increase the packaging 
capacity of foreign DNA up to 36 kb. To ensure packaging of the adenoviral genome, stuffer 
DNA was incorporated into the HC-AdV genome in addition to the therapeutic DNA for 
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achieving the smallest possible packaging size of 27.7 kb (Sandig et al., 2000). Notably, it 
turned out that these additional sequences significantly influence the maintanance of the 
viral vector genomes and stability of transgene expression (Parks et al., 1999). For instance, 
bacterial DNA, extensivley shorten the duration of protein expression in vivo due to the high 
GC content and destabilizes the whole genome (Parks et al., 1999). Several versions of 
HC-AdV genomes with varying genomic composition were developed. The vector used in 
our laboratory contains, a 16 kbp long DNA fragment of the centromeric region of human 
chromosome 17 and a matrix attachment region of the murine immunoglobulin kappa locus 
(Ehrhardt and Kay 2002; Taylor et al., 2002; Yant et al., 2002).  
Besides the stuffer DNA also the DNA composition of the expression cassette plays a crucial 
role in robustness of transgene expression. For instance, Schiedner and colleagues used 
the liver-specific hAAT (human α1-antitrypsin) promoter together with parts of the first intron 
of the human coagulation factor IX (FIX). In comparison to the viral cytomegalovirus 
promoter this approach significantly improved the expression profile in liver cells (Schiedner 
et al., 1998). The construct was also used in hemophilia B dogs and could demonstrate for 
the first time partial phenotypic correction of the FIX gene deficiency for up to 4.5 months 
with negligible toxicity (Ehrhardt et al., 2003). This demonstrated that the use of tissue-
specific promoters in the context of Ad vectors clearly improves the outcome of the gene 
therapeutic approach. Also for targeted expression of transgenes in lung, skeletal and 
smooth muscle cells tissue-specific promoters could be used successfully. A disadvantage 
of cell-specific promoters is their relatively low expression rate compared to virus-derived 
promoters. The incorporation of regulatory elements such as woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) or the before mentioned intron of the FIX gene, 
also have a positive effect on the expression profile of the transgene and can increase the 
transgene expression up to 50-fold in vivo (Xu et al., 2003b). Also inducible promoters such 
as the Tet system (Invitrogen) offer advantages for certain indications (Xu et al., 2003a). 
Especially in systems requiring short-term expression of a toxic transgene, negative side 
effects directed against these factors can be reduced.  
The remaining, virus-derived DNA sequences within the HC-AdV are the two ITRs on both 
ends of the adenovirus DNA molecule and the packaging signal near the 5 'end. An 
investigation showed that cis-activating elements, which are located next to the 5' ITR along 
with the ITRs exhibit transcriptional activity and affect nearby expression cassettes (Hearing 
et al., 1987; Shi et al., 1997; Rubinchik et al., 2001; Yamamoto et al., 2003; Xing and Tikoo 
2004; Xing and Tikoo 2005). Therefore, it is not surprising that two groups demonstrated that 
tissue specific promoters could be both inhibited and activated by these viral sequences, 
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and thus lose their specific properties (Shi et al., 1997; Hoffmann et al., 2005). One may 
speculate that these elements are also able to modulate transgene expression over long 
distances. Hence, the location of the therapeutic DNA within the HC-AdV genome is 
important, but an in depth study analyzing transcriptional activity of solely the left and right 
arm of the HC-AdV genome is still lacking.  
With respect to vector modifications and the capsid composition several different 
approaches can be followed to improve the viral vector and its biological properties. 
The limiting factor covering all areas of gene therapeutic use of adenoviruses are developing 
or pre-existing anti-adenoviral neutralizing antibodies, leading to a rapid elimination of the 
particles after systemic administration (Raper et al., 2003). For instance, in the case of 
repeated administration of vectors, which are often required for vaccination regimen. In 
primates it was shown that a pre-immunization with Ad5 can strongly decrease the T-and B-
cell response, thus reducing the success of a vaccination (Barouch and Nabel 2005). 
Moreover, within the most commonly used serotypes 2 and 5, a high serum prevalence in 
the human population can be observed, for instance in about 40-90% of the Caucasian 
population neutralizing antibodies (NAs) are detected (Schmitz et al., 1983; Chirmule et al., 
1999; Arnberg 2009). Another limitation of commonly used Ads is represented by the strong 
tropism for liver cells when injected systemically into the bloodstream. The group led by 
Andrew Baker was able to uncover the mechanism in 2008. The binding of coagulation 
factor X to hyper variable regions of the hexon in the viral capsid mediates liver transduction 
independent of the interaction between fiber and CAR receptor (Waddington et al., 2008). 
Since most of the negative effects listed above are mediated by viral surface proteins, 
capsid modifications to improve vector properties in favour of a lower immune response and 
a transport into specific target cells is of great interest to the research community. Both fiber 
and hexon modifications, which are mainly based on serotype switch, could reduce toxicity; 
significantly improve the tropism and the biological vector properties (Havenga et al., 1996; 
Roy et al., 1998).  
In addition to the replacement of individual capsid components, one can also perform a 
complete serotype switch. There are 53 human serotypes with varying biological features 
available (Table 1) and therefore this can alter the specific tropism to another cell type and 
may probably reduce clearance by pre-existing antibodies. The serum prevalence of Ad35 
and 11 for example is in contrast to Ad5 (40-90%) very low (5-18%) (Arnberg 2009).  
Another strategy to reduce the innate immune response is to improve the administration 
technique. It could be demonstrated in mouse experiments and in baboons that a (pseudo-) 
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hydrodynamic injection of an HC-AdV increases transduction of the liver by 4-fold without 
inducing cytotoxic side effects. Furthermore one could circumvent the innate immune 
response by ex vivo administration of the viral vector into the liver, but this implies at least a 
certain risk as an invasive surgery is needed (Brunetti-Pierri et al., 2007). Moreover, targeted 
administration to the desired tissue, such as an intra-muscular injection or aerosol catheter 
administration into the lung significantly decreased organ toxicity, while increasing 
transduction efficiency (Gilbert et al., 2003; Koehler et al., 2005).  
Upon infection adenoviruses persist as episomal DNA molecules within the nucleus (Jager 
and Ehrhardt 2007). In resting cells, thus an expression of up to two years can be achieved 
in dogs and chimpanzees. However, in rapidly dividing cells a much faster clearance of the 
transgene could be observed because the episomal genome is lost during cell devision due 
to lacking retention mechanisms (Ehrhardt and Kay 2002; Ehrhardt et al., 2003; Brunetti-
Pierri et al., 2005; Brunetti-Pierri et al., 2007). For most gene therapeutic purposes in 
humans a longer therapeutic time span is needed. Hence, there is accumulating interest in 
developing hybrid vectors, which combine the advantages of the transduction efficiency of 
Ads with the potential of other viral and non-viral integration systems. Adenovirus / retrovirus 
or Ad / Foamy virus hybrids utilizing the integration machinery of retroviruses allow stable 
expression in transduced cells; however, always include the risk of insertional mutagenesis, 
since retroviruses preferentially insert in gene regions (Zheng et al., 2000; Murphy et al., 
2002; Picard-Maureau et al., 2004). To reduce the oncogenic potential of hybrid vectors, 
non-viral integration systems have been explored. Both the Sleeping Beauty (SB) 
transposase and the PhiC31 integrase proved to be an adequate system for stable 
integration of the transgene cassette into the host genome (Kuhstoss and Rao 1991; Ivics et 
al., 1997; Groth et al., 2000; Ivics et al., 2007). Both mechanisms have already 
demonstrated their effectiveness in in vivo experiments in small and large animal models 
(Babiss et al., 1986b; Olivares et al., 2002; Yant et al., 2002; Yant and Kay 2003; Ehrhardt et 
al., 2007; Hausl et al., 2010). Also the Rep protein derived from the adeno-associated virus 
mediates integration into the genomic DNA from the AdV, uses in 25% of all cases the 
AAVS1 locus on chromosome 19 (Wang and Lieber 2006), is speculated as a safe "harbor". 
Quite new is the use of a non-viral plasmid replicon called pEPito in the context of AdV, 
which examines autonomously replication in cells in association with AdVs (Haase et al., 
2010). This would exclude the risk of insertional mutagenesis and simultaneously ensure 
long-term transgene expression. 
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1.2 RNA interference 
Since the discovery of RNA interference (RNAi) in 1998 by Fire and Mello, research in the 
field of double-stranded RNA (dsRNA) was revolutionized, which resulted in 2006 by the 
awarding of the Nobel Prize in medicine for both investigators (Fire et al., 1998). 
In the nematode Caenorhabditis elegans (C. elegans), Fire and Mello made the pivotal 
observation that dsRNA can inhibit the expression of homologous endogenous genes. This 
discovery could be confirmed in Drosophila melanogaster and also in Xenopus laevis (Fire 
et al., 1998; Caplen 2000; Nakano et al., 2000). 
The breakthrough of the RNAi mechanism in the field of genetic engineering was achieved 
by Tom Tuschl in 2001, as he demonstrated for the first time the function of small synthetic 
interfering RNAs (siRNAs) in mammalian cells (Elbashir et al., 2001a).  
Nowadays it is known that RNAi is a highly conserved mechanism, as it could be found in 
many living organisms such as plants, protozoa, eukaryotes and viruses. Up to now 1100 
human miRNAs and 45 000 potential targets have been discussed and function range from 
gene regulation, disease and cancer development, immune activation, DNA methylation to 
the morphogenesis and differentiation of cells, and one can expect that more new functions 
will be identified (www.microrna.org; Kloosterman and Plasterk 2006; Krutzfeldt and Stoffel 
2006; Skalsky and Cullen 2010). 
1.2.1 The RNA interference mechanism 
The RNA interference pathway, which results in the post-transcriptional silencing of a 
specific gene, takes place in the cytosol (Figure 1.6). In vertebrates, this step is initiated by 
a group of molecules, called micro-RNAs (miRNAs) (Lagos-Quintana 2001).  
MiRNAs are non-coding RNA molecules that are basically transcribed by RNA 
polymerase II. It is estimated that approximately 75% of the miRNA sequences are located 
in independent, non-coding regions or intron sequences of genes (Lagos-Quintana 2001; 
Cai 2004; Lee et al., 2004). Moreover, they are often produced in a tissue specific manner or 
dependent on the developmental stage. In C. elegans, they were first described and their 
particiation at key developmental processes recognized (Pasquinelli and Ruvkun 2002). The 
transcription first leads to about 160 nucleotide (nt) long primary RNAs (pri-RNAs), which are 
processed in the nucleus by the RNase III enzyme Drosha in cooperation with the RNA-
binding enzyme DGCR8 (DiGeorge critical region 8) in 60 nt pre-miRNA precursors 
(Pasquinelli and Ruvkun 2002; Han 2004; Lee et al., 2004; Zeng and Cullen 2004; Kim et 
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al., 2005; Zeng and Cullen 2005). The transport into the cytoplasm is regulated via the 
energy-dependent Exportin-5/RanGTP pathway that is also used by cellular mRNAs (Yi 
2003; Zeng and Cullen 2004). In the cytosol the pre-miRNA binds to the RNase III Dicer, 
which generates an imperfect 21-25 nt long double-stranded RNA (Hutvagner et al., 2001; 
Ketting 2001). Characteristic for these dsRNAs are the 2 nt long, overhanging 3' OH ends 
and 5' phosphat residues. One strand, the so-called "guide" strand is then incorporated into 
a complex containing ribonucleoproteins (miRNP, microRNA-containing ribonucleoproteins). 
This multimeric complex greatly resembles the RNA induced silencing complex RISC in 
composition as well as in function (Mourelatos 2002; Hutvagner 2005). A thermodynamically 
      
Figure 1.6: Schematic overview of the RNA interference pathway mediated by miRNAs and its 
inhibition by the RNAi supressor protein P19. The primary micro RNA (pri-miRNA) is generated 
from RNA polymerase II transcription of the chromosomal DNA. In the nucleus the pri-miRNA is 
processed by Drosha and DGCR-8 into 60 nt long pre-miRNAs, which are transported out of the 
nucleus through the Exportin5 pathway. The pre-miRNA is then cut by the cytoplasmatic protein Dicer 
in 21-23 nt long dsRNAs. One strand, the so-called guide strand (red) is then loaded into the RNA 
induced silencing complex (RISC), which subsequently initiates sequence-dependent mRNA 
degradation or translational inhibition. The framed picture shows the function of the RNAi suppressor 
protein P19. P19 binds to ds miRNAs after Dicer processing and is able to destroy RISC-miRNAs 
complexes. Upon binding, P19 sequesters the miRNA either in processing bodies (p-bodies). 
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unstable 5' end determines the strand that is loaded into the miRNP complex by the RISC 
loading complex (RLC). At the same time the complementary strand is degraded. In general, 
functional ribonucleoprotein particles that are associated with miRNAs are referred to as 
miRNPs, complexes associated with synthetic small interfering RNAs (siRNAs) are 
determined as RISC (Meister 2004). The single-stranded RNA is now opening and 
sequence-specific post-transcriptional inhibition of a complementary mRNA by cleavage of 
the mRNA or termination of translation is initiated. The destruction of the mRNA only occurs 
with full (100%) complementarity between miRNA and the respective mRNA. In mammalian 
cells this is a relatively rare event, thus usually the inhibition of translation rather than mRNA 
destruction occurs. During the blockade of translation the miRNA seed region between 
nucleotides 2-8 (viewed from the 5 'end) is crucial as it determines the contact to the mRNA 
(Chiu and Rana 2003; Haley and Zamore 2004). Recent studies showed that following this 
principle one miRNA can regulate up to 200 different transcripts (Lindow and Gorodkin 
2007). Notably, there are also other gene silencing mechanisms mediated by dsRNAs and 
enzymes of the RNAi pathway, like the dsRNA-mediated DNA methylation. This mechanism 
leads to methylation of cystein residues predominantly in promoter regions and 
subsequently to transcriptional silencing of the transgene (Kawasaki and Taira 2004a). 
1.2.2 Viral miRNAs and RNAi suppressor proteins 
In 2004, three years after the discovery of the first siRNAs it was shown that viruses also 
express miRNA sequences within their genome (Pfeffer 2004). In general, viruses can be 
divided into three categories: 1) Members of the herpes viruses like Epstein-Barr virus and 
Kaposi sarcoma virus, which transcribe for a number of miRNAs, 2) nuclear viruses, like 
polyomavirus, which express only a few miRNAs and 3) RNA or cytoplasmatic DNA viruses 
that contain no miRNA coding sequences (Cullen 2010). Up to now over 200 viral miRNAs 
have been identified so far (Skalsky and Cullen 2010). 
The target mRNAs of the viral miRNAs and therefore their biological function are largely 
unknown, but it is believed, that two basic mechanisms are affected. First, the miRNAs 
probably inhibit cellular immune responses. For instance, the polyomavirus SV40 expresses 
a miRNA that inhibits the viral T-antigen, thus preventing the destruction of the infected cells 
by cytotoxic T lymphocytes (Sullivan et al., 2005). Secondly, viral miRNAs may affect the 
stabilization of the latent infection status, a mechanism that primarily plays a role in the 
replication cycle of herpes viruses. In herpes simplex virus for example, latency associated 
miRNAs are generated that deregulate the trans-activators ICP0 and ICP4. These are only 
expressed during latency and the effect of the miRNAs probable delays the entry into the 
lytic life cycle (Cullen 2010). 
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Simultanousley to the expression of viral miRNAs different mechanisms evolved that causes 
the inhibition of cellular and viral miRNAs. Lecellier et al. first reported a cellular miRNA 
inhibiting the replication of the primate foamy virus (Lecellier et al., 2005). Especially in 
plants, this strategy based on endogenous generated miRNAs is widespread, as plants only 
rely on the RNAi interference pathway to protect themselfes from the attack of viruses 
(Baulcombe 1999; Voinnet 2001). Plant viruses usually have an RNA genome and are 
therefore accessible for degradation by host miRNAs (Vargason et al., 2003). As a 
counterdefensive mechanism plant viruses express so-called RNAi suppressor proteins that 
inhibit miRNA-mediated destruction. One of the best-studied RNAi suppressors is the 19 
kilodalton P19 protein, which is expressed by the tomato bushy stunt virus and other related 
viruses. The efficacy of this protein has already been demonstrated in several model 
organisms, including mammalian cells (Qu 2002; Voinnet 2003; Lakatos et al., 2004; 
Lecellier et al., 2005). P19 acts as a dimeric protein in the cytoplasm. The tryptophan 
residues at the N-terminal ends of both monomers and the basic, polar amino acids on the 
surface of the protein are responsible for the binding of specific 21-23 nt long dsRNA 
molecules. Presumably, the P19 molecule sequesters one miRNA and initiates the 
destruction of the dsRNAs. Because miRNAs are suggested to be translocated to cellular 
processing bodies (P-bodies), it is assumed that also P19 bound miRNAs are transported to 
this cytoplasmatic foci (Beckham and Parker 2008; Eulalio et al., 2008). In general, this 
mechanism inhibits the activation of the RISC complex and finally the post-transcriptional 
silencing (Scholthof 2006). A schematic representation of the P19-mediated inhibition of the 
RNAi pathway is shown in Figure 1.6. As a crucial factor it was shown, that the amount of 
P19 in the cell seems to be important (Qiu et al., 2002; Szittya et al., 2002). It was assumed 
that this is due to the interaction of P19 with the miRNAs which follows a 1:1 stoichiometry, 
which limits the downregulation of all miRNAs (Scholthof 2006). However, there is a second 
controversy model available, explaining the mechanism of P19 binding. Rawlings 
disapproved the accepted hypothesis of Scholthof and showed, that the P19-miRNA 
interaction is a sub-stoichiometry event and subsequently relies on fast association and 
dissociation of the complex. Thus, concluding binding is a reversible mechanism (Scholthof 
2006; Rawlings 2010). Furthermore it was demonstrated that there is an over 20-fold bias for 
siRNA-P19 complexes in comparison to siRNA-Dicer and in addition also mature RISC 
complexes are targeted, emphasizing the high efficieny of P19. Importantly, in her study, the 
dosage effect was confirmed, too. It is of note that also in other organisms RNAi inhibitors 
exists (Rawlings 2010). Examples are the HIV TAT, the vaccinia virus E3L protein, the Ebola 
virus derived protein VP35 and virus-associated RNAs (VA-RNAs) of adenovirus (Li et al., 
2004; Andersson et al., 2005; Bennasser et al., 2005; Haasnoot et al., 2007). 
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1.2.3 Adenovirus associated RNAs (VA-RNAs) 
Computational programs postulated that the Ad genome has a probability of 60% to contain 
miRNA sequences (Pfeffer 2004). Until now only the two non-coding virus-associated RNAs 
I and II (VAI- and VAII-RNA) are known to interfere with the RNAi pathway (Aparicio et al., 
2006; Sano et al., 2006). VAI- and VAII-RNA and are 160 nt long, hairpin-shaped molecules 
that are transcribed by the cellular RNA polymerase III (Thimmappaya 1982; Liao et al., 
1998; Aparicio et al., 2006). During a normal infection cycle, approximately 108 VA-RNA 
molecules are formed, which are transported across the cellular Exportin-5/RanGTP 
pathway into the cytoplasm (Ma 1996). The main function of VAI-RNA is the blockade of 
protein kinase R (PKR), a serine-threonine protein kinase that is activated upon infection by 
long dsRNAs resulting in the abrogation of the viral and cellular protein translation (O’Malley 
1986; Akusjarvi et al., 1987).  
Mellitis and colleagues demonstrated by mutational studies, the binding of the apical domain 
of the VAI-RNA to PKR, wheras the central domain is responsible for its inhibition (Mellits 
and Mathews 1988; Mellits et al., 1990). The terminal stem of the VA-RNA however, is the 
effector for the RNAi pathway. The interaction of VA-RNAs with the RNAi pathway starts 
with the export from the nucleus, since these export proteins are shared with the 
endogenous miRNAs and mRNAs and are therefore blocked for cellular molecules (Yi 2003; 
Aparicio et al., 2006). In the cytoplasm, both Dicer and the RISC complex are inhibited 
probably also by competitive inhibition of VA-RNAs with these components of the RNAi 
machinery (Lu and Cullen 2004). This was confirmed by studies of Sano and Aparicio, 
where they showed that VA-RNAs are substrates of the cytoplasmic RNase III Dicer. Dicer 
cuts the terminal end of the VAI and VAII-RNA into small 21-29 nt long virus-associated 
RNAs (svaRNAs) that can be loaded into the RISC complex and thereby inhibit 
complementary RNA fragments (Aparicio et al., 2006; Sano et al., 2006). Although the VAI-
RNA is quantitatively superior to the VAII-RNA, it was shown that the sva-RNAs of VAII-RNA 
are preferably incorporated into the RISC complex (Xu et al., 2007). In the beginning, the 
function of the svaRNAs was not completley understood, as no target mRNA sequences 
could be identified. The inhibition of the sva-RNAs originated from VAI-RNA by antagomir 
RNAs (2'O Methyl oligonucleotides) demonstrated a significant attenuation of virus 
replication (Aparicio et al., 2006). Recent in silico studies, together with conventional 
methods have now identified the protein TIA-1 as a cellular target protein. TIA-1 is an RNA-
binding protein located within processing bodies that was associated with splicing and 
translation and it is a known apoptosis-inducing factor (Beckham and Parker 2008; Aparicio 
et al., 2010). Probably thereby, adenoviruses regulate their RNA metabolism in the cell and 
manipulate the cellular antiviral mechanisms. Other proteins that have been shown to play 
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an important role in cellular signaling pathways, transcription, DNA repair mechanisms and 
RNA metabolism were also recognized as potential target proteins, but must be validated by 
molecular biological methods (Aparicio et al., 2010). The precise mechanism of how the two 
functions are regulated, the inhibitory effect on the RNAi mechanism and the blockade of 
gene expression through the sva-RNAs remains unknown. There is speculation, however, 
that in the early infection period, the inhibition of gene expression takes place, whereas the 
blockade of RNA interference occurs more in the late phase to protect own viral gene 
expression.  
1.3 RNAi in gene therapeutic applications 
In modern molecular medicine miRNAs are widely explored for therapeutic purposes. 
SiRNA-based therapies mainly include the treatment of tumors and anti-viral strategies. In 
addition, with respect to vector development persistence and transduction properties can be 
improved and the immune response reduced utilizing miRNAs. However, not only the 
efficient and sequence specific degradation of mRNA target molecules plays a key role but 
also the restoration of degenerate expression profiles of proteins and miRNAs.  
Most therapeutic approaches are based on the targeted application of small inhibitory 
dsRNAs. Two systems are currently being explored. On the one hand modified, synthetic 
RNAs are transfected into cells. This represents a very effective method because these 
RNAs can be easily produced in large quantities, there is no need to be processed by the 
endogenous miRNA pathway and it was shown that the inhibitory effect can be maintained 
approximately for up to one week in dividing tissues (Bartlett and Davis 2006). The most 
medical approaches, however, require a more sustained therapeutic effect. Towards this 
end, viral vectors were constructed that express short-hairpin RNAs (shRNA) mostly from 
RNA polymerase III promoters (Paddison et al., 2002). These shRNAs are produced in 
sufficient quantities and can stably block transgene expression over a long period of time 
(Grimm et al., 2006). In addition, viral vectors infect both primary and embryonic stem cells, 
thus widening the range of applications (Stewart et al., 2003; Hoelters et al., 2005). In 
contrast to siRNAs, the generation of shRNA sequences is very complex, since these 
molecules have to be recognized and processed by enzymes of the endogenous RNAi 
pathway. Moreover, the therapeutic window of the shRNA seems very small because with 
low quantities only insufficient effects could be observed but a high dose may induce toxicity 
(Grimm et al., 2006). In general, the design of the dsRNA molecules is critical regardless of 
their origin and only a detailed characterization of different siRNAs prevents undesired "off-
target" effects. 
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Besides the use of small inhibitory RNAs in anti-tumor approaches, siRNAs are appropriate 
to treat viral infection. The fight against viral infection by siRNAs is usually based on the 
inhibition of viral gene expression. Especially for chronic infections, this technology offers an 
attractive alternative to conventional therapies. For instance, during chronic infection with 
Hepatitis B virus (HBV) lifelong infections occur that are associated with a high incidence of  
liver cirrhosis and cancer (Rehermann and Nascimbeni 2005). Current strategies for the 
treatment of HBV reduce the disease symptoms in the liver but could not eliminate the 
infection itself. It was already demonstrated that upon introduction of small hairpin RNAs 
(shRNAs) directed against HBV proteins, infection parameters could be improved (Uprichard 
et al., 2005; Grimm et al., 2006). 
Several vector models for effective transport of shRNA to hepatocytes have been evaluated. 
Grimm and colleagues developed an adeno-associated virus vector (AAV) for the delivery of 
a very potent shRNA, the HBVU6no.2, and demonstrated reduction of HBV-specific 
antigens, although toxic effects occurred due to saturation of the miRNA pathway (Grimm et 
al., 2006). Also in 2004, the group of Susan Uprichard published the use of a first-generation 
AdV delivering a shRNA cassette (shHBV765) in mouse hepatocytes, which were 
chronically infected with HBV. Already 4 days after administration, a 5.5-fold reduction of 
HBV-specific antigens could be observed and further 13 days later barely any HBV RNA- 
based molecules could be detected (Uprichard et al., 2005). 
Besides these therapeutic approaches the presence of conserved, endogenous and tissue-
specific miRNAs can be used for the modification of vector systems. For instance one 
limiting factor in many gene therapy trials is an immune response against the therapeutic 
protein when expressed in antigen-presenting cells (APCs). Based on the miRNA 
expression pattern of hematopoietic cells Brown and colleagues generated a lentiviral vector 
that expressed four miRNA target sequences in the 3´UTR of the reporter gene GFP 
recognized by the miRNA miR-142-3p, which is exclusively expressed in hematopoetic stem 
cells. By integrating these miR-142-3p target sequences into the lentiviral vector they could 
reduce transgene expression in hematopoetic stem cells below one percent after systemic 
administration of the vector into mice. Importantly, with this approach they maintained long-
term expression of the transgene in normal cells (Brown et al., 2007). Also in development of 
conditional replicating adenoviruses, this system has already been applied. The miRNA 
target sequence of liver-specific miR-122 was introduced into the 3'UTR of the E1A gene 
(with a 24bp deletion) and led to a drastically reduced viral replication in hepatocytes. This 
allowed a greatly enhanced toxicity profile for tumor therapy (Ylosmaki et al., 2008).  
In addition to viral vectors also non-viral vector systems may benefit from the RNAi pathway. 
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Evolutionarily determined, it is assumed that the RNAi mechanism primarily pursues the goal 
of protecting cells from jumping elements (transposons), and all kinds of foreign nucleic 
acids. Yang and Kazazian (2006) demonstrated that L1 retrotransposition is inhibited by 
endogenous siRNAs (Yang and Kazazian 2006). In gene therapy systems, the transposon-
mediated integration of the transgene, based on the Sleeping Beauty transposon (SB), 
Piggy Bac or Tol 2, is an efficient mechanism to achieve stable long-term expression (Ivics 
et al., 2009). Also AdVs systems in concert with non-viral integration systems such as SB 
transposase have been explored, resulting into high transduction efficiency and SB-
mediated integration into the host genomic DNA of the target cell. Nevertheless, it was found 
that after SB-mediated transposition, transgene expression is reduced or completely 
disappears (Garrison et al., 2007). With respect to that, the composition of the system and 
the integration mechanism seem to be a critical factor. A schematic overview of the SB-
mediated integration mechanism is shown in Figure 1.7. The transposon containing the 
transgene cassette is flanked by two oppositely directed repeat sequences (IRs; inverted 
repeats). The SB uses a so-called "cut and paste" principle. It binds in a dimeric form to the 
IR cuts out the transgene flanked by the IRs, from the circular plasmid and integrates the 
transposon into the genomic DNA. The genome target site of SB is composed of a 
dinucleotide containing a tyrosine and an adenosine (TA) (Ivics et al., 1997). Notably, 
Mikkelsen and colleagues showed that the two flanking IRs exhibit inward transcriptional 
activity (Moldt et al., 2007). Presumably by the convergent transcription of the IRs, double-
stranded RNA molecules are being generated, which are potential substrates for the cellular 
miRNA pathway, and thereby block transposon based gene expression. The exact 
involvement of the RNAi pathway has yet to be confirmed. Nevertheless, for the 
development of therapeutic vectors that are based on SB-mediated transposition the 
                              
Figure 1.8: Mechanism of Sleeping Beauty mediated transposition. Sleeping Beauty (SB, white) 
binds in a dimeric form to the inverted repeats (IR, yellow) flanking the transgene (blue). By a cut and 
paste mechanism SB cuts out the transgene cassette and integrates it into a TA site (black; site 
composed of a tyrosin and an adenosin) in the chromosomal DNA. 
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introduction of insulators that inhibit a transcription seems to be advisable. With that respect 
it has been shown that such insulating elements significantly prolonged transposon-derived 
reporter gene expression.  
1.4 Aims of the project 
Adenoviral vectors are one of the most prominent gene therapeutic vehicles to date. 
Different generations of adenoviral vectors were produced and the most advanced version is 
represented by the high-capacity adenoviral vectors (HC-AdV). These vectors are deleted 
for all viral coding sequences, display a low toxicity profile and it was shown that they result 
into long-term transgene expression in quiescent cells in vivo. Nevertheless, also for HC-
AdVs there are still limitations and therefore, in the present study we aimed at improving the 
features of the HC-AdV in several directions. 
1. The first aim was the generation of a detailed protocol for large-scale production and 
precise titration of HC-AdVs. In addition, the plan was to evalute the feasibility of HC-AdV 
not only for the transfer of transgenes but also to deliver short-hairpin RNAs (shRNAs). In 
order to demonstrate efficacy for delivery of shRNAs, the aim was to treat a mouse model of 
medical relevance, the hepatitis B virus infection, aiming at downregulation of infection 
parameters in vitro and in vivo. 
2. Since it was demonstrated that transcriptional activity of the ITRs strongly influences 
transgene expression from the Ad5 vector, other adenovirus serotypes gained more 
importance for gene transfer. Therefore, the goal was to investigate the potential of other 
than Ad5 ITRs to drive transcription and to discover potential candidates with less impact on 
transgene expression. Results of this study can be used for improved design of recombinant 
HC-AdVs.  
3. Ad5 based HC-AdVs predominantly target the liver and persist in the nucleus as episomal 
and linear DNA monomers. Upon cell cycling, however, viral genomes are lost by cellular 
degradation processes and lacking retention mechanisms. Thus, for the treatment of cycling 
cells, adenovirus hybrid vectors were developed, which utilize Sleeping Beauty (SB) 
transposase for somatic integration of foreign DNA from the HC-AdV genome into host 
chromosomes at high efficiency. Nevertheless, it was demonstrated that silencing of the 
transgene takes place upon transposition. In this work it was hypothesized that convergent 
transcription initiated by the SB inverted repeats, flanking the transgene, could lead to the 
formation of double-stranded RNAs (dsRNAs). These dsRNAs may be incorporated into the 
RNA induced silencing complex (RISC) and guide silencing of the transgene after 
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transposition. Hence, the plan was to analyze transposition efficiencies and transgene 
expression after transposition in RNAi knockdown cells, which could have important 
implications for improving SB-based systems in the future. 
4. In order to generate more advanced recombinant adenoviral vectors for gene therapy, the 
knowledge about basic virus-host interactions is essential. Especially, the RNA interference 
mechanism became of major interest within the last years as it was shown to regulate 
several viral pathways. Thus, the goal was to investigate whether the RNAi pathway plays a 
role in the adenoviral life cycle, with a special interest in virus replication and particle 
production. The hypothesis was that if one can get further insights into the interaction 
between the virus and the RNAi pathway, this knowledge can be used to further improve the 
production of recombinant adenovirus vectors including HC-AdVs or the fate of the vector 
during infection. 
In general, this work is going to provide novel insights into adenovirus host-interactions, 
especially the impact of the RNAi pathway, and paves the way towards innovative strategies 
to further improve adenovirus vector properties for gene therapy. 
. 
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2 Treatment of HBV infections by shRNAs delivered 
by an high-capacity adenoviral vector 
The enveloped hepatitis B virus (HBV), a member of the hepadnavirus family, can cause 
lifelong infection, cirrhosis of the liver, acute and chronic hepatitis, and liver cancer 
(Rehermann and Nascimbeni 2005). Worldwide, two billion people have been infected with 
hepatitis B virus (HBV), 350 million have chronic infection (Wright 2006). Current therapeutic 
strategies against HBV infection reduce symptoms of liver disease but complete eradication 
of the infection is one of the major challenges of our time. Therapeutic options include 
therapy with lamivudine and/or interferon (IFN) alpha, Adefovir, and Entecavir treatment 
(Zoulim 2006), but resistance to these drugs due to the relatively high mutation rate of HBV 
genomes remains a problem (Tillmann 2007). Gene therapy approaches for the treatment of 
HBV infection based on introduction of gene drugs into hepatocytes by various viral and 
non-viral gene transfer systems may represent an attractive alternative to conventional 
treatment strategies. In previous studies gene drugs included antisense RNA and DNA 
approaches (Madon and Blum 1996; Wu and Gerber 1997), ribozymes (Beck and Nassal 
1995; Welch et al., 1997), dominant negative HBV antigen mutants (Scaglioni et al., 1996), 
single chain antibodies (Ogata et al., 1993), gene products for enhancement of anti-HBV 
immunity and small hairpin RNAs (shRNA). It was demonstrated that expression of shRNAs 
expressed from a non-viral (McCaffrey et al., 2003) or a viral vector, including first 
generation adenoviral vectors (fgAd) (McCaffrey et al., 2003; Moore et al., 2005; Uprichard 
et al., 2005; Carmona et al., 2006; Grimm et al., 2006; Chen et al., 2007), leads to RNA 
interference mediated post-transcriptional reduction of HBV target transcripts. Our study 
focused on recombinant adenoviral vectors for shRNA delivery against HBV, but also 
prototype foamy virus (Moore et al., 2005) and adeno-associated viruses (AAV) (Grimm et 
al., 2006; Chen et al., 2007) were evaluated in the past.  
To date adenoviral vectors are the most frequently used vectors for clinical applications as a 
statistic from “Gene Therapy Clinical Trials World Wide” demonstrated (Figure 1.1) (Wiley 
2010). The majority of adenovirus gene transfer is based on first- and second-generation 
adenoviral vectors, deleted in several viral coding genes including E1 and E3 or E1, E3 and 
E4, respectively. These vectors can be easily produced to very high titers by using different 
producer cell lines, all based on HEK293 cells complementing the respective defect 
(Weinberg and Ketner 1983; Luo et al., 2007). Furthermore, commercial kits for production 
and purification of adenovirus 5 (Ad5) derived vectors are available (Sartorius). However, a 
major hurdle in gene therapy using these vectors is the strong immune response activated 
by leaky expression of viral proteins (Yang et al., 1994; Yang et al., 1995a; Yang et al., 
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1995b; Kay et al., 2001). Thus, the most advanced generation of adenoviral vectors, the 
high-capacity adenoviral vectors (HC-AdV) were generated, lacking all viral coding 
sequences, just containing the 5´and 3´ inverted terminal repeats (ITRs) and the packaging 
signal (Parks et al., 1996; Hardy et al., 1997) as remaining viral sequences. This design 
allows the transfer of foreign DNA up to 35 kb. Various studies showed efficacy of these 
vectors and in vitro and in vivo long-term transgene expression in rodents and non-human 
Figure 2.1: Schematic overview of the entire HC-AdV large-scale production procedure. After 
direct cloning of the gene of interest (red arrow: promoter; blue bar: gene of interest; white bar: 
polyadenylation signal) into pAdFTC, the linearized plasmid is transfected into 116 cells and cells 
were co-infected with helper virus AdNG163R-2 at a mulitplicity of infection (MOI) of 5. Three serial 
passages are used to amplify HC-AdV in adherent cells and then the 116 cells were cultivated in a 3 
liter spinner flask. HC-AdV is purified by cesium chloride centrifugation, dialysed and quantitative 
Real-Time PCR with primers located in the ITR and the packaging signal (black arrows) are used to 
titrate the virus. ITR: Inverted terminal repeat; HV: helper virus; HC-AdV: High-capacity adenoviral 
vector. 
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primates for up to 3 years with a significantly reduced cytotoxic response was observed 
(Toietta et al., 2005; Brunetti-Pierri et al., 2009). Hence, HC-AdVs were already used for 
several therapeutic applications with a focus on monogenetic diseases such as Duchenne 
muscular dystrophy (Gilbert et al., 2003), hemophilia A (Brown et al., 2004) and B (Ehrhardt 
et al., 2003) and hyperbilirubinemia (Toietta et al., 2005).  
For in vivo experiments and clinical applications large-scale production of HC-AdVs is 
necessary. The principle of all currently used systems is based on a pivotal study by Parks 
et al. (Parks et al., 1996). Herein, HC-AdV production is dependent on a two-vector system, 
which encompasses the HC-AdV genome and a helper virus deleted in E1 and E3 (Parks et 
al., 1996). This helper virus provides all essential proteins for amplification, generation and 
packaging of viral genomes in trans. In order to prevent undesirable helper virus 
contamination, its packaging signal is flanked by loxP sites and is excised upon infection by 
Cre-recombinase expression in the adenovirus producer cell line. By this mechanism helper 
virus contamination can be reduced to less than 1% in the final vector preparation.    
However, the complex, sophisticated and time consuming cloning and production procedure 
of HC-AdV was a major limitation to many laboratories. Therefore, we aimed at developing a 
detailed protocol including all steps from the HC-AdV cloning to the amplification, purification 
and titration of the HC-AdV. A schematic overview is shown in Figure 2.1. Furthermore we 
evaluated HC-AdV produced with our improved protocol, for the delivery of short hairpin 
RNAs. To test efficacy of HC-AdV in a therapeutic setting, we aimed at suppressing HBV 
transcripts using a previously published shRNA coding sequence against HBV (HBVU6no.2) 
(McCaffrey et al., 2003). HBVU6no.2 was demonstrated to be highly efficient for RNA 
interference mediated knockdown of HBV transcription products using a non-viral approach 
(McCaffrey et al., 2003) and AAV vectors (Grimm et al., 2006). However, after systemic 
administration of an AAV2/8 vector-encoding HBVU6no.2 at high dose lethality was 
observed in mice.  
2.1 Materials and Methods 
2.1.1 DNA constructs and enzymes 
For HC-AdV production the shuttle vector pHM5 and the pAdFTC were used (Ehrhardt and 
Kay 2002). The nucleotide shRNA expression cassettes against luciferase and HBV 
(HBVU6no.2) were described elsewhere (McCaffrey et al., 2002; McCaffrey et al., 2003; 
Grimm et al., 2006). Throughout the study the plasmid, encoding shRNA against HBV, will 
be referred to as pHBVU6no.2. All shRNAs were transcribed under the control of the U6 
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promoter. High-capacity adenoviral vectors (HC-AdV) with shRNA expression cassettes 
(FTC/lucRNAi and FTC/HBVU6no.2) and the vectors FTC-hFIX-attB-(FRT)2 and 
AdFTC/cFIX/ChMAR without shRNA expression cassette were based on the adenoviral 
backbone pAdFTC. As additional stuffer DNA FTC/lucRNAi and FTC/HBVU6no.2 comprised 
a transgene expression cassette encoding the human coagulation factor IX (hFIX) (Ehrhardt 
and Kay 2002). For the construction of the vector pFTC/lucRNAi, the bacteriophage 
integrase PhiC31 recognition site attB and the inverted repeats (IR) for Sleeping Beauty 
transposase mediated somatic integration were flanked by the Flp recognition sites (FRT). 
FTC-hFIX-attB-(FRT)2, a HC-AdV with a split hFIX expression cassette, and 
AdFTC/cFIX/ChMAR containing the canine FIX expression cassette, were used as control 
vectors and were described elsewhere (Ehrhardt et al., 2003; Ehrhardt et al., 2007). The 
plasmids pTHBV2 with the complete HBV genome and the plasmid pRSV.hAAT.bpA 
(phAAT) expressed the human α1-antitrypsin (hAAT) coding sequence transcribed under the 
control of the rous sarcoma virus (RSV) promoter were described previously (Yang et al., 
2002; Chen et al., 2007). All enzymes for cloning were obtained from NEB and used as 
recommended by the manufacturer. Molecular biological methods were performed following 
the instructions from Sambrook and Russel (Sambrook 2001). Cloning of the viral constructs 
was performed by Anja Ehrhardt. 
2.1.2 Cell lines and viruses 
HEK293 and HeLa cells were obtained from ATCC and cultivated in DMEM supplemented 
with 10% FBS and 1% penicillin/streptomycin (P/S). 116 cells were kindly provided by Philip 
Ng and cultivated in MEM with the addition of 10% FBS, 1% P/S and 100 µg/ml hygromycin 
if not stated otherwise. Selection medium was used during amplification, hygromycin was 
not added during the infection procedure as this can interfere with efficient virus production. 
Huh7 cells and 2.2.15 cells were cultivated in DMEM with 10%FBS, 1% P/S and 1% non-
essential amino acids. All cell lines were grown at 37°C in a 100% humidity atmosphere and 
5% CO2. Cell culture reagents were obtained from PAA.  
The helper virus AdNg163R-2 was a kind gift from Philip Ng. The fg adenoviral vector 
fgAdluc was based on the adenoviral plasmid pAdHM4 (Mizuguchi and Kay 1998). The 
luciferase expression cassette contained in fgAdluc encodes luciferase under the control of 
Simian Virus 40 (SV40) promoter and was based on the pGL3-Control vector (Promega). 
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2.1.3 In vitro studies to characterize efficacy of HC-AdV mediated delivery of 
short-hairpin RNAs to reduce hepatitis B virus infection 
For in vitro assays using adenovirus in HeLa cells, cells were co-infected with the fg 
adenoviral vector fgAdluc using an MOI of 10 and the HC-AdV FTC/lucRNAi expressing 
shRNA against luciferase at an MOI 10, 50, 100, and 500, respectively. To infect all cells 
with the identical total amount of virus, groups were spiked with an irrelevant HC-AdV 
(AdFTC/cFIX/ChMAR) (Ehrhardt et al., 2003). Luciferase levels were measured three days 
post infection using a luciferase reporter assay system (Promega). 
For plasmid based assays in Huh7 cells, either 0.67 µg of the plasmid pFTC/HBVU6no.2 
(used for production of the HC-AdV FTC/HBVU6no.2) or 0.67 µg of pHBVRNAno.2 were co-
transfected with 0.67 µg pTHBV2 into a well of a 6-well plate. Control groups received stuffer 
DNA, respectively. As an internal control and for normalization, all groups received the 
plasmid pRSV.hAAT.bpA. Hepatitis B virus antigen (HBsAg) levels in the supernatant were 
measured 3 days post-transfection by enzyme immunoassay (Abbott Laboratories, Abbott 
Park, IL, USA). 
For studies in Huh7 cells using adenoviral vectors, cells were transfected with the plasmid 
pTHBV2. Twenty-four hours post transfection cells were transduced with the HC-AdV 
FTC/HBVU6no.2 and FTC-hFIX-attB-(FRT)2 at an MOI of 300, 30, and 10. Control groups 
received pTHBV2 and pHBVU6no.2, the plasmid pTHBV2 only, or stuffer DNA. As an 
internal control and for normalization, all groups received the plasmid pRSV.hAAT.bpA, 
respectively. To analyze shRNA mediated knock-down during an established HBV infection, 
2.2.15 cells (stably transduced with the HBV genome) were infected with FTC/HBVU6no.2 
and FTC-hFIX-attB-(FRT)2 using an MOI 100 and MOI 500. HBsAg levels in the supernatant 
were measured three days post infection by enzyme immunoassay (Abbott Laboratories, 
Abbott Park, IL, USA). 
2.1.4 Animal studies 
C57Bl/6 mice (Jackson Laboratories) and HBV transgenic mice were kept under the 
Stanford rules and regulations (Yang et al., 2002). Due to the fact that varying starting levels 
of serum HBsAg levels are present when using this HBV transgenic mouse line, each 
individual was pre-screened for HBsAg levels before treatment. For transient HBV studies 
C57Bl/6 mice (8 weeks old) were co-injected via high-pressure tail vein injection with 12 µg 
pTHBV2 and either 5 µg of pHBVU6no.2 or stuffer DNA. As an internal control for 
transduction efficiencies all individuals received pRSV.hAAT.bpA. This plasmid encodes the 
human α1-antitrypsin gene (hAAT), which can be monitored by ELISA in mouse serum. 
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Adenoviral vectors were diluted in Phosphate Buffered Saline (PBS) and a total volume of 
200 µl per mouse was injected. Blood samples were obtained by retro-orbital bleeding. For 
bioluminescent images and measurements of emitted light units we used an in vivo imaging 
system (IVIS, Xenogen, Alemeda, CA).	  
Hepatitis B surface antigen (HBsAg) levels in mouse serum were monitored by enzyme 
immunoassay (Abbott Laboratories, Abbott Park, IL, USA). SGPT (alanine aminotransferase 
activity) assays were performed using a diagnostic kit for colorimetric determination of SGPT 
(Sigma procedure No. 505-OP). All animal experiments were performed by Anja Ehrhardt 
and Hui Xu in cooperation with Patricia L. Marion at the Stanford University.  
2.1.5 Southern Blot analysis to measure HBV genome replication 
For genomic DNA isolation, mouse liver was removed and used for DNA extraction as 
previously described (Ehrhardt and Kay 2002). Blots were hybridized with [α-P32]–
deoxycytidine triphosphate (dCTP)–labeled cDNA lacZ probe (HindIII / StuI fragment from 
pRSV/β-Gal) and a HBV probe (EcoRI / AccI digested plasmid pTHBV2). To quantify the 
adenoviral vector genome copy number per cell and to generate a standard curve we 
digested the plasmid pHD28E4LacZ (Ehrhardt and Kay 2002) with the restriction enzyme 
HindIII.  
2.1.6 Northern Blot to approve processing of short-hairpin RNAs 
To test for small hairpin RNA expression and to verify processing into mature small inhibitory 
RNA molecules we performed a Northern blot analysis. These in vitro studies were 
performed in HEK293 cells (human embryonic kidney cells). HEK293 cells were seeded in 
6-well plates and infected with the adenoviral vector FTC/HBVU6no.2 at an MOI of 20. As a 
positive control for HBVU6no.2 short hairpin RNA expression we transfected the previously 
described plasmid pHBVU6no.2 (McCaffrey et al., 2003) and the plasmid 
pBS/hFIX/HBVU6no.2. The plasmid pBS/hFIX/HBVU6no.2 represents a subclone of the 
pFTC/HBVU6no.2. Both vectors contain the identical expression cassette for hFIX and 
HBVU6no.2. Other controls received either pBS/hFIX/lucRNAi expressing shRNA against 
luciferase and pBS/hFIX/empty without shRNA expression cassette. Forty-eight hours post-
transfection and infection, cells were harvested and small RNAs isolated using a Trizol 
(Invitrogen) based procedure. Total RNA (20 µg) was separated on a 17% polyacrylamide 
gel containing 7 M urea in 0.5 x tris-borate-EDTA (TBE) buffer. As a positive control 
representing also the length marker we ran the reverse oligonucleotide of the first 21 
nucleotides of the DNA oligo probe HBV-sense (see below) and the first 21 and 25 
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nucleotides of the DNA oligo probe Luc-antisense (see below). We performed a semi-dry 
transfer in 0.5 x TBE onto a Hybond-N+ membrane (GE Healthcare). Northern hybridizations 
were performed with the following radioactively end-labeled DNA oligonucleotide probes:  
HBV-sense (5’ CTC AGT TTA CTA GTG CCA TTT GTT C 3’), HBV-antisense (5’ GAA CAA 
ACG GCA CTA ATA AAC CGA G 3’), Luc-antisense (5’ GGA TTC CAA CTC AGC GAG 
AGC CAC CCG AT 3’), and as an internal control the oligonucleotide 5.8 S-rRNA 34 (5’ TTC 
ATC GAC GCA CGA GCC GAG TGA TCC 3’). Hybridization was performed in Denhardt’s 
solution at 50ºC. Blots were washed two times for 10 min with 5X SSC/0.1%SDS and 1 time 
for 10 min with 1X SSC/0.1% SDS at 50 ˚C. 
2.2 Results 
2.2.1 Cloning of high-capacity adenoviral vectors 
Several HC-AdV systems are available to insert a transgene of interest into the HC-AdV 
genome (Hillgenberg et al., 2001; Shi et al., 2006). Within these systems one has to 
consider the minimum packaging size of 27.7 kb, which in most cases requires insertion of 
stuffer sequences. The plasmid pAdFTC, the HC-AdV production plasmid used in our 
laboratory for instance contains DNA sequences derived from a centromere region on 
human chromosome 17 and a matrix attachment region, potentially stabilizing vector 
genomes in the nucleus (Ehrhardt and Kay 2002). 
Our cloning system is based on two vectors. One vector is the shuttle vector pHM5 that 
contains a multiple cloning site (MCS) for easy insertion of the transgene expression 
cassette (Ehrhardt et al., 2003). Furthermore, the pHM5 MCS is flanked by the rare 
restriction enzymes recognition sites I-Ceu and PI-SceI and has a kanamycin selection 
marker. The second plasmid, the pAdFTC harbours the left and right ITR, stuffer sequences 
as mentioned before and near the 3´end the two rare restriction enzyme sites compatible to 
pHM5. The latter vector can be selected on ampicillin plates, which is of favour for the 
cloning procedure because there is a negative selection pressure for pHM5 plasmids. 
Notably, the pAdFTC plasmid is constructed, to keep inserts with a size ranging from 5 kb to 
12 kb to reach an optimal packaging size. Therefore, if the transgene cassette of interest is 
too small, insertion of additional stuffer sequences is suggested.   
The whole cloning procedure and helper virus amplification were performed by Martin Hausl. 
In brief, after insertion of the transgene of interest into the pHM5, this plasmid and pAdFTC 
were sequentially digested with I-Ceu and PI-Sce as recommended by the manufacturer’s 
instruction. After each digestion step, a phenol-extraction is required, because both enzymes 
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change the performance of the DNA in an agarose gel. In order to prevent re-ligation, the 
pAdFTC is applied to a CIP reaction and on the basis of DNA amounts (calculated from an 
analytic agarose gel) both plasmids were ligated over night. The next day the ligation 
reaction has to be purified by phenol extraction and ethanol (EtOH) precipitation. Afterwards 
a SwaI digest of the purified ligation was performed, which destroys empty pAdFTC 
plasmids in the reaction, because it cuts between the two restriction enzymes used for 
cloning. Ligation samples were transformed into DH10B cells and selected on ampicillin 
containing plates. The colonies obtained from the cloning were tested for the correct 
fragment by I-Ceu and PI-Sce digest and large scale preparation was performed. For HC-
AdV production 20 µg of the plasmid pAdFTC containing the trangene of interest has to be 
digested with NotI, purified using phenol extraction and precipitated with EtOH.  
2.2.2 Helper virus amplification 
High-capacity adenoviral vector production is dependent on a two-vector system, comprised 
of the HC-AdV pAdFTC and the helper virus, in our case AdNG163R-2 (Ng et al., 2001; 
Palmer and Ng 2003), that provide all adenoviral proteins required for genome packaging. 
Amplification of the helper virus AdNG163R-2 was performed by infection of a 6 cm dish of 
HEK293 cells at a multiplicity of infection (MOI) of 5. Two days post infection cytopathic 
effect should be detectable and cell lysates were harvested, supplied to 4 consecutive 
freeze/thaw cycles performed with liquid nitrogen and a 37°C water bath and used to infect 
two 10 cm dishes of HEK293 cells each with one third of the lysate. For cesium chloride 
purification twenty 15 cm dishes are required which are prepared following the conditions 
used before. Detailed description of the purification of viruses is described in section 2.2.4. 
The viral titer was determined by optical density (section 2.2.5) and plaque forming assay 
described in (Curiel and Douglas 2002). Helper virus amplification and titration were 
performed by Lorenz Jäger and Martin Hausl, respectively.  
2.2.3 Large scale production of high-capacity adenoviral vectors in a spinner 
flask system 
Most of the present protocols for large-scale production of HC-AdV are based on adherent 
cell culture, which is cost and time intensive. Herein, a suspension culture system is used to 
produce high amounts of HC-AdV, which is less labour intensive.   
Production of HC-AdV was performed in the special producer cell line 116. The 116 cells are 
HEK293 derived cells that stably express Cre-recombinase. Within the helper virus genome 
the packaging signal Ψ is flanked by loxP sites, which are recognized by the 
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Cre-recombinase. Upon infection, the helper virus expresses all viral proteins essential for 
HC-AdV amplification and packaging, whereby Cre-recombinase mediates the excision of 
the packaging signal from the helper virus genome, consequently inhibiting its packaging. 
The amplification of HC-AdV starts with the transfection of 5 µg linearized pAdFTC, 
containing the respective transgene generated in section 2.2.1, using 30 µl of Superfect 
reagent (Qiagen) in a 6 cm dish of 116 cells at a confluency of 50-80%. Sixteen to eighteen 
hours post transfection the cells were infected with helper virus applying 5 transducing units 
(TUs) per cell. It is very important to make sure that the virus is distributed equally on the 
tissue culture dish. Forty-eight hours post transfection the cells were harvested and virus 
was released by four freeze/thaw cycles, resulting in passage PO. Afterwards, one 6 cm 
dish of 116 cells (80-90% confluency) was infected with one third of the lysate of P0 and co-
transduced with 2 TUs of helper virus (P1). This step was repeated to reach passage P2. Of 
note, if cytopathic effect (CPE) is not observed from the 6 cm dish after two days an 
additional amplification step of one 6 cm dish should be performed to guarantee proper virus 
amplification. Two days post infection of P2, when CPE starts, the cells were harvested and 
virus was released from the cells following the infection of one 15 cm dish 116 cells with two 
thirds of the lysate and co-transduced with 2 TUs helper virus. Two days later the cell lysate 
was collected and stored at -80°C for further use.  
For the spinner flask amplification, ten 15 cm dishes 116 cells were flushed off using 10 ml 
of fresh culture medium for each plate and cells were transferred to a 3 liter spinner flask 
containing 900 ml culture medium. Notably, 116 cells growing as adherent cells are relatively 
loosely attached to the tissue culture dishes, therefore no trypsin is required. In fact, trypsin 
may negatively affect growth of suspension cells. The spinner flask is incubated for 24 hours 
at 37°C on a magnetic stirrer adjusted to 70 rounds per minute (rpm). Twenty-four hrs and 
48 hrs later 500 ml and 72 hours later 1 liter of fresh medium have to be added to grow the 
cells. In order to monitor health of 116 suspension cells, 3 ml of the spinner flask culture 
were transferred to a 6 cm dish and 2 hours later adherent cells can be obtained if cells are 
viable.  
The infection of the 116 cells should be performed in a volume of 150 ml, therefore, the cells 
of the bioreactor were centrifuged at 500 g for 10 min and resuspended in 130 ml of fresh 
medium but supplemented with only 5% FBS (without hygromycin). The viral lysate (20 ml) 
from the 15 cm dish was subjected to 4 consecutive freeze and thaw cycles and added to 
the 130 ml fresh medium to reach the recommended volume of 150 ml. Assuming a density 
of 3x105 cells per ml, the total amount of cells in a 3 liter spinner flask is 9x108 cells. Thus, 
one needs to add 1.8 x 109 TU of the helper virus in order to reach 2 TU/cell. Infection was 
2 Treatment of HBV infections by shRNAs delivered by a high-capacity adenoviral vector 
 
 
32 
incubated for 2 hrs at 37°C on a magnetic stirrer with 60 rpm. Afterwards, the whole infection 
lysate was transferred back to the spinner flask containing 2 liter of fresh culture medium 
(without hygromycin but 5% FBS) and maintained for two days at 37°C stirring at 70 rpm. 
Forty-eight hours later cells were harvested, centrifuged using 890 g for 10 min at room 
temperature and supernatant was removed carefully. For purification the cell pellet was 
resuspended in 28 ml sterile PBS and can be stored at -80°C for several weeks until 
purification.  
2.2.4 Purification of HC-AdV by cesium chloride centrifugation and buffer 
exchange 
Purification of the viral lysate was performed by a two-step cesium chloride centrifugation. 
An overview of the whole procedure is schematically shown in Figure 2.2. In order to 
release the virus from the cells, the PBS-virus solution was applied to 4 freeze and thaw 
cycles and cellular debris were centrifuged down at 500 g for 8 min. The remaining 
supernatant was then used for purification. The first centrifugation was performed using a 
step gradient, comprised of 0.5 ml 1.5 g/cm3 cesium chloride (CsCl; 45.41 g CsCl, 54.50 ml 
H2O) solution, 3 ml of 1.35 g/cm3  (35.18 g CsCl, 64.22 ml H2O) and 3.5 ml of 1.25 g/ cm3 
CsCl (26.99 g CsCl, 73.01 ml H2O), which were carefully overlayed with 4.5 ml of cleared 
vector supernatant and approximately 0.5 ml PBS to reach the top of the ultra-clear 
centrifuge tube (Beckman Coulter; Figure 2.2B, left panel). The gradient was centrifuged at 
12°C for 1.5 hours at 226.000 g using slow acceleration and deceleration in a ultra 
centrifuge to separate viral particles from remaining cellular fragments. A picture of the 
gradient after centrifugation is shown in Figure 2.2B (middle panel). The particular virus 
band was carefully removed and a second continuous gradient should concentrate the virus. 
Therefore the virus solution was filled up to 24 ml with 1.35 g/cm3 CsCl solution, mixed and 
transferred to two centrifuge tubes. Of note, it is not recommended to use more than 3 ml of 
virus solution in one centrifuge tube because the viral band may be diffuse after 
centrifugation. The second centrifugation step was performed overnight for 18-20 hrs at 
12°C and 226.000 g and results in a clear virus containing band appearing in the upper 
region of the tube (Figure 2.2A and 2.2B, right pannel).  
The virus solution was carefully removed and dialysis of the solution cleared the virus from 
cesium chloride, which is toxic for cells. Dialysis was performed in tubes (Spectra/Por 
Membrane, MWCO 50.000), which were first washed three times with sterile, deionised H2O, 
then the tube was closed (Spectra/Por Closures) on one side to pipette the viral lysate inside 
and closed also on the other side. Dialyze solution contains 10 mM Tris-HCl (pH7.5), 10% 
glycerol, 1 mM MgCl2 in deionised water. First buffer exchange was done after 2 hrs at 4°C 
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on a magnetic stirrer (32 rpm) in 1 liter of dialyze solution and was then extended in a new 
two liter dialyze solution for 24 hrs under the same conditions. The next day viral lysate was 
collected, multiple aliquots were made and stored at -80°C. 
               
Figure 2.2: Flow chart of CsCl purification of HC-AdV. For both centrifugation steps centrifuge 
tubes are shown before and after centrifugation. The cesium chloride steps are indicated as well as the 
respective centrifugation parameters. (A) Schematic diagram of CsCl gradients. After three freeze and 
thaw cycles the viral lysate is carefully loaded onto the top of the CsCl gradient. After centrifugation at 
226,000 x g (1.5 hrs) the band containing the HC-AdV is harvested from the top. Empty particles 
concentrate in the 1.25 g/cm3 CsCl-phase complete HC vector particles concentrate in the 1.35 g/cm3 
CsCl-phase. In the continuous CsCl gradients, the HC-AdV particles concentrate in the upper part of 
the tube. Note, empty particles are concentrating above the complete particles. Be sure to harvest the 
complete particles in an as small as possible volume in order to concentrate them. (B) Photographs of 
the collection tubes before (left picture) and after the step gradient centrifugation (middle picture) and 
after the continuous gradient centrifugation (right picture). The particle bands (empty and complete) 
appear white with a light blue shadow.  
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2.2.5 Titration of HC-AdV by optical density and quantitative Real-Time PCR 
Titration of purified virus can either be performed by measuring the physical titer in order to 
obtain all viral particles in your preparation or one can do quantitative Real-Time PCR (qRT-
PCR) to calculate the actual TUs. 
For the optical density (OD) 25 µl of purified virus was supplemented with 475 µl lysis buffer 
(10 mM Tris-HCl (pH 7.5), 10 mM EDTA (pH 8.0), 0.5% SDS) and shaked for 15 min at 37°C 
at 1000 rpm. After centrifugation of the virus solution at 15.000 g for one min., the OD was 
measured at 260 nm. The following formula was used to calculate optical particle units 
(OPU):  
OPU/ml = (absorbance at 260nm) x (dilution factor) x (1.1x1012) x (36) / (size of HC-AdV in 
kb).  
In order to determine TUs of HC-AdV and to analyze helper virus contamination, qRT-PCR 
was performed. The helper virus contamination can be evaluated by treatment of 25 µl of 
purified virus with 200 µl Proteinase K solution (0.5 mg/ml proteinase K, 10mM Tris-HCl (pH 
7.5), 0.5% SDS, 10mM EDTA (pH 8.0)) for 4 hours at 55°C. Afterwards the DNA was 
precipitated using 1 volume ethanol and 3 M Natrium acetat (pH 5.0) and was resuspended 
in 25 µl of sterile H2O. Five µl were used for qRT-PCR. For the standard curve serial 
dilutions of purified wtAd5 DNA were generated and genome copy numbers were calculated 
by the formular:  
10-12/plasmid size (bp)* 6.02*1023 
QRT-PCR was carried out with the Taqman 7500 Fast Real-Time PCR System (Applied 
Biosystems) amplifying a 235 bp fragment of the adenoviral late gene 3 (L3), using the 
oligonucleotides L3 forward 5´AGA AGC TTA GCA TCC GTT ACT CGA GTT G and L3 
reverse 5´ATA AGC TTG CAAT GTT GGT ATG CAG GAT GG together with an L3 specific 
probe 5´Fam CCA CCC GTG TGT ACC TGG TGG ACA-Tamra (Ella Biotech). The PCR 
was performed using the following program: AmpErase UNG reaction at 50°C for 2 min, 
pre-incubation/activation at 95°C for 10 min, amplification and data collection during 40 
cycles  (95°C for 15 sec and 60°C for 1 min). Universal PCR master mix (Roche) was used 
for Taqman qRT-PCR. On the basis of the standard curve, helper virus genomes were 
calculated in the final vector preparation.  
For measuring TUs of the HC-AdV in the final virus preparation, HEK293 cells were seeded 
in a 6 cm culture dish to reach 90% confluence at the time point of infection. Two µl of 
purified virus was used to infect HEK293 cells. Two hours infected and non-infected cells 
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were harvested using trypsin to remove not internalized viral particles. Whole genomic DNA 
was isolated from the cells, ten-fold dilutions of the genomic DNA was prepared to perform 
qRT-PCR with the primer ITR Ad5ItRfw1-24 5´CAT CAT CAA TAA TAT ACC TTA TTT and 
436Rev 5´ACG CCA CTT TGA CCC GGA ACG using LightCycler FastStart DNAMasterPlus 
SYBR Green I kit (Roche) under the following conditions: Preincubation at 95°C for 10 min, 
amplification 45 cycles at 95°C for 10 sec, 55°C for 5 sec and 72°C for 30 sec. As described 
above, for the standard curve, purified wtAd5 DNA was used in serial dilutions. The primers 
used in this assay amplify the ITR/packaging signal region, which is in reverse orientation in 
the helper virus genome, and therefore only the ITR from the HC-AdV and not helper virus is 
amplified in this step.  
Notably, for accurate measurements and production of clinical-grade HC-AdV the adenoviral 
reference material (ARM) could be used for titration. ARM is distributed by ATCC and is fully 
characterized regarding particle concentration and the amount of infectious units per 
volume. The advantage of this method is that adenoviral preparations produced in different 
laboratories can be directly compared also with respect to future clinical trials.   
2.2.6 HC-AdVs for the delivery of short-hairpin RNAs to mediate inhibition of 
luciferase expression by RNAi in vitro and in vivo 
After production of HC-AdVs utilizing our detailed protocol, we aimed at evaluating efficacy 
of our HC-AdVs in a clinically relevant animal model. Over the recent years various viral and 
non-viral vector systems have been studied for delivery of short hairpin RNA (shRNA) 
expression cassettes for instance to reduce hepatitis B virus transcripts. However, the in 
vitro and in vivo efficacy of HC-AdV lacking all viral coding sequences remains to be studied. 
In order to determine optimized conditions for shRNA delivery, we co-transduced HeLa cells 
with the HC-AdV FTC/lucRNAi expressing shRNA against luciferase (Figure 2.3B) and the 
first generation (fg) adenoviral vector fgAdluc expressing luciferase (Figure 2.3A). We 
observed a 77% reduction in luciferase expression at a 1:1 ratio (fgAdluc : FTC/lucRNAi). At 
a 1:5, 1:10, and 1:50 ratio (fgAdluc : FTC/lucRNAi) we measured up to 94% reduction in 
luciferase expression levels (Figure 2.3F). To demonstrate that this effect was specifically 
related to shRNA mediated transgene silencing, control cells received an adenoviral vector 
with an unrelated shRNA expression cassette (FTC/HBVU6no.2, Figure 2.3C). As 
showndemonstrated in Figure 2.3B there was no reduction of luciferase expression in 
control cells. 
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Figure 2.3: DNA sequences contained in the recombinant adenoviral vector genomes and 
inhibition of luciferase expression by luciferase RNAi-mediated RNA interference in vitro and 
in vivo. (A) The first generation adenoviral vector fgAdluc contained a luciferase expression cassette 
encoding luciferase (luc) under the control of Simian virus 40 promoter (SV40-p). pA: polyadenylation 
signal. (B) The adenoviral vector FTC/lucRNAi contained an expression cassette encoding a 
previously described small hairpin RNA (shRNA) against luciferase (Luc RNAi) under the control of 
the U6 promoter. The stuffer DNA contained in the high-capacity adenoviral vectors was based 
pAdFTC. In addition this vector contained a previously described human coagulation factor IX (hFIX) 
expression cassette17 and the following DNA sequences: AttB: bacteriophage integrase phiC31 
attachment site; IR: inverted repeats for Sleeping Beauty transposase; FRT: recognition sites for Flp 
mediated recombination. (C) The adenoviral vector FTC/HBVU6no.2 contained the shRNA expression 
cassette HBVU6no.2 and the identical hFIX expression cassette as described already for 
FTC/lucRNAi. (D) The control vector FTC-hFIX-attB-(FRT)2 without shRNA coding sequence 
contained a previously described split transgene expression cassette for hFIX under the control of the 
liver specific human α1-antitrypsin promoter (hAAT-p). (A)-(D) ITR: inverted terminal repeat. (E) The 
HC-AdV HD28E4LacZ was described previously (Palmer and Ng 2003) and contains the β-
galactosidase cDNA (lacZ) under the control of the murine cytomegalovirus (CMV-p) promoter. (F) 
Optimization of RNA interference mediated post-transcriptional silencing by a high-capacity adenoviral 
vector (HC-AdV) with a shRNA expression cassette against luciferase. HeLa cells were co-transfected 
with the first generation adenoviral vector fgAdluc at an MOI of 10 and the shRNA expressing 
adenovirus FTC/lucRNAi at an MOI of 10, 50, 100, and 500 respectively. Mean ± SD is shown 
(n=3/group). Luciferase levels were measured 3 days post-infection. (G) Inhibition of luciferase 
expression by the HC-AdV FTC/lucRNAi. The negative control group received the adenoviral vector 
FTC/HBVU6no.2 with an irrelevant shRNA expression cassette. Mean ± SD is shown (n=3/group). (H) 
RNA interference in FVB mice (n=3/group). Shown are representative images of light emitted from 
mice, which received the luciferase expressing vector and a second adenoviral vector which 
expressed short hairpin RNA against luciferase (FTC/lucRNAi). Control groups received an adenoviral 
vector with an irrelevant shRNA (FTC/HBVU6no.2), no shRNA (AdFTC/cFIX/ChMAR22), or the vehicle 
control. Representative individuals of each group are shown. Cloning of the viral plasmids (A-D) and 
the animal experiment (H) were performed by A. Ehrhardt. 
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In order to demonstrate in vivo efficacy, FVB mice (n=3 per group) were co-injected with 
1.2x1010 TUs of the adenoviral vector FTC/lucRNAi and 4x109 TUs of the fg adenoviral 
vector fgAdluc. Control mice were co-injected with 4x109 TUs fgAdluc and either 1.2x1010. 
TUs of the HC-AdV AdFTC/cFIX/ChMAR (Ehrhardt et al., 2003) without shRNA coding 
sequence or the HC-AdV FTC/HBVU6no.2 (Figure 2.3C) with an irrelevant shRNA coding 
sequence. Negative control mice received the vehicle for adenoviral delivery (PBS). We 
found up to 96% reduction of luciferase expression seven days post-injection in mice, which 
received the adenoviral vectors FTC/lucRNAi and fgAdluc. Figure 2.3H shows 
representative images of light emitted from mice in all groups (this experiment was 
performed by Anja Ehrhardt). The effect of shRNA mediated post-transcriptional silencing of 
luciferase expression lasted for 2 weeks (data not shown). Long-term studies were not 
feasible because luciferase expression levels from the fg adenoviral vector fgAdluc 
decreased to undetectable levels 4 weeks post-injection. It was concluded that HC-AdVs are 
sufficient to mediate RNA interference mediated post-transcriptional gene silencing in vitro 
and in vivo.  
2.2.7 Inhibition of hepatitis B virus infection in vitro 
Using a non-viral gene therapy approach, it was demonstrated that a 25-mer shRNA against 
HBV (HBVU6no.2) driven by the polymerase III U6 promoter resulted in efficient knockdown 
of HBV infection in vitro (up to 94% reduction in hepatitis B virus surface antigen levels 
(HBsAgs)), a marker for progression of HBV infection (McCaffrey et al., 2003). HBsAg of 
HBVU6no.2 treated mice was reduced by 84.5% in a transient animal model for HBV 
infection (McCaffrey et al., 2003). Interestingly, another study reported that the identical 
shRNA, HBVU6no.2, was lethal at high dose in HBV transgenic mice and regular mice in the 
context of an AAV2/8 vector (Grimm et al., 2006). It is speculated that this phenomenon was 
due to oversaturation of the micro RNA/shRNA pathways. 
This study evaluated HC-AdV for delivery of HBVU6no.2. To verify expression and 
processing of the shRNA against HBV and luciferase contained in our shRNA expression 
plasmids and in the viral vector FTC/HBVU6no.2, we performed a Northern blot analysis. As 
depicted in Figure 2.4 we detected expression and processing of the highly efficient shRNA 
against luciferase and the shRNA against HBV (Figure 2.4B). Notably, in contrast to the 
shRNA expression cassette against luciferase, we found that the ratio of hairpin to 
processed siRNA for HBVU6no.2 seems to be shifted towards the hairpin (Figures 2.4A,B).  
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This was in concordance with a previously described study showing efficacy of HBVU6no.2. 
In this study the identical hairpins were delivered by AAV2/8 vectors and analyzed by 
Northern blot analysis.  
 
 
 
 
Figure 2.4: Expression of small hairpin RNA and inhibition of hepatitis B virus infection in 
vitro. (A) Small-hairpin expression and processing of the shRNA against luciferase. Cells were 
transfected with the luciferase shRNA expression plasmid pBS/hFIX/lucRNAi. As a standard we 
loaded the 21-mer and the 25-mer of the reverse sequence of the oligonucleotide Luc-antisense on 
the gel. The blotted membrane was probed with the radioactively labelled probe Luc-antisense. (B) 
Northern blot analysis to show expression and processing of short hairpin RNA (shRNA) against HBV. 
In order to show that equal amounts of total RNA were loaded on the gel, the membrane was 
subsequently hybridized with the 5.8S-rRNA oligonucleotide. As a standard we loaded the 21-mer of 
the reverse sequence of the oligonucleotide HBV-antisense. (C) DNA sequences contained in the 
HC-AdV FTC/HBVU6no.2 induce silencing of hepatitis B virus surface antigen (HBsAg). Huh7 cells 
were co-transfected with pTHBV2 and pHBVRNAno.2, or pFTC/HBVU6no.2 or stuffer DNA. HBsAg 
levels in the supernatant were measured two days post infection by enzyme immunoassay 
(n=2/group). (D) RNA interference induced silencing of HBsAg levels in the Huh 7 cells. Huh7 cells 
were transiently transfected with the plasmid pTHBV2 containing the HBV genome. Twenty-four hours 
post-transfection cells were transfected with the HC-AdV FTC/HBVU6no.2 or FTC-hFIX-attB-(FRT)2 
at an MOI of 300, 30, and 10. Control groups were either co-transfected with the plasmids pTHBV2 
and pHBVU6no.2, the plasmid pTHBV2 only or the negative control plasmid phAAT. HBsAg levels in 
the supernatant were measured two days post infection by enzyme immunoassay. Mean ± SD is 
shown (n=3/group). (E) RNA interference induced silencing of HBsAg from an adenoviral vector in 
2.2.15 cells (stably transfected with the HBV genome). Control groups either were untreated or 
received the HC-AdV FTC-hFIX-attB-(FRT)2. HBsAg levels in the supernatant were measured three 
days post-infection by enzyme immunoassay. Mean ± SD is shown (n=3/group). 
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In order to demonstrate that the shRNA sequences against HBV contained in our adenoviral 
vector FTC/HBVU6no.2 (Figure 2.4C) are functional, an in vitro study solely based on 
plasmid transfection was performed. Human hepatoma cells (Huh7) were co-transfected 
with pTHBV2 (a plasmid that contained the complete HBV genome for establishment of 
transient HBV infection) and either the plasmid pHBVU6no.2 or pFTC/HBVU6no.2. A 68% 
and 47% drop in HBsAg levels was observed, respectively (Figure 2.4C). 
In a further step we evaluated potency of the adenoviral vector FTC/HBVU6no.2 (Figure 
2.4C). Huh7 cells were transiently transfected with the plasmid pTHBV2. This step was 
followed by infection with either the HC-AdV FTC/HBVU6no.2 or the control vector FTC-
hFIX-attB-(FRT)2 (Figure 2.4D) at an MOI of 300, 30, and 10. For groups, which received 
the HC-AdV FTC/HBVU6no.2, we observed a 94%, 60%, and 30% reduction in HBsAg 
levels in the supernatant of Huh7 cells, respectively (Figure 2.4D). We observed vector 
related cellular toxicity at the highest adenoviral vector dose (MOI 300). This observation 
may explain reduction of HBsAg levels in the group, which received the highest dose of the 
control vector FTC-hFIX-attB-(FRT)2 (Figure 2.4D). The positive control group received the 
plasmids pTHBV2 and pHBVU6no.2 for RNA interference induced silencing of HBV 
transcripts. In concordance with results presented in Figure 2.4C, we observed a 75% 
reduction in HBsAg levels in the supernatant of Huh7 cells of this group (Figure 2.4D). All 
groups, including the negative control group, received the plasmid pRSV.hAAT.bpA 
encoding secreted human α1-antitrypsin (hAAT) for normalization of transfection 
efficiencies.  
The 2.2.15 cells are stably transfected with the HBV genome and thus pre-existing HBV 
infection is present. In order to test susceptibility of 2.2.15 cells to super infection with 
adenovirus, we infected these cells at various MOIs with the HC-AdV expressing the marker 
gene β-gal. We found that an MOI of 100 was sufficient to transduce 100% of 2.2.15 cells 
(not shown). Thus, 2.2.15 cells were transduced at an MOI of 100 with the HC-AdV 
FTC/HBVno.2. We observed up to 60% reduction of secreted HBsAg levels in the 
supernatant (Figure 2.4E). This was in contrast to the control group which was transfected 
with the adenoviral vector FTC-hFIX-attB-(FRT)2 without shRNA expression cassette. 
HBsAg levels in this group were comparable to HBsAg levels in the supernatant of 
untransfected 2.2.15 cells.   
2.2.8 HC-AdV results in reduction of hepatitis B surface antigen in small animal 
models for hepatitis B infection 
In previous studies it was demonstrated, that hydrodynamic transfection of non-viral DNA 
containing the complete HBV genome represents a transient animal model for HBV infection 
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(Yang et al., 2002; McCaffrey et al., 2003). In this animal model blood antigen levels drop to 
undetectable concentrations as early as 7 days post-injection due to formation of 
neutralizing antibodies against HBV gene products (Yang et al., 2002). McCaffrey et al. 
found that secreted HBsAg in mouse serum were significantly reduced after co-delivery of a 
plasmid containing the HBV genome (pTHBV2) and a second plasmid driving expression of 
the shRNA HBVU6no.2 (pHBVU6no.2) (McCaffrey et al., 2003). To test efficacy of the HC-
AdV FTC/HBVU6no.2 in this transient animal model, we sequentially injected pTHBV2 
containing the HBV genome and the adenoviral vector FTC/HBVU6no.2 into C57Bl/6 mice 
(n=4 per group). The plasmid pTHBV2 was injected by high-pressure tail vein injection 
followed by injection of 5x109 TUs of the HC-AdV FTC/HBVU6no.2. We measured HBsAg 
levels 2 and 4 days after adenoviral delivery and we observed a 68% drop in serum HBsAg 
levels (Figure 2.5A). Mice, which either received the HC-AdV HD28E4LacZ with a β-gal 
expression cassette (Figure 2.3E) (Palmer and Ng 2003) or pHBVU6no.2 showed a 
reduction of 73% and 66% in HBsAg levels, respectively (Figure 2.5A). This finding may 
suggest that the transgene product β-gal itself may be responsible for reduction in HBsAg 
levels (experiments 2.5A and B were performed by A. Ehrhardt).  
Recent studies by Uprichard et al. and Carmona et al. used fg adenoviral vectors (deleted 
for the adenoviral early genes E1 and E3) for delivery of HBV specific shRNAs (Uprichard et 
al., 2005; Carmona et al., 2006). After systemic application of the adenoviral vector into a 
transgenic mouse model for HBV infection, this approach resulted in reduced HBV infection 
levels for up to 26 days. Our goal was to evaluate HC-AdV lacking all adenoviral coding 
sequences in HBV transgenic mice. HBV transgenic mice (n=4 per group) were injected with 
5x109 TUs of the HC-AdV FTC/HBVU6no.2. After a transient increase in HBsAg levels, we 
observed an up to 68% reduction in serum HBsAg levels compared to the vehicle control 
group (Figure 2.5B, performed by A. Ehrhardt).  
To analyze knockdown of HBV replication by other means, we performed a Southern blot 
analysis of HBV transgenic mouse liver genomic DNA. Compared to the control group, 
which received the vehicle (PBS), we found that HBV viral DNA is reduced in mice, which 
received FTC/HBVU6no.2 (Figure 2.5C).  
In order to rule out unspecific effects of HC-AdV on HBV replication, we performed a second 
experiment in HBV transgenic mice. Individual mice were either transduced with 5x109 
transducing units of the HC-AdV FTC/HBVU6no.2 or 5x109 transducing units of the HC-AdV 
FTC/lucRNAi (Figure 2.3B). The latter group functions as a control with an irrelevant shRNA 
expression cassette.  We observed a transient decrease in HBsAg levels up to 7 days post-
injection followed by an increase in HBsAg levels (data not shown, experiment was 
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performed by A. Ehrhardt). This finding was in contrast to our first experiment in HBV 
transgenic mice (Figure 2.5B). One fatality was accounted for in the group, which received 
FTC/HBVU6no.2, but the reason for this observation remains to be investigated. In contrast 
to FTC/HBVU6no.2 treated mice, only one mouse of the group, which received the HC-AdV 
FTC/lucRNAi showed a slight decrease in HBsAg levels. In concordance to our first 
experiment, we observed increased release of liver enzymes as demonstrated by SGPT 
levels (data not shown, experiment performed by A.Ehrhardt).  
 
 
 
 
 
Figure 2.5: Reduction of hepatitis B virus surface antigen (HBsAg) levels in vivo by a high-
capacity adenoviral vector (HC-AdV) in a transient and trangenic mouse model for hepatitis B 
virus infection. (A) Reduction of HBsAg levels in mouse serum. C57Bl/6 mice were injected with a 
plasmid containing the HBV genome (pTHBV2). This step was followed by injection of 5x109 
transducing units of either the HC-AdV FTC/HBVU6no.2 or HD28E4LacZ. Control groups were 
injected with pTHBV2 or co-injected with pTHBV2 and pHBVRNAno.2. Serum HBsAg levels were 
measured two and four days after adenovirus injection by enzyme immunoassay. Mean is shown 
(n=4/group). (B) Relative hepatitis B virus surface antigen (HBsAg) levels after injection of the 
adenoviral vector FTC/HBVU6no.2 into HBV transgenic mice. Mean ± SD is shown (n=4). Control 
mice solely received the vehicle PBS. Mean ± SD is shown (n=3). Serum HBsAg levels were 
monitored by enzyme immunoassay. Mean ± SD is shown (n=4). (C) Analysis of HBV genome 
replication after injection of the HC-AdV FTC/HBVU6no.2 and HD28E4LacZ. We performed Southern 
blot analysis of mouse genomic DNA. Blots were hybridized with a [α-P32]–deoxycytidine triphosphate 
(dCTP)–labeled HBV probe. Experiments 5A and 5B were perfomed by Anja Ehrhardt. 
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2.3 Discussion 
In conclusion, our in detail protocol for the fast and less labour intensive, large-scale 
production of HC-AdVs offers the opportunity to generate these vectors, even in non-
experienced laboratories. The advanced cloning procedure, using rare restriction enzymes 
makes the insertion of the transgene cassette of interest independent of sophisticated and 
inefficient homologous recombination processes (section 2.2.1) (He et al., 1998; Luo et al., 
2007). In addition, the helper virus AdNG163R-2 provided a pre-condition for a safe HC-AdV 
production, as it guarantees low helper virus contamination in the final vector preparation 
(Ng et al., 2001).  
The amplification procedure was adapted to HEK293 based cell line 116, which can be 
grown in suspension culture. Therefore, HC-AdVs production can be performed in a 3 liter 
spinner flask system, making the entire process less labour and cost intensive and allows 
amplification of multiple different HC-AdVs, as 5 pole magnetic stirrers (Belco) are already 
available (Figure 2.1). Moreover, the protocol for the cesium chloride gradient purification 
provides useful information about the composition of cesium chloride solutions, specifically 
optimized for Ad5 purification (Figure 2.2), and of course the ingredients of the dialyze 
buffer, which is in our case a glycerol based buffer. There are also sucrose-based buffers for 
dialysis available (Offringa et al., 2005), as they should reduce the probability of precipitates 
within the final virus preparation; however the coherence of glycerol and precipitates has not 
been confirmed yet.  
For calculation of transducing units a protocol for qRT-PCR is provided, whereby one can 
also perform Southern Blot analysis (experiment was performed by L. Jager within this 
study), but quantification of the infectious particles is faster and more precise. We used 
primer directed against the ITR and the packaging signal, which can be subjected to every 
generated HC-AdV, independent from the introduced transgene expression cassette. Thus, 
the calculation of different preparations is better comparable (section 2.2.5). 
Furthermore, our study demonstrates that HC-AdV deleted for all viral coding sequences is 
suitable to deliver shRNAs. These shRNAs were recognized and processed by the RNAi 
enzymes, which render mature miRNAs (Figure 2.4) that have the potential to reduce 
transient and pre-existing HBV infection significantly. However, the present study also 
emphasizes that the design of DNA sequences contained in the vector and virus-host 
interactions during super infection need to be carefully considered. 
The effect of shRNA mediated RNA interference against luciferase lasted for two weeks in 
vivo (data not shown, experiment done by A. Ehrhardt). A long-term study was not 
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applicable because luciferase expression levels from the first generation (fg) adenoviral 
vector fgAdluc decreased to undetectable levels 4 weeks post-injection. Persistence of 
transgene expression levels from fg adenoviral vectors depends on the promoter which 
controls transgene expression and the mouse strain (Schiedner et al., 1998; Ehrhardt and 
Kay 2002). In the present work) luciferase expression was driven by the Simian virus 40 
(SV40) promoter. However, tissue specific promoters may result in stabilized transgene 
expression levels with a reduced toxicity profile (Schiedner et al., 1998; Ehrhardt and Kay 
2002). Thus, future studies may investigate a HC-AdV with a liver specific promoter driving 
luciferase expression or transgenic mice for hepatic luciferase expression. With respect to 
long-term suppression of luciferase expression or therapeutically relevant target transcripts 
(e.g. viral transcription units or endogenous genes), shRNA may be delivered with recently 
developed HC-AdV for somatic integration (Ehrhardt et al., 2007). These vectors were 
shown to result in stabilized transgene expression levels even during rapid cell cycling in 
vivo (Ehrhardt et al., 2007).  
We observed a transient increase in serum HBsAg levels shortly after HC-AdV 
administration the transgenic mouse model for HBV infection (Figure 2.5B). This was in 
contrast to studies performed by Uprichard and Carmona (Uprichard et al., 2005; Carmona 
et al., 2006). After adenoviral injection there was no transient increase in HBsAg antigen 
levels. One explanation for these observed differences might be the fact that the two latter 
studies utilized fg adenoviral vectors. We speculate that the remaining adenoviral genes in 
fg adenoviral vectors and their gene products in contrast to HC-AdV may have an additional 
inhibitory effect on HBV infection. In fact, it was demonstrated that inflammatory cytokine 
induction after systemic administration of HBV transgenic mice with an fg adenoviral vector 
resulted in reduced HBV replication (Cavanaugh et al., 1998). In contrast to fg adenoviral 
vectors, HC-AdV lack all viral coding sequences. Thus, immunomodulatory adenoviral gene 
products are not present after infection with HC-AdV. However, the host response against 
the incoming adenoviral viral capsid proteins and the subsequent change in the expression 
profile of the host cells may directly or indirectly result in increased HBsAg levels.  
In our first experiment performed in HBV transgenic mice we found that HBsAg levels were 
transiently increased up to two weeks post-injection of the HC-AdV FTC/HBVU6no.2 (Figure 
2.5B). This was in contrast to our second experiment in which we measured a decrease in 
HBsAg levels shortly post-injection (data not shown, experiment performed by A.Ehrhardt). 
We speculate that this difference may be related to the HBV viral load of each individual pre-
injection of the adenoviral vector. At average HBV transgenic mice used in the first 
experiment had higher starting HBsAg levels (989 ng/ml, 548 ng/ml, 475 ng/ml, and 365 
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ng/ml) pre-injection compared to individuals used in the second experiment (103 ng/ml, 323 
ng/ml, 276 ng/ml).  
Very recently it was reported that injection of high dose of recombinant AAV vectors 
expressing various short hairpin RNAs caused lethality in mice (Grimm et al., 2006). It was 
speculated that oversaturation of the shRNA/micro RNA pathways may be responsible. In 
contrast to superinfection with AAV2/8 vectors expressing the shRNA HBVU6no.2, we only 
observed one case of lethality in HBV transgenic mice after systemic administration of a high 
dose of a HC-AdV with the identical shRNA expression cassette (data not shown, 
experiment was performed by Anja Ehrhardt). However, it is important to point out that the 
reason for this fatality remains to be investigated and that further studies need to be 
performed. It was proposed that oversaturation of the micro/short hairpin RNA pathways 
may be responsible for lethality in AAV8 injected mice. Both, recombinant AAV2/8 and 
adenoviral vectors have the ability to infect 100% of mouse hepatocytes. However, for 
sufficient transduction of all mouse hepatocytes using single-stranded AAV2/8 vectors, a 
high vector dose (7.2 x 1012 viral genomes per mouse) is required. It was demonstrated by 
Nakai et al. that this dose resulted in up to 1000 vector genome copies per cell (Nakai et al., 
2005). Even for double-stranded AAV2/8 vectors with improved transduction efficiencies, 
1x1012 AAV vector genomes per mouse are required to efficiently transduce all mouse 
hepatocytes (Grimm et al., 2006). This feature of AAV vectors is in sharp contrast to 
adenoviral vectors. After transduction of 100% of mouse hepatocytes we only detected up to 
12 adenoviral vector genomes per hepatocyte (data not shown, experiment performed by A. 
Ehrhardt). We believe that this vector genome copy number per cell and subsequent shRNA 
expression levels were not sufficient to oversaturate the micro RNA/shRNA pathways. To 
further shed light on the differences between AAV and adenoviral vectors for shRNA delivery 
against HBV, further studies remain to be performed. One may consider to analyze and to 
compare additional blood parameters or major factors of the innate immune response. 
In summary, HC-AdV can be produced at high titers utilizing our detailed protocol. Since 
helper virus contamination is only negligible, final vector preparation can be used in small 
and large animal models and in the future potentially also in the clinics. We believe that HC-
AdV have the potential to mediate potent shRNA mediated gene silencing in vivo but the 
design of DNA sequences including shRNAs contained in the vector need to be carefully 
considered. In addition, we believe that it will be essential to further elucidate biological 
virus-host interactions during super infection with HBV and adenovirus. Moreover, further 
understanding of the micro RNA/shRNA pathways will be required before pursuing these 
gene therapy approaches in a clinical setting. 
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3 Transcriptional activity of inverted terminal repeats 
of various human adenovirus serotypes 
Recombinant adenoviral vectors (rAdVs) represent the most frequently used gene transfer 
system for preclinical and clinical approaches (Morral et al., 1998; Brunetti-Pierri et al., 
2007). Different generations of rAdVs were developed by removing various viral coding 
regions, being replaced by foreign DNA. This largely expanded the potential of rAdV and to 
date rAdVs are extensively studied as oncolytics for the treatment of tumors and for treating 
genetic disorders.  
To date 53 human wild type adenovirus (wtAds) serotypes have been identified, which are 
divided into the seven subgroups A, B1, B2, C, D, E and F. They differ by their tropism and 
their clinical manifestations. For instance, subgroups B1, C, and E cause respiratory 
infections, group B2 causes infections of the kidney and the urinary tract, group F viruses 
cause gastroenteritis, and subgroup D viruses are associated with epidemic 
keratoconjunctivitis. The most commonly used adenovirus serotype for generation of rAdVs 
is represented by the human adenovirus serotype 5 (Ad5) from subgroup C. However, over 
the recent years there was an increased interest in generation of other than Ad5-based 
rAdVs (Yang et al., 1995a; Bromberg et al., 1998) because Ad5 is restricted by its tropism 
and there is a high prevalence of neutralizing antibodies within the human population 
against Ad5 (Arnberg 2009). Therefore, by exploring the complete spectrum of all available 
human wtAds one could benefit from the diverse tissue tropism and one may circumvent 
pre-existing immunity.    
All rAdVs used for genetic engineering of cells share the serotype-specific ITRs flanking both 
sides of the adenovirus genome as one common feature in their genomic composition. It is 
established that the ITRs play an important role in adenovirus DNA (Curiel and Douglas 
2002). Dependent on the serotype the ITRs are approximately 160 base pairs (bp) in length 
and sequence comparisons revealed that in particular the first 50 bp from the ends contain 
sequences that have been well conserved in adenovirus evolution (Tolun et al., 1979; Ishino 
et al., 1987). There is evidence that transcriptional activity is located within the ITRs of Ad5 
(bp 1-103) (Yamamoto et al., 2003), nucleotide sequences 1 to 190 and 1 to 342 within the 
ITR (Yamamoto et al., 2003), and downstream of the adenoviral ITR sequences within the 
packaging/enhancer region (bp 194-458) (Hearing et al., 1987; Shi et al., 1997; Rubinchik et 
al., 2001). This feature is important because transcriptional activity derived from the ends of 
the adenovirus genome can influence the performance of a given transgene inserted into a 
rAdV genome. Towards this end it was shown that even highly tissue-specific promoters 
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delivered by rAdV display an altered transcriptional activity (Babiss et al., 1986a; Hatfield 
and Hearing 1991; Imler et al., 1996; Shi et al., 1997). Additionally, in the relatively rare case 
of integration of the vector genome into the chromosomal host DNA (Harui et al., 1999; 
Stephen et al., 2008) a transcriptional active ITR may force or downregulate expression of 
nearby genes or even oncogenes. Although the left arm of Ad5 including the ITR and 
packaging/enhancer region were studied in the past, there is virtually no information about 
ITRs with respect to transcriptional activity from other than Ad5 human adenovirus 
serotypes. There are only studies based on Ad5 (Yamamoto et al., 2003) and porcine 
adenovirus type 3 (Xing and Tikoo 2005; Xing and Tikoo 2006) indicating that promoter 
activity exists from the ITR itself.  
Herein we investigated for the first time in a plasmid-based system whether ITRs from 
human adenovirus subgroups A, B1, B2, C, D, E and F show transcriptional activity in 
various cell lines.  
3.1 Materials and Methods 
3.1.1 Cell lines and viral lysates 
HEK293, HeLa, Huh7 and ARPE-19 cells were obtained from the American Tissue Culture 
Collection (ATCC), A549 cells were a kind gift from Carsten Rudolph (Ludwig-Maximilians-
University Munich, Germany) and HCT116 cells were obtained from Mark A. Kay (Stanford 
University, USA). All cell lines were cultivated at 37°C under a 5% CO2 atmosphere. For 
HEK293, HeLa and A549 cells DMEM supplemented with 10% FBS and 1% 
Penicillin/Streptomycin (P/S) was used. The retinal cell line ARPE-19 was grown in a 1:1 
mixture of F9: DMEM supplemented with 10% FBS and 1% P/S. The liver cell line Huh7 and 
the colon carcinoma cell line HCT116 were cultivated using DMEM supplemented with 1% 
non-essential amino acids, 10% FBS and 1% P/S.  
Wild type Ad5 was obtained from ATCC. Genomic DNA of all other adenovirus serotypes 
Ad4, Ad7, Ad11, Ad12, Ad17 and Ad41 were a kind gift of the clinical virology of the Max von 
Pettenkofer-Institute (Ludwig-Maximilians-University Munich, Germany).   
3.1.2 Plasmid constructs 
All plasmid constructs were based on the pGL3-Control vector supplied by Promega. The 
control plasmid pGL3ΔSV40 was constructed by restriction enzyme digest of the plasmid 
pGL3-Control with HindIII and XhoI followed by religation. The forward orientated ITRs were 
constructed by direct cloning of the amplified PCR product digested with the restriction 
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enzymes KpnI and SacI (grey nucleotides in Table 3.1) into the KpnI and SacI sites of the 
plasmid pGL3ΔSV40, resulting into the plasmid pGL3∆ITR forward. For reverse orientation 
of the ITRs the KpnI and the SacI sites were exchanged and obtained PCR products were 
directly cloned blunt-ended into the blunted KpnI and SacI sites of the plasmid pGL3ΔSV40 
resulting in pGL3∆ITR reverse. For the constructs containing the PGK promoter the plasmid 
pPGK (kindly provided by Martin Hausl, Max von Pettenkofer-Institute, Ludwig-Maximilians-
University Munich, Germany was used to amplify the PGK promoter by PCR. The purified 
PCR product was then digested with MluI and NheI (grey nucleotides in Table 3.1) and 
directly cloned into the MluI and NheI site of pGL3-Control. For primer sequences please 
refer to Table 3.1.  
 
3.1.3 Dual luciferase reporter assay to measure transcriptional activity of the ITRs 
Potential transcriptional activity of the respective ITRs was determined by measuring firefly 
luciferase activity utilizing the dual luciferase reporter assay (Promega). Our experimental 
approach was based on seeding the respective cell lines in a 24-well dish and subsequently 
transfecting 250 ng of the different constructs displayed in Figure 3.1A. Two days post-
transfection cells were harvested and prepared for luciferase assay. For normalization, 100 
ng of the pRL-TK (Promega) plasmid were co-transfected and the ratio of firefly activity to 
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renilla luciferase activity was measured to determine the relative light units. A p-value < 0.05 
demonstrated a significantly enhanced or reduced activity of the ITR in comparison to the 
negative control pGL3∆SV40 lacking the SV40 promoter. An insignificant result means that 
the ITR has no influence on the transcription of the luciferase.  
3.1.4 5´rapid amplification of cDNA ends 
HEK293 cells were transfected with ITR constructs for Ad5 and Ad7 utilizing the same 
conditions as for luciferase assays shown in Figure 3.2. RNA was isolated based on Trizol 
reagent (Invitrogen) and samples were analyzed using a RACE Kit from Biozym according to 
the manufacturer’s instructions (ExactSTARTTM Eukaryotic mRNA 5’-& 3’-RACE Kit, Cat. 
No. ES80910). In brief, total RNA was isolated, treated with ApexTM Heat-Labile Alkaline 
Phosphatase, followed by Tobacco Acid Pyrophosphatase treatment to remove 5’CAPs. 
After T4 RNA ligase mediated tagging of the 5’end with the 5’ RACE Acceptor Oligo we 
performed cDNA synthesis and amplified products with PCR primer 1 and PCR primer 2 
provided with the Kit. This step was followed by a second PCR reaction utilizing the gene 
specific primer for luciferase (luc rev) in combination with PCR Primer 1 which binds to the 
5’-RACE Acceptor Oligo. Sequences of these primers are shown in Table 3.1. PCR 
products were subcloned into the pCR-BluntII-Topo vector (Invitrogen) and sequenced. For 
Ad5 and Ad7 ITRs we analyzed 4 clones each. 
3.2 Results 
3.2.1 Constructs to analyze transcriptional activity of ITRs from different 
adenovirus serotypes 
To cover the complete spectrum of all subgroups we have chosen one serotype from each 
group [Ad12(A), Ad7(B1), Ad11(B2), Ad5(C), Ad17(D), Ad4(E), Ad41(F)] and generated 
constructs, in which the luciferase expression is dependent on the transcriptional strength of 
the respective ITR. For amplification and cloning of the different ITRs, primers were 
designed to clone either the forward or the reverse orientation of the ITR. Respective 
primers and the accession number of the different adenovirus serotypes are provided in 
Table 3.1. All vector constructs tested in the present study were based on the pGL3-Control 
vector (Promega), in which the luciferase expression is under the control of the Simian virus 
40 (SV40) promoter (Figure 3.1A). This vector served as a positive control for reporter gene 
expression. The negative control vector pGL3∆SV40 (Figure 3.1A) was generated by 
deleting the SV40 promoter. In order to analyze all possible directions into which 
transcription can run, either into the transgene expression cassette or, in case of integration, 
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into the chromosomal DNA, the ITRs were cloned upstream of the reporter gene in forward 
and reverse orientation (Table 3.1 and section 3.1.2). 
 
3.2.2 In silico analysis of transcriptional binding sites of ITRs 
To search for potential transcription factor binding sites in the ITRs, which were used in our 
study, we used the “Transcription Element Search System” (TESS), a free online tool 
provided by the University of Pennsylvania (webpage: http://www.cbil.upenn.edu/cgi-
bin/tess/tess?RQ=WELCOME (Schug 2008)). In all ITRs derived from different serotypes 
nucleotides 10 to 16 (TAATAT) could serve as a TATA box (Figure 3.1B) and multiple 
transcription factor binding sites (e.g. Oct-1, NFI, TBP, SP1, ATF) were predicted.  
    
F    Figure 3.1: Vector constructs and TATA box predictions within the inverted terminal repeats 
(ITRs). (A) Final vector constructs for analysis of the transcriptional activity of adenoviral ITRs and the 
respective adenovirus subgroups. pSV40: promoter of the Simian virus 40; polyA: SV40 
polyadenylation signal; pPGK: phosphoglycerate-kinase promoter; SV40E: Simian virus 40 enhancer. 
The respective restriction enzyme nucleases used for generation of the constructs are indicated. For 
cloning procedures please refer to the materials section. (B) Search for transcription factor binding 
sites in the ITRs utilizing a transcription element search system. As schematically shown as TFBS X, 
Y, and Z multiple transcription factor binding sites (TFBS) were identified. For all ITRs derived from 
different serotypes nucleotides 10 to 16 (TAATAT) could serve as a TATA box.  
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3.2.3 Transcriptional activity of ITRs derived from different adenoviral serotypes 
In order to analyze if the transcriptional potential of the ITRs is cell-type dependent, different 
cell lines were used. First, we tested cells, which are permissive to adenovirus infection such 
as carcinoma and A549 cells originated from lung epithelia cells. Because of the natural liver 
tropism of Ad5, we also studied transcriptional activity in the hepatoma-derived human liver 
cell line Huh7. Adenovirus 41 displays a distinct tropism to the intestinal tract and therefore 
we analyzed transcription in the colon carcinoma cell line HCT116. Furthermore, the adult 
retinal pigment epithelia cell line ARPE-19 was studied because of the natural tropism of 
some adenoviral serotypes to the eye (Ad17 and Ad4).  
Potential transcriptional activity of the respective ITRs based on the constructs displayed in 
Figure 3.1A was determined by measuring firefly luciferase activity utilizing a dual luciferase 
reporter assay. In the adenovirus permissive cell lines HEK293, HeLa and A549 we detected 
robust promoter activity of the ITRs from subgroup A, C and F if they appear in forward 
orientation (Figure 3.2A, B, C). Notably, expression levels were comparable or even higher 
compared to the strong SV40 promoter within the vector pGL3-Control. Most other forward 
orientated ITRs promote minor changes (ITRs 17) or background luciferase expression 
levels (ITRs 7 and 4). In contrast, in reverse orientation only serotypes 11 and 17 are 
transcriptional active in HEK293-, HeLa- and A549 cells, whereas all other ITRs seem to 
inhibit luciferase expression (ITR 4,5,7,12,41) emphasizing ITR 12 with even no detectable 
luciferase expression (Figure 3.2A, B, C). Similar results were obtained in the liver specific 
Huh7 cells and the colon carcinoma cell line HCT116 (Figure 3.2D, E). In forward 
orientation ITRs from adenovirus serotypes 12, 5 and 41 show strong luciferase expression. 
In reverse orientation ITRs 11 and 17 display slight promoter activity and the other ITRs 
negatively interfere with transcription.  
We also investigated transcriptional activity in the retinal pigment epithelial cell line ARPE-
19. Herein, the ITRs from subgroups A, C and F show the highest activity in comparison to 
the negative control lacking the SV40 promoter (Figure 3.2F). In concordance with results 
obtained in all other cell lines the reverse orientated ITRs from Ad serotypes 11 and 17 
display robust activity and ITRs 5, 7, 12, 41 inhibiting function (Figure 3.2F). However, in 
contrast to results obtained in all other cells lines we measured slightly enhanced luciferase 
expression levels in ARPE-19 cells for the ITR from subgroup E (ITR 4) when cloned in 
reverse orientation (Figure 3.2F). The reason for this finding remains to be elucidated. 
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Figure 3.2: Analysis of the transcriptional activities of the ITRs from each adenoviral subgroup 
in various cell lines. Shown in light grey are pGL3-based constructs with the adenoviral ITRs in 
forward orientation, in dark grey constructs in reverse orientation. The nomenclature of the different 
groups mentions the subgroup as a capital and the respective serotype in parenthesis. Relative light 
units were calculated by determining the ratio of firefly luciferase activity to renilla luciferase activity. 
Relative light units in HEK293 cells (A), HeLa cells (B), A549 cells (C), Huh7 cells (D), Hep1a cells (E), 
and ARPE-19 cells (F) are displayed. The dashed line indicates the base line of luciferase expression 
after transfection of the promoter-less vector pGL3∆SV40. pGL3: pGL3-Control; ∆SV40: pGL3 ∆SV40 
lacking the SV40 promoter; n.s.: not significant, p-value >0.05. 
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3.2.4 Influence of ITR sequences upstream of the PGK promoter 
To address the question whether ITRs from various adenovirus serotypes can influence a 
nearby promoter we analyzed the influence of the ITRs on the transcriptional activity of the 
ubiquitously expressed PGK promoter (pPGK). Towards this end the PGK promoter was 
cloned downstream of the forward orientated ITRs from each adenovirus subgroup (Figure 
3.1A, lower panel). The experimental set up was identical to experiments shown in 
Figure 3.2. Unexpectedly, we detected that almost each ITR upstream of the pPGK 
significantly reduced luciferase expression to background level or even less (Figure 3.3). 
With the exception of results obtained in A549 cells, only the ITR 7 from subgroup B1 seems 
to have no or only minor influence on the activity of pPGK in the cell lines HEK293, HeLa, 
Huh7 and HCT116. This is in concert to results obtained for the ITR 7 without the pPGK. In 
all tested cell lines serotype 7 shows either no or only a minor influences on the 
      
Figure 3.3: Influence of adenoviral ITRs on transcriptional activity of the PGK promoter. The 
nomenclature of the groups contains the ITR subgroup as capital and the respective serotype used in 
parenthesis. Additionally, each construct contains the phosphoglycerate kinase promoter (pPGK; see 
also Fig.1). Relative light units were calculated by determining the ratio of firefly luciferase activity to 
renilla luciferase activity. The dashed line indicates the base line of luciferase expression after 
transfection of the promoter-less vector pGL3∆SV40. Relative light units in HEK293 cells (A), HeLa 
cells (B), A549 cells (C), Huh7 cells (D), Hep1a cells (E), and ARPE-19 cells (F) are shown. ∆SV40 
PGK: pGL3 ∆SV40 with PGK promoter; n.s.: not significant, p-value >0.05. 
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transcriptional level in forward as well as in reverse orientation (Figure 3.2). This 
observation remains to be elucidated, but nevertheless this ITR seems to be a good 
candidate for the optimized design of rAdVs. However, it also remains to be elucidated 
whether this phenomenon is a special feature of the PGK promoter and whether another 
promoter may be differently influenced in its transcriptional activity by the ITRs. 
3.3 Discussion 
In summary, we show that solely the ITRs from several human adenovirus serotypes 
enhance or inhibit transcriptional activity in a tissue independent manner and that this 
activity can down regulate nearby promoters.  
Our results may have important implications for the design of other than subgroup C based 
rAdVs. There is evidence that the position of the inserted transgene expression cassette 
within the rAdV genome has an impact on the expression level of the transgene. One may 
speculate that convergent promoter activity from an introduced, internal promoter and the 
ITR may occur. This would then lead to formation of double-stranded RNAs and may induce 
gene silencing due to RNA interference, influencing transgene expression (Hammond et al., 
2000; Hutvagner 2005) Furthermore, it was shown that the enhancer near the 5´end could 
lead to a leaky expression from the tissue-specific promoter even in non-target cells (Babiss 
et al., 1986a; Shi et al., 1997) and it has been reported that sequences around the ITR can 
reduce promoter activity up to 50-fold (Shi et al., 1997). As these sequences can influence 
transgenes over large distances it is recommended to insert sequences preferentially at the 
3´end, comparable to our present pAdFTC plasmid we use in our laboratory (Ehrhardt et al., 
2003). In addition, ITRs showing low or no inward transcriptional activity into the adenoviral 
genome may be advantageous for optimized vector design. To avoid interference between 
adjacent genes without termination signal (Proudfoot 1986) when inserting a transgene 
expression cassette into the rAdV genome, ITR sequences derived from an adenovirus 
serotype, which has no or less effect on transcription initiation could be beneficial especially 
when using tissue-specific or controllable promoters.  
Moreover, the outward oriented transcriptional activity derived from ITRs could have a 
special importance for adenoviruses that show integration activity into the host genome of 
infected cells, such as Ad12 into hamster cells (Sutter et al., 1978; Sawada et al., 1979). In 
our experiments ITR 12 from subgroup A results into strongly inhibited luciferase expression 
when cloned in reverse orientation suggesting that this activity may result into inhibition of 
nearby genes. On the other hand, as we refer to a plasmid- based assay, ITR 12 may have 
insulator functions.  
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Notably, we used a plasmid based approach to investigate ITR transcriptional activity, in a 
viral background it could be, that transcriptional activity is further enhanced, due to viral 
proteins bound to the ends of the viral genome. The viral terminal protein for instance, that is 
attached to the ends of the viral DNA may serve as chaperon to guide transcription factors to 
the ITRs as shown by Yamamoto et al. (Yamamoto et al., 2003). Therefore it would be of 
great interest to further investigate whether ITRs from other than subgroup C Ads in a viral 
context show the same expression pattern as in our plasmid based experiment. As the 
serotypes from subgroup B (7) and A (12) display the most advantageous transcriptional 
profile they might be possible alternatives to the standard Ad5 serotype in future studies.
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4 The RNA interference pathway is responsible for 
silencing of transgene expression after Sleeping 
Beauty mediated transposition 
 Over the recent years various improved recombinases for somatic integration into the host 
genome were developed. Predominant integration systems currently being explored in 
mammalian cells are the transposable elements represented by the Sleeping Beauty (SB) 
transposase, the Frog Prince (FP) transposon, the piggyBac transposable element and the 
bacteriophage-derived integrase PhiC31 for targeted integration (Kuhstoss and Rao 1991; 
Ivics et al., 1997; Groth et al., 2000; Miskey et al., 2003). All systems are widely being 
studied in multiple applications including gene therapeutic applications and functional 
genomics (Yant et al., 2002; Ehrhardt et al., 2005; Kaufman et al., 2005; Patel and Yang 
2010). 
The SB transposase system represents one of the most prominent non-viral gene therapy 
vectors because it can efficiently and stably integrate therapeutic DNA into mammalian 
genomes. SB transposase is a synthetic transposable element derived from fish (Ivics et al., 
1997). For increased integration activities mutational analysis has been performed and 
hyperactive variants were developed (Ivics et al., 2007; Mates et al., 2009). The integration 
reaction is based on a cut-and-paste mechanism, which leads to genomic integration of the 
gene of interest, flanked by the SB inverted repeats (IRs) into a TA-dinucleotide. Multiple 
SB-based animal studies demonstrated efficacy in mice including stable correction of 
genetic disorders in clinically relevant animal models (Yant et al., 2000; Yant et al., 2002; 
Ehrhardt et al., 2005). 
There is accumulating evidence in invertebrates that DNA transposition is regulated by the 
endogenous RNA interference (RNAi) pathway (Vastenhouw et al., 2003; Robert et al., 
2004; Vastenhouw and Plasterk 2004), a mechanism responsible for post-transcriptional 
gene silencing (Fire et al., 1998; Elbashir et al., 2001a; Elbashir et al., 2001b). In these 
systems endogenously produced 21- to 25-nucleotide long non-coding micro RNAs 
(miRNAs) play a major role in downregulation of the transposase leading to inhibition of 
transposition in the respective cell (Hammond et al., 2000; Vastenhouw and Plasterk 2004)..  
However, only limited information is available regarding the potential influence of miRNA 
pathway on DNA transposons in mammalian cells. A recent study showed that the LINE-1 
retrotransposition is suppressed by endogenous small interfering RNAs (Yang and Kazazian 
2006). Hereby, bidirectional dsRNA transcripts from the transposon represent targets for the 
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RNAi machinery indicating that the RNAi pathway controls transposition in mammalian cells, 
too. Herein, we hypothesized that the SB transposase machinery may be regulated by the 
endogenous miRNA pathway as well, because recent data demonstrated that IRs display 
inward transcriptional activities in eukaryotic cells (Moldt et al., 2007; Walisko et al., 2008). 
This convergent transcription may lead to formation of double-stranded RNA templates for 
the endogenous RNAi machinery, thus silencing transgene expression.  
Our experimental approach was based on generation and detailed characterization of RNAi 
knockdown cell lines based on the RNAi inhibitor protein P19 derived from the tomato bushy 
stunt virus (Voinnet et al., 1999; Scholthof 2006), which inhibits 21 nt long small interfering 
RNAs (siRNAs) (Silhavy et al., 2002; Dunoyer et al., 2004a; Omarov et al., 2006). After 
showing functionality of P19 in our RNAi knockdown cell lines, transposition events were 
quantified. We found that SB mediated transposition events were enhanced up to 4.2-fold in 
our RNAi knockdown cells indicating that transposition is regulated by the RNAi pathway in 
mammalian cells.  
4.1 Materials and Methods 
4.1.1 Plasmid construction 
The plasmids used for the stable transfection of a P19 expression cassette were constructed 
with the gateway technology (Invitrogen). First the p19 expression cassette was PCR 
amplified (without stop codon) with the primer Gp19forwK 
(5´AAAAAGCAGGCTCCGCCATGGAACGAGCTATACAAGGAA-3´) and the reverse primer 
Gp19rev (5´AGAAAGCTGGGTCGCTTTCTTTTTCGAAGGTTTGAG 3´) harboring a Kozak 
sequence for eukaryotic expression. To create homologous regions for recombination, attB 
specific primers were used for the nested PCR (One-for-all-forward: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ and One-for-all-reverse: 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGTC-3’). Using BP clonase the PCR fragment 
was introduced into the attP sites of pDonr207 and in the second LR clonase reaction p19 
was cloned into the destination vector pCR3.1 N-His. All Gateway compatible vectors were 
kindly provided by A. Baiker (Uetz et al., 2006; Vizoso Pinto et al., 2010). These cloning 
steps resulted into the plasmid Kp19, which was used to generate a stable p19 expressing 
cell line under G418 selection pressure (500 µg/ml) using Superfect transfection reagent 
(Qiagen). The p19 encoding retroviral vector p19-MIE, for generation of the stable cell line 
G4 by retroviral transduction, was produced by triple transfection of plasmids providing all 
necessary factors for retrovirus production, the gag-pol proteins as well as the VSV 
glycoprotein (all plasmids were kindly provided by Charles Lecellier (Institut de Génétique 
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Humaine, Montpellier, France) and Olivier Voinnet (Institut de Biologie Moléculaire des 
Plantes, Strasbourg, France)).   
The plasmids for the quantitative Real-Time PCR were constructed as follows. HoxB8 and 
GAPDH were amplified from human genomic DNA from HEK293 cells with the following 
primer, HoxB8forw_PD (5´-TGGAGCTGGAGAAGGAGTTC-3´), HoxB8rev_PD 
(5´-CTCCTCCTGCTCGCATTT-3´), hGAPDHforw (5´-TGCCTCCTGCACCACCAACT-3´) 
and hGAPDHrev (5´-CGCCTGCTTCACCACCTTC-3´) and either cloned into the EcoRI site 
of the the pBS P/P ΔNot vector (Yant et al., 2002; Ehrhardt et al., 2007) or into the 
commercial available pCR-Blunt II-TOPO (Invitrogen) vector, respectively, following the 
manufacturer instructions. Further plasmids used for luciferase assays in Figure 4.1 were a 
kind gift from Olivier Voinnet and Charles Lecellier. 
The plasmids pCMV-SB, pCMV-mSB, and pTnori (Yant et al. 2000) the plasmids pCI-Int, 
pCI-mInt and P7 were described elsewhere (Thorpe and Smith 1998; Ehrhardt et al., 2005). 
The plasmids for Frog Prince transposition, pFV-FP, pFP-4a, pFP-neo, pFP-MCS and 
pT/neo-HS4 were kindly provided by Csaba Miskey and Zoltan Ivics (Max-Delbrück Center, 
Berlin, Germany). For construction of the plasmid pTMCS-IP, pIRESpuro2 (Clontech) was 
digested with XhoI, NruI and NheI and the resulting 2678 bp fragment containing the 
puromycin resistance cassette was introduced into the BglII restriction site of pT-MCS (Yant 
et al., 2000) by blunt end cloning. Moreover, the same 2678 bp fragment was inserted into 
the EcoRI site of pFP-MCS resulting into the plasmid pFP-IP. Finally the attB site was 
isolated from the P7 plasmid by EcoRI restriction enzyme digest and was inserted into the 
BglII site of pIRESpuro2. This resulted into the plasmid pIP-attB. The stuffer plasmid pBS 
P/PΔNot was described elsewhere (Yant et al., 2002; Ehrhardt et al., 2007). Transfection 
efficiencies in RNAi knockdown cell lines were determined using the plasmid pRL-TK 
expressing renilla luciferase (Promega). 
4.1.2 Testing functionality of P19 in mammalian cells by luciferase assays 
HEK293 cells were seeded in 24-well plates (DMEM supplemented with 10% FBS and 1% 
penecillin/streptomycin) and 24 hrs later (confluency of 60-70%) the p19 expression plasmid 
or a plasmid expressing a non-functional version of p19 (p19m) together with the pGL3-
SV40 (Promega) vector or the pGL3-Control plasmid alone, harboring the luciferase 
expression cassette were transfected using lipofectamin 2000 (Invitrogen). The next day the 
GL3 siRNA (5´-CUUACGCUGAGUACUUCGATT-3´,) or an unspecific siRNA (5´-
GAAGUUGGAUCUCUCAGAATT-3´) were transfected using lipofectamin 2000 (Elbashir et 
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al., 2001a). Twenty-four hrs after the latter step, cells were harvested and dual luciferase 
reporter assays were performed (Promega).   
4.1.3 Generation of cell lines stably expressing P19 
HEK293 cells were cultured in DMEM supplemented with 10% FBS and 1% 
penecillin/streptomycin. Stable transfection of HEK293 cells with plasmid Kp19 at 70% 
confluency was performed using Superfect (Qiagen) according to the manufacturer 
instructions. Two days post transfection cells were seeded in 10 cm dishes at two 
concentrations (1x105 and 1x104 cells/dish) and 500 µg/ml medium G418 was added. After 
14 days of selection, single cell clones were picked and amplified under G418 selection 
pressure.  
For the production of the retrovirus harboring the p19 cDNA, the plasmids p19-MIE, the gag-
pol expressing plasmid and the VSV-glycoprotein expressing plasmid were triple transfected 
into HEK293T cells using calcium phosphate transfection following the protocol from 
Promega (ProFection @ mammalian cells, Promega). Two days post transfection cells were 
harvested and filtered through a 0,45 µm filter (Millipore) to remove the remaining cellular 
material. The viral lysate was then supplemented with the same volume of Polybrene 
(Invitrogen), which facilitates cellular entry of the virus. Subsequently a 95% confluent 10 cm 
dish of 293T cells was transduced with the prepared retroviral lysate. Two days post 
infection, cells were sorted by fluorescent activated cell sorting (FACS) and single cell 
clones exhibiting GFP expression were sorted in a 96-well plate. These cell clones were 
amplified. To check cells for GFP expression, several amplified cell clones were tested by 
flow cytometry using FACS-DIVA. In brief, stable GFP expressing cells as well as untreated 
HEK293 cells were harvested, washed once with PBS and centrifuged 3 min at 500 g. The 
cell pellet was then resuspended in PBS containing 0.1% FBS and supplied to the flow 
cytometer. Analysis was performed using FACS Diva software and the percentage of GFP 
positive cells within one population was calculated. 
4.1.4 Western Blot analysis to investigate P19 protein expression 
For Western Blot analysis a 6 cm tissue culture dish of the cell lines stably expressing a His-
tagged version of P19, HEK293 control cells and transfected HEK293 cells with Kp19 were 
collected, washed once with PBS, treated with 300 µl NP-40 lysis buffer (150 mM NaCl, 1% 
NP-40, 50 mM Tris (pH 8.0)) and incubated for 30 min on ice. Protein lysates were 
separated on a 12% SDS-polyacrylamid gel and transferred to a PVDF membrane 
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(Millipore). Detection of P19 was carried out by a peroxidase labeled anti-His antibody 
(Invitrogen) and ECL reaction (Amersham).  
4.1.5 P19 specific reverse transcription PCR to analyse expression from 
retrovirus transduced cells 
The RNA of 3.2x106 cells was isolated using the RNeasy kit (Qiagen) following the 
manufacturer instructions. After determining the RNA amount by measuring the optical 
density, 1 µg RNA was used for reverse transcription using polydT primer supplied in the 
First strand DNA synthesis kit (NEB). As a control, a reaction without the reverse 
transcriptase enzyme was performed to exclude non-integrated plasmids. The generated 
cDNA was then subjected to a PCR reaction with p19 specific primers or for quantification of 
HoxB8 expression with HoxB8 specific primers (for primer sequences see plasmid 
construction section).  
4.1.6 Quantitative Real-Time PCR for quantification of HoxB8 expression levels 
A quantitative Real-Time PCR (qRT-PCR) was performed using 4 µl of cDNA, 0.5 µM primer 
specific for HoxB8 and human GAPDH (see plasmid construction section) and the 
LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche). The PCR reaction was run in 
the Light cycler 2.0 (Roche). For semi-quantitative analysis, the vectors pBSHoxB8 and 
pTopo-GAPDH were diluted and several 10-fold dilutions were used to create a standard 
curve. The fold increase in HoxB8 amount was determined in a semi-quantitative manner.  
*: p-value< 0.05. 
4.1.7 Colony forming assays for quantification of integration events 
For each colony forming assay HEK293 cells and the RNAi knockdown cell lines B6 and G4 
were seeded in 6-well plates. At 60% confluency cells were transfected with a total of 1 µg 
plasmid DNA and 10 µl transfection reagent (Fugene 6, Roche). Experiments were 
performed in triplicates. Two days post transfection cells were split and cells of each 6-well 
were diluted (1:30) into three 10 cm dishes. Selection with either 500 µg/ml G418 or 
600 ng/ml puromycin was started 72 hours post transfection and maintained for 2 weeks. 
The generated colonies were stained with methylene blue and counted. 
The analysis of SB mediated transposition was performed by co-transfecting 50 ng pCMV-
SB or 50 ng pCMV-mSB, 650 ng pBS P/P Δ Not  (stuffer DNA) and either 300 ng pTMCS-IP 
if B6 cells and puromycin selection were used or 300 ng pTnori if G4 cells and G418 
selection were used.  
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Frog Prince mediated transposition events were measured by transfection of 100 ng pFV-FP 
or 100 ng pFV-4a, 275ng pBS P/P Δ Not and either 625 ng pFP-IP in B6 cells or 625 ng 
pFPneo2 in G4 cells.  
Integration events of the PhiC31 integrase were analyzed using 168 ng pCMV-Int or 168 ng 
pCMV-mInt, 682 ng pBS P/P Δ Not and 150 ng pIP-attB for selection in B6 cells or 150 ng 
P7 for selection with G418 in the G4 cell line. 
To calculate the transposition events, the ratio of colony forming units between groups that 
received the functional transposase or integrase and groups that received a non-functional 
protein was determined. The fold increase in transposition or integration events could be 
identified by directly comparing this ratio in HEK293 cells and the RNAi knockdown cell 
lines. Significance of the data could be demonstrated by the p-value.  
Finally, the transfection efficiency was determined in the context of the colony forming assay 
procedure by transfection of 100 ng pRL-TK plasmid instead of 100 ng of the stuffer plasmid 
pBS P/P Δ Not. Two days post transfection one sixth of the cell suspension was used to 
perform luciferase assays using the dual luciferase reporter assay (Promega). 
4.2 Results 
4.2.1 Analysis of the functionality of P19 in mammalian cells 
There is clear evidence that SB transposase derived IRs display convergent transcriptional 
activities in eukaryotic cells (Moldt et al., 2007; Walisko et al., 2008). This inward 
transcription may lead to formation of double-stranded RNA templates for the endogenous 
RNAi machinery. These findings motivated us to investigate whether SB transposase 
mediated somatic integration in mammalian cells is influenced by these miRNAs. To address 
this question our experimental approach was to generate RNAi knockdown mammalian cell 
lines, which can then be used for evaluation of transposase activities.  
To establish RNAi knockdown cell lines we took advantage of the P19 protein, which is 
derived from the tomato bushy stunt virus (Voinnet et al., 1999; Scholthof 2006). It binds and 
inhibits 21 nucleotide (nt) long, small interfering RNAs (siRNAs) and was shown to 
sufficiently suppress RNAi (Silhavy et al., 2002; Dunoyer et al., 2004b; Omarov et al., 2006). 
To check whether P19 is functional in a cell line typically used to study transposition, we 
performed reporter assays in the human embryonic kidney cell line HEK293. In this assay 
the abrogated effect of an established small inhibitor RNA (siRNA) against a reporter directly 
correlates with P19 activity. We transfected a luciferase expressing plasmid together with a 
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P19 expressing plasmid (p19Topo or p19HA) or a mutated and inactive version of P19 
(p19mHA) in HEK293 cells via lipofectamin 2000 (Invitrogen) following the manufacturer 
instruction. Twenty-four hours later we transfected either a previously published siRNA 
against firefly luciferase (GL3) or an irrelevant siRNA also by the use of lipofectamin 2000 
and 48 hours after the first transfection round we performed luciferase assays (Dunoyer et 
al., 2004a). All plasmid constructs used were shown in Figure 4.1A. We found that P19 
could restore the downregulation of firefly luciferase expression to up to 85% (Figure 4.1B, 
bars 4 and 6), whereas the mutated form of P19 (p19mHA) could not (Figure 4.1B, bar 8). 
Furthermore our data revealed, that the HA-tagged P19 molecules were not as sufficient in 
blocking activity of siRNAs as an untagged version of P19 (Figure 4.1B; compare bars 6  
(tagged) and 4 (untagged)). Nevertheless, P19 was effective in suppressing siRNA-
mediated silencing in HEK293 cells 
                        
Figure 4.1: Functionality of P19 in mammalian HEK293 cells. (A) Plasmids used to analyze the 
functionality of P19 in mammalian HEK293 cells. pSV40: promoter of the simian virus-40; p19: p19 
expression cassette; p19m: inactive p19 containing a Arg72 to Glycin exchange; polyA: 
polyadenylation signal of the simian virus-40, HA: hemaglutinin-tag. (B) Luficerase assay to check the 
functionality of p19. Each sample analyzed contains the pGL3-Control plasmid (Promega). In addition, 
for samples displayed in black bars either a non-specific stuffer plamsid, a functional p19 (p19Topo or 
p19HA) or the mutated version of p19 (p19mHA) was transfected together with a non-specific siRNA. 
In the samples referring to the grey bars, however, the GL3 specific siRNA was transfected together 
with the pGL3 alone or with a one of the plasmids displayed in Figure 1A. RLU: relative light units; 
GL3: luciferase specific siRNA; *:p-value > 0.5. 
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4.2.2 Generation and characterization of a stable p19 expressing cell line by 
retrovirus transduction and plasmid transfection 
In order to analyze the effect of RNAi on SB transposition we established RNAi knockdown 
cell lines stably expressing P19. For this purpose we followed two different strategies. In a 
first approach we infected HEK293 cells with a retrovirus expressing P19 as an un-tagged 
version and with a green fluorescent protein (GFP) encoding cDNA (p19-MIE, Figure 4.2A). 
Using an un-tagged version of P19 could be advantageous because the tagged version of 
the P19 protein may be less biologically active compared to an un-tagged version (see also 
Figure 4.1B). Upon retrovirus transduction, single cell clones expressing GFP were isolated 
by fluorescence-activated cell sorting and individual cell clones expressing GFP were 
amplified without selection. By this method we could establish 6 cell clones (G3, G4, G5, G6 
G14 and G16) of which 4 clones (G3, G4, G5, G16) expressed GFP as analyzed by flow 
cytometry (Figure 4.2B and C). Clones G4 and G16 showed highest amount of GFP 
expression and RT-PCR analysis of cDNA generated from the GFP positiv cell lines could 
demonstrate expression of the untagged p19 mRNA (Figure 4.2B and C).  
The second approach was based on stably transfecting the p19 and neomycin resistance 
gene encoding plasmid Kp19 into HEK293 cells (Figure 4.2A, upper panel). After plasmid 
transfection and subsequent G418 selection with 500 µg/ml, 15 single, neomycine resistant 
HEK293-based cell clones were isolated and amplified. To analyze p19 expression, we 
performed Western Blot analysis using a peroxidase labeled anti-His antibody and found 
that cell clone B6 showed highest expression levels of both monomeric and dimeric P19 
(Figure 4.2E) in comparison to two other cell clones (A1 and A2). 
To investigate whether all generated cell lines express a functional P19 protein, we chose 
the HoxB8 gene as a marker. The HoxB8 gene encodes a homeobox protein, a transcription 
factor that is only active during development. In differentiated cells HoxB8 is permanently 
suppressed by the endogenous miRNA miR-196a (Kawasaki and Taira 2004b; personal 
communication, Charles H. Lecellier, Institut de Génétique Humaine, Montpellier, France).  
Thus, if P19 is functional in our generated cell lines, HoxB8 expression should be 
upregulated, which can be measured by quantitative Real-Time PCR. By this approach we 
could show a 3.5 to 8-fold upregulation (p-value <0.05) of HoxB8 in the stable cell clones G4 
and B6, respectively, clearly indicating that P19 is a sufficient inhibitor of the RNAi 
mechanism in this established cell lines (Figure 4.2F).  However, all other clones showed 
only slight or no increase in HoxB8 amount (Figure 4.2F). Therefore, the following studies 
were performed using the RNAi knockdown cell lines B6 and G4.  
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Figure 4.2: Generation and characterization of the RNAi knockdown cell lines. (A) DNA 
sequences used to generate stable p19 expressing cell lines. Kp19 was used for stable plasmid 
transfection of HEK293 cells. The plasmid p19-MIE was used to produce a P19 expressing 
recombinant retrovirus for stable infection of HEK293 cells. K: Kozak sequence;  pCMV: promoter of 
the cytomegalo virus; p19: p19 expression cassette; pRSV: promoter of the rous sarcoma virus; RGS-
His: 6 histidin residues connected to the P19 protein by an arginin-glycin-serin motive; Neo: neomycin 
resistance cassette that mediates G418 resistance; poly A: polyadenylation signal derived from the 
simian virus; GFP: green fluorescent protein expression cassette; LTR: long terminal repeats; IRES: 
internal ribosome entry site. (B) Flow cytometric analysis of cell clones generated by retroviral 
transduction. Single cell clones from cell sorting were amplified and analysed by flow cytometry. Cells 
appearing in quadrant Q2 refer to GFP+ cells. X-axis: Fluoresceinisothiocyanat (FITC) amount; Y-
Axis: SSC : side scatter, to measure cell viability. (C) Quantitative analysis of GFP positive clones 
generated by cell sorting shown in Figure 4.2B. (D) Expression of p19 mRNA in the stable cell lines 
G3, G4, G5 and G16. The generated cDNA was used for PCR amplification with p19 specific primers. 
As positive control the p19 expression cassette from the plasmid Kp19 (+ crl) was amplified. +: 
sample with RT; -: sample without RT; 0: untreated HEK293 cells; M: marker. (E) Detection of P19 
expression by Western Blot analysis in cell lines, which expressed the His-tagged version of the P19 
protein. Monomeric and dimeric P19 molecules were detected using a peroxidase labeled anti-His 
antibody. As a positive control HEK293 cells were transiently transfected with p19 expressing 
plasmids (two left lanes). (F) Functionality of P19. RNA was isolated from HEK293, B6, G3, G4, G5, 
G16 cells and reverse transcribed. The cDNA was used for quantification of the HoxB8 mRNA 
amount by qRT-PCR. Normalization was performed by GAPDH measurement with GAPDH specific 
primers. The fold increase of the HoxB8 amount in the RNAi knockdown cell lines was determined in 
a semi-quantitative manner. *: p-value < 0.05.  
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4.2.3 Influence of the RNA interference pathway on different integration 
machineries 
As a next step we analyzed the influence of the RNAi pathway on transposase and integrase 
mediated transposition events in our RNAi knockdown cell lines. As previously described 
(Ehrhardt, et al. 2005) we performed colony forming assays, which allow for selection and 
quantification of transposition events in eukaryotic cells. Importantly, in this particular 
experimental setup transgene expression most likely correlates with the transposition 
       
Figure 4.3: DNA constructs used in this study. Shown are all DNA constructs, which were used to 
test transfection efficiencies and to analyze the influence of the RNAi pathway on transposition and 
integration in HEK293 cells and the RNAi knockdown cell lines B6 and G4. Colony forming assays 
performed in G4 cells were performed with the respective substrate plasmids encoding neomycin 
(pTnori, pFP-neo2, and P7) and colony forming assays in B6 cells were performed using the 
respective substrate plasmids encoding puromycin (pTMCS-IP, pFP-IP, and pIP-attB). CMV: major 
immediate early promoter/enhancer; IRES: internal ribosome entry side of the encephalomyocarditis 
virus (ECMV); IVS: synthetic intron; Puro: puromycin-N-acetyl-transferase gene mediates puromycin 
resistance; bpolyA: bovine growth hormone A polyA signal; polyA: SV40 polyA signal; Neo: neomycin 
resistance cassette mediating G418 resistance; SV40: promoter of the simian virus.  (A) Plasmids 
used to analyze Sleeping Beauty (SB) mediated transposition in HEK293 cells and the RNAi 
knockdown cell lines B6 and G4. SB: Sleeping Beauty transposase; mSB: mutated version of the 
Sleeping Beauty transposase; IR: Inverted repeats recognized by SB and mSB. (B) Vector constructs 
for Frog Prince mediated transposition. P beta actin: beta actin promoter; FP: Frog Prince 
transposase; IR: Inverted repeats and recognition sites for Frog Prince transposase. (C) Plasmids 
used for PhiC31 integrase mediated integration. PhiC31: PhiC31 integrase; mPhiC31: mutated 
version of the PhiC31 integrase; attB: attachment site B recognized by the PhiC31 integrase. (D) 
Plasmids for determination of the transfection efficiencies in HEK293 cells and the RNAi knockdown 
cell lines. HSV-TK: Herpes simplex virus thymidin kinase promoter; Renilla luc: renilla luciferase 
expression cassette. (E): Plasmid pTneo/HS4 containing insulator sequence in between the IR and 
the neomycin resistance cassette, used in combination with the SB machinery. 
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efficacy. Thus, increased integration events are speculated to be due to improved transgene 
expression in RNAi knockdown cells. All DNA constructs utilized in this study are 
schematically displayed in Figure 4.3. 
Since these colony forming assays are based on plasmid transfection into eukaryotic cells, 
we initially analyzed plasmid transfection efficiencies in our RNAi knockdown cell lines and 
the parental cell line because the knockdown of the RNAi pathway potentially may have 
influenced the uptake of plasmid DNA. Therefore, we co-transfected a reporter plasmid 
expressing renilla luciferase (Figure 4.3D) to determine transfection efficiencies for each 
experiment performed in HEK293 cells, G4 cells and B6 cells,. We found that transfection 
efficiencies varied between the RNAi deficient cell lines B6/G4 and the parental cell line 
HEK293, but the ratios of functional protein (SB, Int, FP) compared to the mutated version 
    
Figure 4.4: Luciferase assay to measure transfection efficiencies. Transfection efficiencies were 
measured as relative light units two days after transfection of plasmids to analyse either Sleeping 
Beauty transposase, Frog Prince transposase or PhiC31 integrase in HEK293 and G4 cells (A,C,E) or 
B6 cells (B,D,F). However, instead of 100 ng stuffer plasmid as used for integration assays, 100 ng of 
the renilla luciferase expressing plasmid pRL-TK were transfected into 6-well plates and 2 days post 
transfection one sixth of the respective volume was prepared to determine relative light units. For 
details please refer to the material and methods section. The amount of relative light units correlates 
with the transfection efficiency. 
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(mSB, mInt, 4a) were similar between the cell lines for each integration system tested 
(Figure 4.4). It is of note to mention that we also considered this in our transposition 
analysis. First we analyzed the transposition rate in the RNAi deficient cell lines and the 
parental cell line HEK293, independently. Therefore, we calculated the ratio of the functional 
transposase/integrase compared to the respective mutated version for each integration 
machinery. Afterwards, these data were used to compare transposition efficiencies in the 
RNAi knockdown cells and HEK293 cells. Importantly, this also takes into account the 
different cell states or alterations in the expression profile of one cell line within one 
experiment. 
To analyze transposition efficiencies of the SB system, we co-transfected the RNAi 
knockdown cell lines G4 and B6 and the parental HEK293 cell line with the respective 
transposon donor vector and either a plasmid encoding wild type SB (pCMV-SB, Figure 
4.3A) or the respective inactive version of the SB transposase (pCMV-mSB, Figure 4.3A) at 
a molar ratio of 1:4 (SB : transposon donor vector). For colony forming assays performed in 
neomycin resistant B6 cells we utilized the transposon donor vector pTMCS-IP with a 
puromycin resistance gene and for the G4 cell line we transfected the transposon donor 
plasmid pTnori (Figure 4.3A) encoding a neomycin resistance gene. After two weeks of 
G418 or puromycin selection the total number of colony forming units was determined. 
Transposition events for both cell lines and conditions (SB or mSB) were quantified by 
counting colony forming units and displayed as the fold increase of SB transposase 
mediated integration events compared to colony forming units in cells which received the 
inactive version of SB (mSB) (number above the bars). The same set up was used to detect 
transposition in the B6 cell line but instead of pTnori the plasmid pTMCS-IP containing a 
puromycin resistence was introduced. As shown in Figures 4.5A and B, a 4.2- and 2.6-fold 
increase in total transposition events in G4 (Figure 4.5A) and B6 cells (Figure 4.5B) in 
comparison to HEK293 cells was observed. To directly compare transposition events in 
HEK293, G4 and B6 cells this fold increase was set to 1 in the parental cell HEK293 and 
then directly compared to the respective ratio in G4 and B6 cells. All experiments regarding 
SB transposition were performed in triplicates and the average results of three independent 
experiments are shown in Figure 4.5G (left panel). We found that in sharp contrast to the 
parental cell line HEK293, SB-mediated integration showed at average an increase of 3.5-
fold in the RNAi knockdown cell line G4 and an enhancement of 2.4-fold in the B6 cell line 
(p-value < 0.05) (Figure 4.5G). These data indicated that SB transposase-mediated 
integration is enhanced in RNAi knockdown cells. Hence, we concluded that the RNAi 
pathway interferes with transposition in mammalian cells. 
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Figure 4.5: Influence of the RNA interference (RNAi) pathway on integration events mediated 
by Sleeping Beauty transposase, Frog Prince transposase and the PhiC31 integrase. (A) -(F) 
Total number of colony forming units after SB transposase mediated integration, Frog Prince 
mediated transposition and PhiC31 mediated integration in HEK293 cells and the RNAi knockdown 
cell lines G4 (A,C,E) or B6 (B,D,E) are shown. The fold increase in transposition events compared to 
the inactive protein is shown in numbers above the respective bars. The fold increase in integration 
events directly comparing the parental cell line HEK293 and the respective RNAi knockdown cell line 
is provided as a framed number. The data comparing the active integration protein with its inactive 
version within one cell line are statistically relevant (p-value < 0.05). (G) Fold increase of 
transposition/integration events of the functional transposase/integrase compared to the mutated 
version of the respective protein were determined for all cell lines and the respective transposase and 
integrase versions. This ratio in HEK293 cells was set to 1 and directly correlated to the fold increase 
in the RNAi knockdown cell lines G4 and B6. All experiments were performed in triplicates and the 
average results of three independent experiments are shown. * p-value < 0.05. 
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Previous studies suggested that the Frog Prince (FP) transposon does not display 
convergent transgene expression indicating that this transposon may not be influenced 
through the RNAi pathway (Moldt et al., 2007). Therefore, we speculated that FP 
transposition could be potentially used as a negative control for transposition without impact 
of the RNAi pathway. FP is a reconstructed transposon from the Northern Leopard Frog 
Rana pipiens displaying high transpositional activity in vertebrate cells (Miskey et al., 2003). 
It was originally recovered by correction of only two mutations and similar to SB it works by a 
cut-and-paste mechanism leading to somatic integration into TA dinucleotides (Miskey et al., 
2003). In concordance to our studies utilizing the SB transposase system, we performed 
colony forming assays with the FP transposase system in our RNAi knockdown cells and the 
parental HEK293 cell line. DNA constructs used for this study are schematically shown in 
Figure 4.3B. The experimental setup was identical to the one used for SB and the total 
number of colonies for all cell lines are shown in Figures 4.5C and D. In Figure 4.5G the 
relative fold increase of FP transposase mediated integration events compared to colony 
forming units in cells which received the inactive version of FP are displayed. As 
hypothesized we could not detect a significant difference in transposition events (up to 1.5-
fold increase in the cell line G4; p-value > 0.05) in the RNAi knockdown cell lines in 
comparison to HEK293 cells after transfection of the FP expressing plasmid and the donor 
plasmids pFP-IP or pFP-neo2 (Figure 4.3B) at a molar ratio of 1:5 (pFV-FP: substrate 
plasmid) (Figure 4.5C and D and 4.5G, middle panel). We concluded that FP transposase 
mediated integration is not influenced by the RNAi machinery. 
To investigate the influence of the RNAi machinery on integration of non-viral vectors in a 
more global manner, we also analyzed whether the integration reaction of the PhiC31 
integrase system is influenced in our RNAi knockdown cells. PhiC31 integrase is derived 
from a bacteriophage (Kuhstoss and Rao 1991; Groth et al., 2000; Groth and Calos 2004) 
and represents an attractive tool for site-directed recombination in mammalian cells (Groth 
et al., 2000). Its integration reaction is based on recombination between the attachment site 
attB within an episomal substrate plasmid and pseudo attP attachment sites (attP’) present 
in the mammalian genome (Thorpe and Smith 1998; Groth et al., 2000; Thyagarajan et al., 
2001). PhiC31 integrase has successfully been applied in numerous preclinical ex vivo and 
in vivo gene therapy studies (Olivares et al., 2002; Ortiz-Urda et al., 2002; Ehrhardt and Kay 
2005; Ehrhardt et al., 2007) PhiC31 integrase methodology represents a platform for genetic 
engineering of eukaryotic genomes and transgenesis (Belteki et al., 2003; Blaas et al., 2007; 
Thyagarajan et al., 2008; Allen and Weeks 2009).  
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In concordance with our transposition studies, we performed colony forming assays to 
quantify PhiC31 integrase mediated integration events in the RNAi knockdown cell lines B6 
and G4 and the parental cell line with a functional RNAi pathway. We co-transfected a 
PhiC31 integrase expressing plasmid together with either the substrate plasmid pIP-attB in 
B6 cells or P7 in G4 cells (Figure 4.3C) at an equal molar ratio. Integration events in the 
respective cell line were expressed either in total numbers (Figures 4.5E and F) or as fold 
increase of colony forming units of the RNAi knockdown cell lines in relation to HEK293 cells 
(Figure 4.5G, right panel). After puromycin selection of transfected B6 cells or neomycin 
selection of the transfected G4 cells, we detected an up to 2-fold and up to 3-fold increase in 
integration events in the RNAi knockdown cell lines B6 and G4, respectively (Figure 4.5G, 
right panel). This finding indicated that PhiC31 may also be controlled by the RNAi 
interference pathways. However, further studies need to address whether convergent 
expression from hybrid attB and attP’ sites (attR and attL) occurs or whether some other 
mechanisms are responsible for the increase in integration events.  
In order to further characterize the effect we detected in our RNAi deficient cell lines, we 
tested the performance of SB mediated transposition from a substrate plasmid, containing 
two insulating sequences shielding the expression cassette from the influence of the IRs. 
The construct containing the insulating sequences used for this experiment were described 
elsewhere (Walisko et al., 2008). Both insulating sequences prevent convergent 
transcription and therefore generation of dsRNA molecules. We hypothesized that the lack 
of trancriptional activity from the IRs would prevent the formation of dsRNA subsequently 
resulting in decreased RNAi-mediated reduction of transgene expression. We performed 
colony-forming assays transfecting the insulator containing plasmid (p/Tneo-HS4) either with 
functional SB or inactive version of SB (mSB) in HEK293 cells and G4 cells using the same 
conditions as described for experiments shown in Figure 4.6. After two weeks of G418 
selection and in sharp contrast to results illustrated in Figure 4.6A, there was no significant 
difference in the ratio between HEK293 cells and the RNAi knockdown cell line G4 as shown 
in Figure 4.6 (framed number), indicating no silencing of the transgene expression cassette 
mediated by the RNAi pathway. In addition this experiment confirmed the notion that the 
transcription of the region between the two IRs is responsible for the observed phenomenon 
and that the RNAi pathway drives downregulation of expression derived from integrated 
transposons. 
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4.3 Discussion 
In conclusion, our results indicate that SB-mediated transposition in human cells could be 
regulated through the RNAi pathway and that an evolutionary conserved self-regulatory 
mechanism for SB-mediated transposition may exist in eukaryotic cells. Components of the 
SB transposon system and the PhiC31 integrase system may either be directly or indirectly 
targeted by microRNAs. A model for the potential molecular mechanism is schematically 
shown in Figure 4.7. Herein, convergent transcription driven by the left and the right IRs 
(Moldt et al., 2007) leads to formation of double-stranded RNAs, which are exported out of 
the nucleus into the cytoplasm (Yi 2003; Zeng and Cullen 2004). In the cytoplasm these 
RNAs may serve as substrates for Dicer, an endonuclease, which cleaves the long dsRNAs 
into 21-23 nt long siRNAs (Hutvagner et al., 2001; Ketting 2001). One strand of these 
siRNAs, the so-called guide strand can then be incorporated into the RNA-induced silencing 
complex (RISC) and direct siRNA mediated silencing of the transgene after somatic 
integration (Hutvagner et al., 2001; Mourelatos 2002; Meister 2004). This hypothesis is also 
supported by other experiments performed in this study. Analysing the Frog Prince 
transposon system, for which no transcriptional activities derived from the IRs were 
demonstrated in the past, transposition efficiencies were similar in the RNAi knockdown cell 
line and the parental cell line HEK293 (Walisko et al., 2008) (Figure 4.4 and 4.5). In 
                       
Figure 4.6: Influence of insulator sequences in HEK293 cells and the RNAi knockdown cell 
lines B6 and G4. The plasmid pT/neo-HS4 was transfected together with either the function Sleeping 
Beauty transposase (SB) or the inactive version of  SB (mSB) in HEK293 or G4 cells. After 2 weeks 
of G418 selection, cells were stained and blue colonies were counted. Total numbers of colonies are 
displayed. The fold increase of SB to mSB is shown above the respective bars and the ratio between 
G4 cells and HEK293 cells is indicated in a black box. Comparing the data from the active SB 
transposase with the inactive mSB protein, within one cell line the results are statistically relevant (p-
value < 0.05). 
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addition, the inhibition of the inward transcriptional activity by insulating sequences (cHS4-
insulator), shielding the transgene cassette from the influence of the IRs (Walisko et al., 
2008), did not show any differences in transposition efficacy in HEK293 cells and G4 cells 
(Figure 4.6). Finally, preliminary results, which were received after quantifying transposon-
derived reporter gene mRNA levels (here puromycin) in HEK293 and B6 cells upon 
transposition indicated that transgene expression levels were significantly increased in B6 
cells in comparison to HEK293 cells 10 days post transfection (data not presented). Thus, 
the obtained results confirm the assumption that transgene expression and not for instance 
increased transposase activities or levels contribute to the enhanced transposition efficacies.  
Interestingly, although the inhibition of the RNAi pathway seems to be more pronounced in 
B6 cells compared to the G4 cells as indicated by the quantification of the HoxB8 expression 
levels (Figure 4.2F), we could not detect the same trend in the colony forming assays 
analyzing transposition events and PhiC31 mediated somatic integration. However, it is 
important to point out that different plasmid constructs were used to quantify transposition 
events in the G4 and B6 cells (Figure 4.3). All substrate plasmids used for colony forming 
      
Figure 4.7: Model for the influence of the RNAi pathway on Sleeping Beauty mediated 
transposition. Convergent transcription driven by the left and the right inverted repeats (IRs) leads to 
formation of double-stranded RNA (dsRNA). These dsRNAs are exported out of the nucleus and in 
the cytoplasm they serve as substrates for DICER. This endonuclease cleaves the long dsRNA into 
21-23nt long small interfering RNAs (siRNAs). One strand, the so-called guide strand can then be 
incorporated into the RNA induced silencing complex (RISC) and direct siRNA mediated silencing. 
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assays in B6 cells containing the puromycin expression cassette also harbour an intron as 
well as an IRES sequence (Figure 4.3). Since the transcriptional activity of the ITRs is quite 
low (Moldt et al., 2007), these components may function as insulators or they may interfere 
with the convergent transcription levels from the IRs after somatic integration. Subsequently, 
only a small amount of dsRNA can be formed, which in turn may reduce the effect of the 
P19 protein in B6 cells.  
Furthermore, when analyzing SB transposition in G4 cells in comparison to the parental cell 
line HEK293, total transposition events are comparable or even lower in the case of FP or 
PhiC31 integration processes, respectively (Figure 4.5). This discrepancy could be simply 
due to reduced transfection efficiencies or altered transgene expression levels in the 
different cell lines. However, to take this difference into account, the ratio of the transposition 
activities of the functional protein to the inactive version of the protein was calculated within 
one cell line. These data were then used to directly compare transposition efficiencies in the 
RNAi deficient cell lines and the parental cell line HEK293. 
To further elucidate the molecular mechanism responsible for the influence of the 
endogenous RNAi machinery on transposition, future studies need to address which 
sequences of the integrated transposon are processed by the components of the cellular 
RNAi pathway. Pull-down assays for identification of transposon-derived sequences bound 
to the P19 protein in B6 cells or argonaute in normal cells may partially solve this question. 
Furthermore, it has to be clarified, which RNAi-mediated mechanism is responsible for gene 
silencing. If it is due to mRNA degradation, translational inhibition or if silencing is based on 
RNA-directed DNA methylation (Kawasaki and Taira 2004a). The latter mechanism is 
supported by a publication from 2007, where Garrison et al. could revert the silencing effect 
upon transposition by administration of a methyltransferase inhibitor (Garrison et al., 2007). 
Notably, in the present study we analyzed the commonly used two-component vector 
system for SB-mediated integration and observed an up to 4.2-fold increase in transposition 
events (Figure 4.5A). However, effects may be increased when using the wild type SB 
transposase IRs with a 160 bp region between the left IR and the transposase translational 
start site with unknown function. This unknown region was recently shown to enhance 
transcriptional activities from the left IR (Walisko et al., 2008), which in turn may lead to an 
increased amount of dsRNA and therefore, potentially a more pronounced silencing effect.  
In conclusion, we believe that our findings may have important implementations for the 
design of improved non-viral vectors for somatic integration. Furthermore, the established 
RNAi knockdown cell lines G4 and B6 can also be explored to study not only non-viral 
vectors and their regulation by the RNAi machinery, but also the influence of RNAi on viral 
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vectors or viruses in general can be investigated. For instance herpesviruses and 
adenoviruses, which were shown to express siRNAs could be interesting candidates to 
address these questions (Pfeffer 2004; Andersson et al., 2005; Aparicio et al., 2006; Skalsky 
and Cullen 2010). Last but not least our experimental approach based on expression of P19 
may also be applied to study the interference of the RNAi pathway with viral or non-viral 
systems in vivo in a tissue specific manner. P19 could be expressed from a viral vector 
under the control of a tissue specific promoter, which may lead to tissue specific block of 
21 nt long small interfering RNAs and therefore also inhibition of RNAi pathway. 
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5 Adenovirus 5 replication is enhanced by RNAi 
knockdown 
The understanding of basic virus host interactions is a key pre-condition to develop and 
improve viral vector systems for gene therapy. Within a virus life cycle several gene products 
can be modulated by host cell factors or mechanisms such as the RNA interference pathway 
that subsequently influence productive virus replication.  
The RNA interference (RNAi) pathway is a well-conserved mechanism, which results in the 
post-transcriptional silencing of a target gene. Key players within the RNAi pathway are ≈ 22 
nucleotid (nt) long, non-coding, double-strand RNA (dsRNA) molecules, the so-called micro 
RNAs (miRNAs). It is estimated that approximatly 75 % of all miRNA sequences are located 
within non-coding regions or intron sequences of genes (Lagos-Quintana 2001; Cai 2004; 
Lee et al., 2004). In most cases the transcription is mediated by the RNA polymerase II, 
generating a 160 nt long primary miRNA, which is processed inside the nucleus by the 
RNaseIII enzyme Drosha and the RNA-binding protein DGCR8 (DiGeorge critical region-8) 
into 60 nt long, imperfectly pairing stem loop precursors, the pre-miRNAs (Pasquinelli and 
Ruvkun 2002; Lee et al., 2004; Zeng and Cullen 2004; Zeng and Cullen 2005). By the 
energy-dependent Exportin5 pathway these molecules are transported into the cytoplasm, 
where further processing by Dicer renders mature ds-miRNAs with 21-23 nt in length (Yi 
2003; Zeng and Cullen 2004). Afterwards one strand, the guide strand, is incorporated into 
the RNA induced silencing complex (RISC), which is composed of an argonaute protein, 
Dicer and TRBP (the human immunodeficiency virus transactivating response RNA-binding 
protein) of which only the argonaute protein covers the silencing function (Yi 2003; Meister 
2004; Zeng and Cullen 2004). The single-stranded miRNA (ss-miRNA) then guides the 
RISC complex to the target mRNA. Finally, the interaction between the miRNA and the 
mRNA leads to mRNA degradation if there is 100% complementary between both 
molecules, otherwise and more likely in mammalian cells the interaction leads to a inhibition 
of translation and subsequently the downregulation of the protein level. Within the latter 
case, seed nucleotides 2-8 are crucial as they determine the contact to the target sequence 
(Chiu and Rana 2003; Haley and Zamore 2004).  
During the past decade it became clear that the RNAi pathway is conserved throughout 
many organisms including viruses. The target mRNAs of the viral miRNAs and in 
consequence their biological functions are largely unknown but it is assumed that two main 
mechanisms are affected (Cullen 2010). On the one hand viral miRNAs inhibit cellular 
immune responses as it is shown for the polyomavirus SV40, which expresses a miRNA that 
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targets the large T-antigen and therefore reduces the cellular cytotoxic T-lymphocyte 
response (Sullivan et al., 2005). On the other hand viral miRNAs seem to play a critical role 
in establishment and maintenance of latency, a mechanism predominantly important for 
herpes viruses, for which a large number of miRNAs have been identifed so far (Skalsky and 
Cullen 2010).   
But also cellular miRNAs were shown to play a role in virus replication as Lecellier et al. 
demonstrated in 2005 when they identified the cellular miRNA miR32 as inhibitor of the 
replication of the primate foamy virus, based on experiments in an RNAi knockdown cell line 
(Lecellier et al., 2005). Additionally, this and other viruses evolved RNAi suppressor proteins 
such as the primate foamy virus protein Tas, the human immunodeficiency virus Tat protein, 
or the adenovirus VA-RNAs to prevent degradation of its own RNAs (Andersson et al., 2005; 
Bennasser et al., 2005; Haasnoot et al., 2007).  
Adenoviruses (Ad) are non-enveloped viruses, which contain ds-DNA genome of 36 kb in 
length. The viral life cycle starts with the interaction of the Ad fiber protein with the cellular 
coxsackie and adenovirus receptor (CAR), whereas binding of penton to two members of the 
integrin family facilitates uptake of the virus. After internalization and escape from the 
endosome, the Ad is transported to the nuclear membrane, where the viral DNA is inserted 
into the nucleus through the nuclear pore complexes. Inside the nucleus the viral DNA exists 
as monomeric, episomal DNA (Jager and Ehrhardt 2009) and transcription of regulatory and 
structural viral proteins is performed in a time dependent manner. The entire life cycle takes 
about 24 hours and subsequently ends in lysis of the cell (Curiel and Douglas 2002).    
Besides the coding regions spread on both strands of the adenoviral genome, two non-
coding products, the virus-associated RNAs I and II (VAI-RNA and VAII-RNA) are 
transcribed, which are known RNAi inhibitors (Lu and Cullen 2004). VA-RNAs are 160 
nucleotide long panhandle structured products transcribed by the RNA polymerase III 
(Thimmappaya 1982; Liao et al., 1998). During a normal replication cycle about 108 VA-
RNAs are produced and transported to the cytoplasm across the Exportin5/RanGTP 
pathway. Besides blockade of the RNAi pathway, another well established function of VAI-
RNA is the blockade of the protein kinase R (PKR), an interferon-inducible serin threonin 
protein kinase that is activated by foreing dsRNA molecules and initiates apoptosis and 
release of cytokines as antiviral response (O’Malley 1986; Akusjarvi et al., 1987).   
However, the VA-RNAs also target several parts within the RNAi pathway. After 
transcription, VA-RNAs share the export machinery with endogenous miRNAs and mRNAs, 
which leads to a competitive inhibition of the cellular counterpart (Andersson et al., 2005). 
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Furthermore Lu and colleagues showed that VA-RNAs bind to cytoplasmatic RNase III 
enzyme Dicer and the group of Aparicio discoverd that VA-RNAs can be cleaved by Dicer 
into 19-29 nucleotide long small-virus associated RNAs (svaRNAs) (Lu and Cullen 2004; 
Aparicio et al., 2006; Sano et al., 2006). These sva-RNAs were functional as they were able 
to enter the RISC complex and to inhibit expression of complementary reporter genes 
(Aparicio et al., 2006; Sano et al., 2006). In the beginning the naturural function of these 
svaRNAs remained unknown, since no cellular or viral target sequences could be identified. 
The inhibition of sva-RNAs by antagomir RNAs, however, revealed a severe attenuation of 
productive virus replication (Aparicio et al., 2006). Very recently Aparicio et al. identified the 
TIA-1 protein as possible target of the sva-RNAs, a protein that is responsible for apoptosis 
induction (Aparicio et al., 2010). In addition to these findings, it is hypothysized that in the 
early replication phase sva-RNAs were produced, which regulate cellular or viral target 
proteins and in later phases of infection VA-RNAs block the RNAi pathway in order to 
prevent silencing of own viral proteins.  
In this study we aimed at investigating for the first time the influence of the RNAi pathway on 
the adenovirus life cycle in a more global manner and to apply the gained knowledge to 
improve adenovirus vector production systems. Therefore, we used our previously described 
RNAi knockdown cell line B6, expressing the RNAi suppressor protein P19, to analyze 
replication of wtAd5 (compare section 3.2.1). We found that adenovirus replicates up to 10-
fold faster in an RNAi knockdown cell line, and up to 100-fold faster if an RNAi suppressor 
protein is expressed from an adenoviral genome, which generates 10-fold higher titers. This 
upregulation could be due to the higher expression of regulatory viral proteins such as E1B, 
DBP or the E4Orf6 proteins. Furthermore, we could demonstrate that sva-RNAs are bound 
to the dimeric P19 protein and that they were degraded after binding. Finally, we took 
advantage of our results to improve HC-AdV vector production by application of our novel 
established P19 system enhancing helper-adenovirus replication. 
5.1 Materials and Methods 
5.1.1 Plasmid constructs 
The TopohB2m plasmid was kindly provided by Wenli Zhang (Max von Pettenkofer-Institut, 
Munich, Germany) and contains the hB2m expression cassette for normalization of B2m in 
quantitative Real-Time PCR (qRT-PCR). Standard curves for all adenoviral proteins were 
performed using DNA purified from wtAd5 viral particles.  
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The pCR2.1 BluntII-Topo based plasmid pFIPP is the main vector for BAC cloning 
containing the spacer, IRES, p19 and the poly A signal with the flanking homologous 
sequences to the adenovirus genome. The plasmid construct pNEB.PK.fiberIL supplied by 
Dirk Nettelbeck (German Cancer Research Center, Heidelberg, Germany), was basically 
used as main template for several overlapping PCR steps to generate the pFIPP construct. 
Primer sets were designed with 15-20 nt long overhangs if overlapping PCR products had to 
be generated. KOD Polymerase (Merck) was used for each step following the manufacturer 
instruction if not otherwise stated and primers are shown in Table 5.1. In detail to generate 
the 3´overlapping sequence to the adenovirus primer and the spacer together with the IRES 
sequence, first pNEB.PK.fiberIL was inserted into a PCR reaction with the primer set “5´fiber 
forw“ and “IRES p19 rev“ using an annealing temperature of 56°C and an elongation time of 
40 seconds (sec.). Secondly, to generate the fragment containing the p19 expression 
cassette and the poly A signal a KOD based PCR reaction with the primer pair “IRES-p19 
forw“ and the “polyA-3´fiber rev“ using the pZacp19 plasmid was used. For pZacP19 the p19 
expression cassette was introduced by direct cloning of the PCR product into the XhoI and 
XbaI sites of the pZac expression vector. The latter PCR product was generated with the 
primer set “p19forw Xho“ and “p19rev Xba“. The PCR for the p19-polyA fragment was 
performed using an annealing temperature of 57°C and an elongation time of 40 sec. 
running for 35 cylces. Afterwards the 3´fiber fragment containing also homologous 
sequences to the adenovirus genome downstream of the fiber was generated with the 
primer “3´fiber-polyA forw” and “3´fiber rev” using the pNEB.PK.fiberIL as template and 
running 30 cycles with an annealing temperature of 56°C and 30 sec elongation time. The 
last two PCR products were purified by gel column purification (Promega) and subjected to a 
new PCR reaction with the outer primer “p19-IRES forw“ and “3´fiber rev“ using a two- fold 
excess of the long p19 polyA fragment. Conditions for this PCR were as follows: the primer 
annealing temperature was set to 56°C for 10 sec. and an elongation time of 30 seconds 
starting with 16 cycles without adding primer. After these cycles, 1.5 µl of each primer was 
added to the reaction followed by another 35 cycles under the same conditions. The gel 
fragment containing the PCR product was purified and cloned into the pCR-BluntII-TOPO 
vector following the manufacturer instructions resulting in the plasmid pTopop19big. At least, 
a PCR reaction of the PTopop19big plasmid was performed under the same conditions as 
before and the purified PCR product was inserted as a template into a PCR reaction 
together with the product of the first PCR containing the 5´fiber-spacer-IRES construct. For 
this reaction 12.5 µl of each purified product, an annealing temperature of 56°C, an 
elongation time of 50 sec and the primer “5´fiber forw“ and “3´polyA rev“ were used. All 
primer sequences used during these steps are displayed in Table 5.1A. The fragment was 
then gel purified and Topo cloned into the pCR-BluntII-Topo vector following the 
5 Adenovirus 5 replication is enhanced by RNAi knockdown 
 
 
78 
manufacturer instructions, resulting in pFIPP. The right construct was confirmed by 
restriction enzyme digest using EcoRI and sequencing.  
The Fiber-IRES-p19 construct within the pFIPP vector was incorporated into the genome of 
a first-generation adenoviral vector utilizing bacterial artificial chromosome (BAC) cloning 
methods as described elsewhere (Warming et al., 2005). In brief, the galactokinase-
kanamycin (galK-Kan) construct was amplified in two subsequent PCRs using the primer 
pair IRES-p19_IC_5 and IRES-p19_IC_3 and the primers IRES-p19_IC_5_ne and IRES-
p19_IC_3_ne. The purified PCR product from the second PCR step was then transformed 
into SW102 E.coli containing BAC pB-FG (kindly provided by Zsolt Ruzsics, Max von 
Pettenkofer-Institute, Munich, Germany). After induction of homologous recombination and 
selection for kanamycin the intermediate clone pB-FG-fib-GK was isolated, which contains 
the the galK-Kan construct incorporated at the 3’ end of the fiber encoding sequence. 
Subsequently, the construct IRES-p19 was PCR-amplified utilizing pFIPP as template and 
the primers IRES-p19_IC_5_ne and IRES-p19_IC_3_ne. After PCR amplification the 
generated product was purified and transformed into SW102 cells containing the 
intermediate BAC pB-FG-fib-GK. Final clone Bfgp19 was isolated after recombination and 
selection against galK. 
Generation of the helper-virus BAC containing the p19 encoding sequence coupled to the 
fiber gene (BHVp19) was performed analog to method described in Hausl et al., in 
preparation. Briefly, a construct containing a zeocin resistance cassette and the 5’ end of the 
helper-virus AdNG163R-2 (Ng et al., 2002) was PCR-amplified in two steps using the 
plasmid T-PacI-5’Hv-ΔKan as template for the first PCR and the primer pair Ng-Hv_Adv-
pIX_3611 and wt/Hv-BAC-Zeo and the primers Ng-Hv_Adv-pIX_3611 wt/Hv-BAC-nested for 
the second PCR, respectively. The purified product was then transformed into SW102 
bacteria containing the BAC Bfgp19. After induction of recombination and zeocin selection 
the BAC BHVp19 was isolated. Replication-competent adenovirus BAC with the p19 
expression cassette (Bwtp19∆E3) was constructed analog but using plasmid T-PacI-
5’wtAd5-ΔKan as PCR template. This plasmid contains the 5’ end of the wild-type 
adenovirus 5 genome, which was generated analog to T-PacI-5’Hv-ΔKan but using isolated 
DNA from wild-type adenovirus 5 virus particles (Hausl et al., in preparation). Construction of 
negative controls pB-Hv and pB-wtAd5 were described elsewhere (Hausl et al., in 
preparation).  
All PCRs were performed with high-fidelity KOD Hot Start DNA Polymerase (Novagen) with 
95°C denaturation for 20 seconds, 60°C annealing temperature for 20 seconds and an 
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elongation of for 25 sec/kb at 70°C using 35 cycles. Primers used for generation of the BAC 
derived viruses are displayed in Table 5.1B. 
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5.1.2 Cell lines and viruses 
Human embryonal kidney cells (HEK293) were obtained from ATCC and used for 
construction of the p19 expressing cell line B6 described in section 4.2.2. A549 cells were 
supplied by Carsten Rudolph (Ludwig-Maximilians-University Munich, Munich, Germany). 
The 116 cell line used for high-capacity adenovirus production was obtained from Philip Ng 
(Baylor College, Houston, Texas, USA). HEK293, A549 and B6 cell lines were cultured in 
DMEM medium, 116 cells in MEM, both supplemented with 10% FBS and 1% penicillin-
streptomycin (P/S). As selection pressure for B6 cells 100 ng/ml G418 were added. Huh7 
cells were cultured in DMEM supplemented with 1% non-essential amino acids, 10% FBS 
and 1% P/S. All cell lines were cultured at 37°C in a humidity atmosphere with 5%CO2. The 
entire cell culture reagents were obtained from PAA.  
Wildtype adenovirus 5 (Ad5) was obtained from ATCC, the adenovirus vector FG-Adluc was 
described in section 2.2.6. Wildtype adenovirus, first-generation adenoviruses and most 
bacterial artificial chromosome- (BAC-) based viruses (except AdfiberIL and dl705) were 
amplified in HEK293 cells. The VAII-deleted virus dl705 obtained from Göran Akjusjärvi 
(Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden) and 
the AdΔfiberIL provided by Dirk Nettelbeck (German Cancer Research Center, Heidelberg, 
Germany) were amplified in A549 cells and described previously (Akusjarvi et al., 1987; 
Rivera et al., 2004). AdNG163R-2 was kindly provided by Philip Ng and the HC-AdV luc was 
generated by Lorenz Jager (Max von Pettenkofer-Institute, Munich, Germany) expressing 
luciferase under the control of the liver-specific human α1-antitrypsin promoter (hAAT). The 
first generation adenovirus fgAdluc was described in section 2.1.2. 
 For BHVp19 and Bwtp19ΔE3 virus reconstitution, 20 µg of the BAC vector was linearized 
by a PmeI digest and purified by phenol/ chlorophorm/ isoamylalcohol (25/24/1, Roth) 
extraction following a ethanol precipitation. The complete digest was then used for FuGene6 
(Roche) transfection following the manufacturer instructions using 15 µl of FuGene 6 
reagent for transfection of HEK293 cells (kindly provided by Zsolt Ruszicz, Max von 
Pettenkofer-Institute, Munich, Germany) at 40% confluency. Medium was changed every 5 
days, until cytopathic effect (CPE) appeared. Whole cellular lysates were then harvested 
and virus was released from the cells by four consecutive freeze/thaw cycles. Afterwards, a 
95% confluent 6 cm dish with HEK293 cell was infected using 2/3 of the lysate and 2 hours 
later the medium was aspirated and cells were overlayed with a 1:1 mixture of 1% 
autoclaved agarose (diluted in H2O; Peqlab) and 2x DMEM (Invitrogen) supplemented with 
20% FBS and 2% penicillin-streptomycin. The overlay was performed every 3 days (with 0.5 
ml) until viral plaques were obtained. Single plaques were picked and stored in 500 µl of 
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culture medium. After the release of the virus from the cells a 24-well dish of HEK293 cells 
was infected with 400 µl of the lysate. Approximately two days later CPE starts, the cells 
were harvested and one half was subjected to DNA isolation and PCR analysis to confirm 
the correct viral construct. The other half was used to amplify the virus in 12 cm, 6 cm and 
10 cm tissue culture dishes and subsequently in 15 cm dishes of HEK293. Twenty 15 cm 
tissue culture dishes were sufficient for purification. 
Purification of all viruses used within this study was performed by double cesium chloride 
gradient ultra –centrifugation followed by an over-night dialysis step. The whole procedure of 
purification is described in section 2.2.4.  
Titration of viruses was performed by agarose overlay as shown in Curiel and Douglas 
(Curiel and Douglas 2002). In brief, 100% confluent HEK293 cells were infected with serial 
dilutions of virus stocks. Two hours post infection medium was aspirated and cells were 
supplemented with 2.5 ml of a 1:1 dilution of 1% autoclaved agarose (Peqlab) and 2x DMEM 
(see above). The overlay was then performed every 3 days with 0.5 ml of the mixture. After 
approximately 10 days plaques obtained, which were counted and the titer determined.  
5.1.3 Analysis of CAR expression of HEK293 and B6 cells 
HEK293 and B6 cells were counted and 1*106 cells were washed once with PBS 
supplemented with 1% BSA (PBS/BSA). After centrifugation of the cells at 500 g for 3 min 
they were resuspended in 100 µl PBS/BSA and 5 µl CAR antibody (Santa Cruz Biolaps) 
were added following an incubation step at 4°C for 1 hour. As controls each cell line was 
also incubated without supplementation of the primary antibody. Afterwards the cells were 
washed again with PBS/BSA, to remove unbound antibodies and resuspended in 100 µl 
PBS/BSA. To detect CAR expression using flow cytometry, 1 µl of an APC labeled anti-
mouse secondary antibody (kindly provided by A. Baiker, Max von Pettenkofer-Institute, 
Munich, Germany) was supplied to the mixture and incubated for 1.5 hours at 4°C with 
continous shaking. Cells were again washed with PBS/BSA and finally resuspended in 
400 µl PBS for flow cytometry using FACS DIVA (BD). 
5.1.4 Isolation of wtAd DNA from purified particles 
To isolate adenovirus DNA, 100 µl of purified virus stock was incubated with the same 
volume lysis buffer (10 mM Tris (pH 7.4), 10 mM EDTA, 0.5% SDS, 2 mg/ml Proteinase K) 
for four hours at 37°C. The DNA was then purified by adding 180 µl of phenol/ chlorophorm/ 
isoamylalcohol (25/24/1). After centrifugation for 2 min at 15.000 g the upper phase was 
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collected and DNA was precipitated using 60 µl of 3 M sodium acetat (pH 5) and 600 µl of 
100% ethanol followed by a centrifugation step at 15.000 g for 10 min. Afterwards the DNA 
pellet was washed with 500 µl 70% ethanol and centrifuged for 5 min at 15.000 g. The pellet 
was dried and the DNA resuspended in 40 µl sterile H2O. 
5.1.5 Analysis of adenovirus replication in HEK293 and B6 cells 
Either HEK293 and B6 or only HEK293 cells were seeded into 6 cm dishes to reach 80% 
confluency for infection. Notably, for infection B6 cells were cultivated without G418. 
Infection with wtAd5, FgAdluc (see also section 2.1.2) or BAC derived viruses were 
performed using a multiplicity of infection (MOI) of 0.05, 0.1 or 3 respectively. After two 
hours (hrs), 10 hrs, 24 hrs and 48 hrs DNA and RNA were isolated and cellular and protein 
lysates were collected, taking 3 independent samples at each time point. To ensure, that 
only internalized viral particles were analyzed, cells were treated with 5 % trypsin for 5 min, 
centrifugated at 500 g for 3 min and washed once with sterile PBS before preparing for 
different applications. 
5.1.6 RNA isolation and reverse transcription 
Cells of one 6 cm dish were resuspended in 500 µl TRIZOL (Invitrogen) reagent, 
homogenized with a 21-gauge needle and RNA was isolated following the manufacturer 
instruction. RNA was resuspended in 40 µl of RNA-H2O and 4 µl were used for cDNA 
synthesis. Reverse transcription was performed using the cDNA synthesis kit from NEB 
following the manufacturer instruction (ProtoScript®First strand cDNA synthesis kit). For 
quantitative Real-Time PCR (qRT-PCR) 4 µl of the cDNA were used. 
5.1.7 DNA isolation for analysing viral genome copy numbers 
The cell pellet of one 6 cm dish or a 24-well was used to isolate whole genomic DNA, a 
method described elsewhere (Sambrook 2001). DNA amounts were quantified by measuring 
the optical density (OD) at 260 nm. For qRT-PCR, genomic DNA was diluted to 10 ng/µl and 
5 µl were applied for qRT-PCR. Normal taq-polymerase (NEB) based PCR was performed 
with 100 ng of genomic DNA following the manufacturer instructions. 
5.1.8 Quantitative Real-Time PCR (qRT-PCR) 
Quantitative RT-PCR was performed using the Taq-man system (Applied Biosystems) and 
FastStart Universal SYBR Green Master (Roche) reagent following the manufacturer 
instruction. For qRT-PCR of genomic DNA, 50 ng of genomic DNA was used, for cDNA 
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analysis 5 µl of a reverse transcription was subjected to the reaction. Oligonucleotides were 
either designed with the Primer3 design program (Krawetz S, Misener S (eds) Bioinformatics 
Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365-
386) using a maximum template size of 150 bp or in case of human Beta-2 microglobulin 
(hB2m) a previous published primer pair was used (Vandesompele et al., 2002). Table 5.1C 
shows all oligonucleotides, which were used for qRT-PCR. Each sample was normalized to 
either genomic B2m level (10 000 cells) or expression level of 10 000 RNA molecules of 
hB2m. Quantification was performed by calculating known hB2m levels from the plasmid 
pTopohB2m by the following term:  
1 pg plasmid = 10-12 / plasmid size (bp) * 6.02*1023 copies 
5.1.9 Western Blot analysis of adenoviral proteins 
Protein lysates were generated from 3.2*106 cells using 300 µl of NP-40 lysis buffer (50mM 
Tris-HCL pH 8.0, 150mM NaCl, 1% NP-40, storage at -20°C) supplemented with proteinase 
inhibitors without EDTA (Roche) following a 30 min incubation step on ice. To determine 
protein amounts, the Bradford test was applied following the manufacturer instructions 
(Roth). Equal protein amounts were separated on a 10% SDS polyacrylamid gel using a 
BioRad sytem. Afterwards proteins were blotted on a methanol treated PVDF membrane 
and incubated o/n in TBS buffer (10 mM Tris (pH 7.5), 150 mM NaCl) supplemented with 5% 
milk powder (Roth) at 4°C. After three washing steps with TBST (TBS + 0.01 % Tween20 
(Roth)) blots were incubated with either first anti-adenovirus antibodies against DBP (1:250, 
mouse derived), E1B55K (1:1000; mouse derived), both supplied by Matthew Weitzman 
(Salk Insitute, San Diego, USA), E4Orf6 (1:10 anti mouse) obtained from Thomas Dobner 
(Heinrich-Pette-Insitut, Hamburg, Germany), Fiber (1:10 000 mouse derived; NeoMarkers), 
Hexon (1:1000 rabbit, Abcam) or GAPDH (1:1000, anti goat, R&D systems) as control for 1 
hour at room temperature. This step was followed by another 3 washing steps with TBST 
and incubation with secondary peroxidase (POX) labeled antibodies specific to the first 
antibody. All secondary antibodies were obtained from Invitrogen. Finally, blots were washed 
3 times with TBST and POX was activated by adding ECL reagent (GE Healthcare).  
5.1.10 Isolation of small RNAs bound to P19 after His-tag purification 
To investigate, if sva-RNAs from VAI-or VAII-RNA origin bind to P19, the His-tagged protein 
was purified from five 15 cm tissue culture dishes of B6 cells under native conditions after 
wtAd5 infection at an MOI of 3. Purification under native conditions was performed with 
magnetic beats (Qiagen) following the manufacturer instruction. For the destruction of the 
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cells, the lysate was either subjected to 3 consecutive freeze/thaw cycles or cells were 
sonificated at level 2 for 5 times on ice using a Branson 450 sonificator (Calabrese and 
Sharp 2006). For the isolation of siRNAs bound to P19 two methods were used. On the one 
hand Qiazol reagent (Qiagen) was supplied to the protein solution and standard RNA 
isolation was performed (see above). On the other hand protein lysates were incubated for 
15 min with 2 x Proteinkinase K solution (200 mM Tris-Cl pH 7.4, 25 mM EDTA, 300 mM 
NaCl, 2% SDS, 2 mg/ml Proteinase K) and small RNAs were isolated by isopropanol 
precipitation over night at -20°C . Small RNA preparations were resuspended in 30 µl RNase 
free H2O.   
The purified small RNAs were polyadenylated using the polyAAA-tailing kit from Ambion. 
Reverse transcription was performed with polydT primer with an adaptor followed by a 
standard KOD (Novagen) based PCR with the reverse primer (Table 5.1D) 3´Van-r or the 
5´VAII primer (Table 5.1E). The PCR products were either purified by gel extratction 
(Promega) and send for sequencing or they were subcloned in the pCR-Blunt II-Topo 
(Invitrogen) vector following the manufacturer instructions and send for sequencing 
(Eurofins, MWG).   
5.1.11 Isolation of small RNAs and Northern Blot analysis 
To confirm the VAII-RNA deletion in the mutant virus dl705, HEK293 cells were infected at 
an MOI of 3 with dl705 or wtAd5 and small RNA was isolated 2 days post transfection 
following a protocol obtained from Rebecca Schwab (University of Tuebingen, Tuebingen, 
Germany). In brief, cells were treated with Trizol reagent and cell lysates were homogenized 
using a 21-gauge needle. Afterwards, one third volume of chlorophorm was added and cells 
were centrifuged for 10 min at 5000 g at 4 °C. The upper phase was harvested and 
subjected to another phenol purification step using the same conditions as described before. 
Again the upper phase was collected and 1 volume of isopropanol was added to precipitate 
RNAs overnight at -20°C. The next day, RNA solution was precipitated by centrifugation for 
30 min at 5000 g at 4°C and the RNA pellet was washed with 70% EtOH. After 
centrifugation the cell pellet was air-dried and resuspended in 40 µl of RNase-free water. 
Isolated RNAs were then separated on a 17% vertical polyacrylamid gel containing 7 M urea 
in 0.05x tris-borate-ethylenediaminetetracetic (TBE) buffer. As a positiv control for Northern 
Blot analysis also representing the length marker, we ran the reverse oligonucleotide of 
3´Van (3´Van-r) or VAII-RNA (3´VanII and 3´VanII-r) oligonucleotide probe also published by 
Aparicio et al. (Table 5.1E) (Aparicio et al., 2006). We performed a semi-dry transfer in 0.5x 
TBE onto a Hybond-N+ membrane (GE Healthcare) and detected the VAI-RNA and VAII-
RNA, or sva-RNAs by radioactive end labelling of the oligonucleotides with gamma-P32 
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(Quick spin columns, Roche) and incubation in Denhardt´s solution at 50°C for 1 hour. Blots 
were washed twice for 10 min with 5x SSC/0.1% SDS and once for 10 min with 1 x SSC/ 
0.1% SDS at 50°C. Afterwards blots were exposed to phospho-imager plates for 10 min and 
anaylsed in a phospho imager. The same procedure and oligonucleotides were used to track 
the fate of svaRNAs of VAI-RNA and VAII-RNA origin in the P19 expressing cell line B6.  
5.1.12 Comparison of packaging efficiencies of standard helper virus and BHVp19 
To compare the packaging efficiency of our new generated helper virus BHVp19 to the 
standard helper virus AdNG163R-2 (Ng et al., 2001), 116 cells were seeded in two 15 cm 
dishes and grown to a confluency of 90%. The next day each dish was infected at an MOI of 
10 with HC-AdV luc and co-infected either with BHVp19 or AdNG163R-2 at an MOI of 2. 
Two days post infection cells were harvested, viral particles were released by 4 consecutive 
freeze/thaw cycles and different amounts of the lysates were used to infect Huh7 cells at 
90% confluency seeded in a 24-well plate. Twenty-four hours later, Huh7 cells were again 
harvested and prepared for luciferase assay using the dual luciferase reporter assay kit 
provided by Promega.   
5.2 Results 
5.2.1 The coxsackie and adenovirus receptor is expressed at similar rates on 
normal and RNAi knockdown cells 
The uptake of adenovirus 5 (Ad5) in HEK293 cells is dependent on the interaction of viral 
fiber protein and the coxsackie and adenovirus receptor (CAR) on the cellular surface. Thus, 
we first asked the question, whether our previously described RNA interference (RNAi) 
knockdown cell line B6 (compare section 4.2.2), expressing the RNAi suppressor protein 
P19, exhibit similar amounts of CAR receptors on the cellular membrane. Therefore, CAR 
expression was measured from HEK293 and B6 cells by flow cytometry. Similar amounts of 
fluorescent signal in the B6 cells in comparison to HEK293 cells revealed no statistically 
relevant alteration of the CAR expression pattern in our RNAi deficient cell line (Figure 5.1). 
Subsequently, identical infection rates can be expected. 
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5.2.2 Adenovirus replication is enhanced in the RNAi knockdown cell line B6  
It was shown previously that viruses, for instance the primate foamy virus, display an 
enhanced replication profile in an RNAi knockdown cell line (Lecellier et al., 2005). To test 
whether also Ad5 shows accelerated replication, either HEK293 or B6 cells were infected 
with Ad5 at a multiplicity of infection (MOI) of 0.05 and whole cellular DNA was isolated after 
2 hours (hrs), 10 hrs, 24 hrs and 48 hrs. Relatively low MOIs were chosen for infection of 
stably expressing P19 cells to prevent an overload of the cells with viral proteins or RNAs, 
especially the VA-RNAs, which are usually produced in high amounts (Sano et al., 2006). To 
analyze replication of Ad5, viral genome copy numbers were calculated from both cell lines 
by quantitative Real-Time PCR (qRT-PCR). Quantification revealed significantly increased 
viral genome copy numbers with up to 10-fold more genomes 24 hrs and 48 hrs after 
infection in the RNAi knockdown cell line B6 in comparison to the parental cell line HEK293 
(Figure 5.2A). The initial amount of viral genome copies after 2 hrs and subsequently the 
infection efficiencies were comparable in both cell lines. It is of note that within our 
experimental set up a sufficient amount of P19 in the B6 cells during infection is crucial (Qiu 
et al., 2002; Szittya et al., 2002; Rawlings 2010). Therefore, we isolated RNA from infected 
cells and performed reverse transcription (RT). The cDNA was then analysed by qRT-PCR 
to track p19 mRNA molecules. Quantitative RT-PCR results demonstrated that the amount 
of p19 decreased to about 22% of basic value at later time points during infection, which 
may be due to the shut down of the host cell mRNA transport by viral encoded proteins 
(Figure 5.2B). 
                                  
Figure 5.1: Quantification of CAR expression on HEK293 cells and the RNAi knockdown cell 
line B6 by flow cytometry. HEK293 and B6 cells were stained with an anti-CAR antibody labeled 
with FITC and measured by flow cytometry. The light emission of HEK293 cells after treatment was 
set to one and the emission of the B6 cells was caculated and expressed as fold change. p-value > 
0.05. 
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5.2.3 Replication of Bwtp19ΔE3 is significantly enhanced in comparison to wtAd 
and the control virus AdΔfiberIL 
To further improve Ad5 replication, we attempted to increase P19 levels by introducing the 
p19 cDNA into the adenovirus genome and couple its transcription to the adenovirus fiber 
protein. Therefore, an expression cassette containing parts of the flanking regions in the 
adenovirus genome (58 nt overlapping sequence to the 3´end of the fiber and 58 nt 
overlapping nucleotides to the sequence downstream of the fiber gene), the internal 
ribosomal entry site (IRES) of the encephalo myocarditis virus (EMCV), a spacer fragment, 
the p19 cDNA and a polyA signal was introduced into an E3-deleted Ad5 bacterial artifical 
chromosome (BAC) by homologous recombination (Figure 5.3A). We used an E3-deleted 
adenovirus BAC to ensure proper packaging of the adenoviral genome, because we 
introduced a DNA fragment of 1400 bp length, which may exceed the Ad packaging 
capacity. After reconstitution of single plaque forming viruses, respective lyates were used to 
re-infect HEK293 cells. After isolation of whole cellular DNA the specific 1700 bp fragment 
(including parts of the fiber) introduced into the Ad5 BAC could be confirmed by PCR (data 
not shown). Furthermore p19 mRNA expression of two independent single plaques after 
reverse transcription (RT) and PCR with p19 specifiic primers confirmed functional viruses 
(Figure 5.3B). Hence, viral lysate of clone 2 was amplified, purified and titrated resulting in 
the virus Bwtp19ΔE3 (Figure 5.3A, upper panel). Viral titers obtained from Bwtp19ΔE3 were 
comparable to wtAd5 (data not shown). 
 
Figure 5.2: Quantification of adenoviral genome copy numbers derived from B6 cells in 
comparison to HEK293 and analysis of the p19 RNA status during infection. All results are 
statistically relevant with a p-value < 0.05. (A) Quantification of adenoviral genome copy numbers in 
B6 cells and HEK293 cells after infection. HEK293 and B6 cells were infected at an MOI of 0.05 and 
genomic DNA was isolated 2 hrs, 10 hrs, 24 hrs and 48 hrs post infection. Viral genome copy 
numbers were quantified using hexon specific primers for qRT-PCR and were normalized to 
expression levels of human B2m. (B) Analysis of p19 RNA molecules during infection of adenovirus 
at an MOI of 0.05. B6 cells were infected at an MOI of 0.05 and RNA was isolated at indicated time 
points. RNA was then subjected to reverse transcription and cDNA was normalized to endogenous 
human B2m expression levels of 10 000 molecules. 
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To prove that enhanced virus replication in cells infected with the P19 expressing virus 
Bwtp19ΔE3 is due to enhanced P19 expression levels compared to the stably expressing 
cell line B6, p19 mRNA levels were determined by qRT-PCR during virus infection. We 
infected HEK293 cells with the virus Bwtp19ΔE3 at an MOI of 3 and isolated RNA at the 
ndicated time points. After RT reaction, p19 RNA molecules were quantified and the results 
confirmed a strong increase of p19 mRNA levels compared to B6 cells, reflecting the 
expression pattern of the fiber protein (Figure 5.3C). During infection with the virus 
 
Figure 5.3: Design and characterization of a p19 expressing adenovirus deleted in E3 and 
analyzing its replication properties in comparison to wtAd5. (A) Constructs used to analyze 
replication efficiency of a p19 expressing adenovirus. Upper panel: Bwtp19ΔE3: adenovirus 
containing a p19 expression cassette expressed under the control of the fiber promoter. The spacer, 
the internal ribosomal entry site (IRES), P19 and a polyadenylation signal (polyA) containing 
fragment was inserted into the E3-deleted bacterial artificial chromosome (BAC) by homologous 
recombination and virus was reconstituted. Lower panel: wildtype adenovirus genome (wtAd5). (B) 
P19 mRNA expression from the BAC-derived virus Bwtp19ΔE3 in comparison to stably p19 
expressing B6 cells. HEK293 cells were infected with the virus Bwtp19ΔE3 at a MOI of 1 and 24 
hours post-infection RNA was isolated and reverse transcribed. The generated cDNA was then used 
as template for a PCR with p19 specific primers. As control, reverse transcribed RNA from B6 cells 
and genomic DNA of Bwtp19ΔE3 infected cells are shown. (C) Quantification of p19 mRNA 
molecules during infection with Bwtp19ΔE3. HEK293 cells were infected with Bwtp19ΔE3 at an MOI 
of 3 and RNA was isolated and reverse transcribed. The cDNA was subjected to qRT-PCR reaction 
and normalized to 10,000 molecules of the internal control (human B2m). Quantification of viral 
genome copy numbers after infection of HEK293 cells at an MOI of 0.05 is displayed in (D) and at 
an MOI 3 in (E). After infection whole cellular DNA was isolated after given time points and DNA was 
quantified with hexon specific primers and normalized to human B2m.  The amount of viral genomes 
was adopted to 104 cells. * indicates a statistically significant result; * p-value< 0.05. 
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Bwtp19ΔE3, p19 RNA expression levels were enhanced up to 100-fold 24 hrs and 48 hrs 
post infection when compared to the B6 cell line. 
As the generated Bwtp19ΔE3 showed a high P19 expression level we hypothesized that 
there could also be a significant effect in virus replication. Subsequently, we investigated 
whether the newly designed virus Bwtp19ΔE3 displays an advanced replication profile in 
comparison to a control virus. As already mentioned before the amount of P19 protein is a 
major hurdle within the experimental set up and therefore, we first tested pre-conditions 
concerning the adenovirus transducing units required in our assay. We infected HEK293 
cells with Bwtp19ΔE3 or wtAd5 (Figure 5.3A, lower panel) either at an MOI of 0.05 (Figure 
5.3D) or 3 (Figure 5.3E), isolated whole genomic DNA and quantified viral genome copy 
numbers at the standard time points. QRT-PCR results confirmed our hypothesis that at an 
MOI of 3, and therefore higher P19 expression levels, produce sufficient amounts of P19 to 
enhance viral replication up to 10-fold 24 hours post infection, whereas an MOI of 0.05 was 
not sufficient (Figure 5.3D and E). In fact, we observed a slight increase in wtAd5 replication 
levels. This clearly indicated that the P19 effect on virus replication is controlled by the 
amount of P19 protein. Furthermore, we speculated that the slight decrease of Bwtp19ΔE3 
replication compared to wtAd5 using an MOI of 0.05 could be due to an attenuation of virus 
replication because of the deletion of the E3 gene or introduction of a DNA sequence into 
the adenoviral genome, which may destabilize the viral DNA. Therefore, we explored 
another control virus, the virus AdΔfiberIL, harboring the same DNA fragment connected to 
the fiber but with a luciferase cDNA instead of the p19 (Figure 5.4A, upper panel) (Rivera et 
al., 2004). In addition, AdΔfiberIL contains a 24 bp deletion in the E1A gene, however, this 
has no effect on replication in the HEK293 cell line (data not shown). After infection of these 
viruses into HEK293 cells at an MOI of 3, quantification of viral genome copy numbers 
revealed significantly enhanced virus replication of Bwtp19ΔE3 compared to AdΔfiberIL, with 
up to 100-fold more viral genomes 24 hours post infection (Figure 5.4B). Furthermore, after 
titration of the viral lysates we obtained an up to 10-fold higher amount of viral particles from 
Bwtp19ΔE3 infection at 48 hours post infection, indicating a faster replication cycle in the 
presence of proper levels of P19 (Figure 5.4C).  
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5.2.4 Enhanced expression of adenovirus functional proteins 
Adenoviral DNA appears in the nucleus approximately after 50 minutes, whereas replication 
starts around 3 hours post infection. Several viral proteins are involved in this process, thus 
we speculated that enhanced replication measured in the RNAi knockdown cell line B6 and 
with the p19 expressing adenovirus compared to controls may be due to increased 
expression levels of viral proteins. We have chosen 3 proteins encoded by the early 
transcription unit, encompassing the E1B55K protein, the ssDNA binding protein (DBP) and 
the E4Orf6 protein which all are responsible for either replication or mRNA stability and 
transport. Furthermore, also the structural proteins fiber and hexon were analyzed. As 
internal control GAPDH protein levels were detected, to demonstrate equal protein amounts. 
 
Figure 5.4: Bwtp19ΔE3 replication and virus production in HEK293 cells is enhanced in 
comparison to the control virus AdΔfiberIL. (A) Viruses used to analyze the influence of P19 on 
adenovirus replication. Upper panel: Bwtp19ΔE3, an adenovirus lacking E3 but containing the p19 
expression cassette (see also Figure 5.3A, upper panel). Lower panel: AdΔfiberIL, an E3-deleted 
adenovirus harbouring a luciferase expression cassette under control of the major late promoter 
(MLP) and a 24 bp deletion in the E1a gene (Rivera et al., 2004). HEK293 cells were infected with 
Bwtp19ΔE3 and AdΔfiberIL at an MOI of 3. (B) A time course was performed and whole cellular DNA 
was isolated to quantify adenoviral genomes using hexon specific primers and normalized to B2m. (C) 
Lysates were harvested and viral particles were measured after reinfection of HEK293 cells with the 
lysates at the given time points. 2 hours post infection whole genomic DNA was isolated and viral 
genomes were quantified using hexon specific primers and normalized to hB2m. * indicates 
statistically significant results by calculating a p-value< 0.05. 
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In concordance with the experiment shown in Figure 5.2A we analyzed protein expression 
after infection of HEK293 and B6 cells with wtAd5 at an MOI of 0.05. Protein lysates were 
isolated at various time points post infection, equal amounts were separated on a 10% SDS 
polyacrylamid gel (SDS-PAGE) and blotted on a PVDF membrane. Proteins were analyzed 
using anti-DBP, anti-E1B55K, anti-E4Orf6, anti-Fiber and anti-Hexon and the respective 
peroxidase labeled secondary antibodies (Figure 5.5). We found that there was no 
difference in the overall expression levels between the two cell lines HEK293 and B6 as 
demonstrated by similar GAPDH expression leves (Figure 5.5A, GAPDH). Furthermore, the 
levels of the ssDNA-binding protein and hexon protein showed no changed profile in the B6 
cell line (Figure 5.5A, DBP and Hexon), but E1B55K and the E4Orf6 were enhanced during 
 
Figure 5.5: Viral protein expression measured by Western Blot analysis after adenovirus 
infection. HEK293 or B6 cell lysates from assays shown in Figure 5.2A (A) and lysates after 
infection with Bwtp19ΔE3 and AdΔfiberIL shown in Figure 5.4B (B) were used to isolate proteins at 
the given time points. Equal protein amounts were separated on a 10% SDS polyacrylamid gel and 
blotted on a PVDF membrane. Detection was carried out using primary antibodies against respective 
proteins (right panel). Secondary antibodies were peroxidase labelled. Detection was performed 
using ECL solution. Bp19: Bwtp19ΔE3; d24: AdΔfiberIL. 
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infection in the p19 expressing cell line (Figure 5.5A, E1B55K and E4Orf6). Notably, 
E1B55K seems to accumulate during infection, since highest expression was detected 
48 hrs post infection in comparsion to the parental cell line HEK293. In contrast, overall 
protein levels of fiber is decreased in B6 cells in comparison to HEK293 cells, wheras 
monomeric fiber molecules show similar expression at 48 hours post infection (Figure 5.5A, 
Fiber).  
In contrast, the comparison of protein levels from the infection experiment performed with 
the Bwtp19ΔE3 and the control virus AdΔfiberIL (see also Figure 5.4) revealed strongly 
enhanced DBP, E4Orf6 and fiber levels of Bwtp19ΔE3. Nevertheless there was a prominent 
peak 24 hours post infection (Figure 5.5B, DBP, E4Orf6 and Fiber), which reflects the 
highest p19 expression level at this time point (Figure 5.3C). However, E1B55K expression 
is only slightly increased 10 and 48 hours post infection and hexon levels are unaltered 
compared to the stably p19 expressing cell line B6 (Figure 5.5B, E1B55K and Hexon). To 
investigate whether this effect is due to advanced translation, also the mRNA levels of the 
respective proteins (Figure 5.5B) were quantified. We obtained higher RNA expression 
levels for all tested viral proteins (Figure 5.6). The analysis of the structural proteins fiber 
and hexon revealed that the strongest effect could be observed 24 hours post infection 
(Figure 5.6, hexon and fiber). We speculate that this discrepancy in protein expression 
between the stably p19 expressing cell line B6 and the p19 expressing adenovirus is due to 
different P19 protein levels in the systems together with the higher MOIs we used with the 
Bwtp19ΔE3. Nevertheless, viral early proteins amount are enhanced in the presence of p19 
expression, which may be responsible for the increased virus production.  
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5.2.5 Status of VA-RNAs and svaRNAs in the presence of P19 
The wtAd5 VA-RNAs are known to interact with several parts of the RNAi pathway. After 
export into the cytoplasm, VA-RNAs were processed by Dicer into 19-29 nucleotide long 
small virus associated RNAs (sva-RNAs), which are able to enter the RNA induced silencing 
complex RISC. As VA-RNAs share structural features with cellular micro RNAs (miRNAs), 
we speculated that they could also be bound by P19 and may contribute to the observed 
effect on virus replication. Therefore, we isolated His-tagged P19 from infected B6 cells or 
as control infected HEK293 cells, using magnetic beads. After purifcation, small RNAs were 
purified from the protein fraction using different conditions and inserted into a polyA adding 
reaction followed by cDNA synthesis. In order to solely amplify sva-RNAs, specific primers 
for the VAI-RNA (3´VAn-r, Table 5.1) and the VAII-RNA (5´VAII, Table 5.1) were used and 
the generated fragments were subcloned and sequenced (Figure 5.7A and 5.7B, upper 
panel). Using this method we could show that sva-RNAs from VAI-RNA as well as from VAII-
RNA origin are bound to P19 and may be inhibited during infection. 
Figure 5.6: Quantification of viral RNA expression of the Bwtp19ΔE3 in comparison to 
AdΔfiberIL. HEK293 cells were infected with Bwtp19ΔE3 or AdΔfiberIL at a MOI of 3 and RNA was 
isolated at given time points post infection. RNAs were subjected to reverse transcription and viral 
mRNA amounts were quantified from cDNA using different adenovirus primers displayed in Table 5.1. 
Quantitative Real-Time PCR results were normalized to 10 000 molecules of hB2m as internal control. 
* indicates a p-value < 0.05. 
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It is estimated that miRNAs incorporated into the P19 dimer were translocated to the cellular 
processing bodies, where downstream processing of the RNA takes place (Beckham and 
Parker 2008; Eulalio et al., 2008). Thus, we aimed at analyzing the fate of the sva-RNAs 
after interaction with the P19 dimer. HEK293 cells and the p19 expressing cell line B6 were 
infected with wtAd5 at an MOI of 0.05 and small RNAs were isolated at different time points 
post infection (Figure 5.7, lower panel). After performing Northern Blot analysis using an 
sva-RNA specific probe either for VAI-RNA (3´Van probe) or VAII-RNA (3´VAII probe) (see 
 
Figure 5.7: Binding of sva-RNAs to P19 and the fate of the svaRNAs during infection. Upper 
panel: structure of the VAI-RNA (A) and VAII- RNA (B). Highlighted by a grey circle are the predicted 
sva-RNAs generated from the mature VA-RNA by Dicer processing. Middle panel: PCR fragments of 
sva-RNAs. B6 cells were infected with wtAd5 at an MOI of 10 and P19 protein was purified 24 hours 
post infection. Small RNA molecules were isolated from the protein fraction and inserted into a polyA 
polymerase reaction followed by cDNA synthesis. PCR was then performed with an sva-RNA specific 
primer for 3´stem of VAI-RNA (3´Van-r) (A) or 5´stem of VAII-RNA (5´VAII) and a primer of the polydT 
adapter. M: Marker; 293: HEK293 cells; B6f/t: B6 cells were lysed by 4 consecutive freeze/thaw 
cycles; B6s: B6 cells were sonificated 5 times on ice; PK: Proteinkinase buffer was used to isolate 
miRNAs from P19. Other miRNAs were isolated using Qiazol reagent and following the manufacturer 
instructions. Lower panel: Northern Blot analysis to track the fate of sva-RNAs during adenovirus 
infection in HEK293 cells and B6 cells. HEK293 cells and the RNAi knockdown cell line B6 were 
infected at an MOI of 0.05 and small RNAs were isolated at time points displayed in the figure. Equal 
RNA amounts were loaded on a Northern gel, blotted to a NylonBond+ membrane and detected with 
a-P32 labbeled probe specific for either the stem of the VAI-RNA (3´Van) (A) or the VAII-RNA (5´VAII) 
(B). Degradation products observed in the B6 cell line were highlighted in boxes. 
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also Table 5.1) we observed VA-RNAs, sva-RNAs and also products of smaller size 
compared to sva-RNAs, which may refere to degraded sva-RNAs (black boxes in Figure 
5.7, lower panel). Furthermore, svaRNAs from VAI-RNA origin (Figure 5.7A, lower panel) 
are degraded much earlier than the ones from VAII-RNA (3´VAII probe (Figure 5.7B, lower 
panel) as the small fragment appears at 15 hours post infection whereas the ones from VAII-
RNA can be observed not until 42 hours post infection (Figure 5.7B. lower panel). The 
binding of the sva-RNAs to P19 suggests a contribution of the small VA-RNA derived 
fragments to the enhanced replication, however a direct proof is missing.  
Therefore, we investigated a VAII-deleted adenovirus obtained from Göran Akusjärvi 
(Uppsala University, Uppsala, Sweden). The deletion was shown by Northern Blot analysis 
(data not shown). Replication was determined in HEK293 cells and the RNAi knockdown cell 
line B6 infected at an MOI of 0.5 (Figure 5.8). The quantification of viral genome copy 
numbers revealed a strong increase up to 100-fold in viral genome copies 10 hours post 
infection. However, replication adopted to slightly lower levels of viral genome copy numbers 
compared to virus derived from HEK293 cells 24 and 48 hours post infection (Figure 5.8). 
Thus, we speculated that VAII-RNA are rather important at later time points post infection as 
the lack of VAII-RNA leads to abrogation of the virus replication at later time points. This is in 
concordance with our Northern analysis, which showed that svaRNAs were processed only 
at late time points during infection. 
                                 
Figure 5.8: Replication of a VAII-deleted virus in HEK293 cells and the RNAi knockdown cell 
line B6. The VAII-deleted Virus dl705 was infected at an MOI of 0.1 into HEK293 cells and B6 cells. 
Whole cellular DNA was isolated at standard time points and viral genome copy numbers were 
quantified using gexon specific primers. Results were normalized to B2m as internal control and viral 
genome copies were calculated on the basis of 104  cells. * indicates a p-value < 0.05. 
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5.2.6 Application of p19 expression to improve production of high-capacity 
adenoviral vectors 
Recombinant adenoviral vectors are widely used in gene therapy. Especially the most 
advanced generation, the high-capacity adenoviral vectors (HC-AdV) hold great promise 
concerning safety and efficacy. With that respect it was shown that transgenes packaged in 
an HC-AdV introduced into several small and large animal models resulted into long-term 
transgene expression. However, the production of these HC-AdVs is sophisticated and only 
a few groups are able to produce these vectors in sufficient amounts. Therefore, we already 
generated a detailed protocol for their production (compare chapter 2) but we wanted to 
further improve the viral titers. Thus, we took advantage of our finding that Ad replication is 
     
Figure 5.9: Comparison of the packaging efficiency of a luciferase expressing high-capacity 
adenovirus (HC-AdV) using a p19 expressing helper virus (HV) or a conventionally used HV. 
(A) Viruses used to analyse packaging efficiency of HC-AdV by the two different helper viruses. 
Upper panel: BHVp19, an E3-, E1- deleted helper virus that contains the p19 expression cassette 
under the fiber promoter connected via a spacer and an IRES sequence. Additionally, the packaging 
signal is flanked by loxP sites. Middle panel: AdNG163R-2 standard helper virus deleted in E1 and 
E3 contains a loxP flanked packaging signal. Lower panel: HD-Ad luc, HC-AdV, lacking all viral 
coding sequences only containing the two ITRs and the packaging signal. This HC-AdV harbours a 
luciferase expression cassette driven by the human α1-antitrypsin promoter (hAAT) and the SV40 
polyA signal (Jager and Ehrhardt 2007). (B) P19 mRNA expression from the helper virus BHVp19. 
HEK293 cells were infected with BHVp19 single clone lysates and RNA was isolated and reverse 
transcribed. The generated cDNA was then amplified using p19 specific primers. M: Marker; g.DNA: 
genomic DNA from BHVp19 infection; 1, 2: two different single viral plaque lysates. (C) Luciferase 
expression after amplification of HD-Ad luc with either BHVp19 or standard AdNG163R-2. 116 cells 
(HC-AdV producer cell line) were co-infected with HD-Adluc and either BHVp19 or AdNG163-2. 
Forty-eight hours post infection cell lysates were harvested and Huh7 cells were reinfected with the 
generated lysates using different amounts. 24 hrs post infection cells were prepared for quantifying 
luciferase expression. 
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enhanced in the presence of P19. We introduced the p19 expression cassette, also used for 
Bwtp19ΔE3, into a BAC containing a helper virus genome by homologous recombination 
resulting in BHVp19 (Figure 5.9A, upper panel). P19 expression on mRNA level was 
approved after RT by conventional PCR with p19 specific primers. To test whether the newly 
generated helper virus BHVp19 displays advantagous features compared to a standard 
helper virus (Figure 5.9A, lower panel) we measured titers of a high-capacity adenoviral 
vector expressing luciferase (Figure 5.9A, middle panel). After reinfection of Huh7 cells with 
different amounts of the generated lysates, we could clearly observe increased viral titers 
with an average of 6-fold higher luciferase expression (Figure 5.9B). Notably, helper virus 
contamination remains at normal levels under 1%. These experiments clearly demonstrated 
that our novel BHVp19 is superior to the conventionally AdNG163R-2 for HC-AdV production 
 
5.3 Discussion 
In the present study we aimed at getting further insights into adenovirus-host interactions 
with a particular focus on the influence of the RNAi pathway on virus replication. Thus, we 
took advantage of the RNAi suppressor protein P19 in different set-ups to analyze its impact 
on the adenovirus life cycle. Our results showed, that Ad5 replicates significantly faster and 
grows to higher titers in the presence of P19, suggesting an important role of the RNAi 
pathway on the adenovirus life cycle.  
Very recently, de Vries and his colleagues analyzed the influence of the RNAi pathway on 
HIV replication and obtained an upregulation of virus production in the presence of different 
RNAi supressor proteins including P19, which resulted in 50-fold enhanced Sindbis virus 
titers (de Vries et al., 2008). In contrast to our data, they could not see any difference in the 
replication profile of an E1-deleted adenovirus using p19 expressing cells in comparison to 
control cells. Notably, de Vries et al., investigated adenovirus titers 6 days post infection at 
an MOI of 0.05. We on the other hand observed 10-fold faster replication in the presence of 
the RNAi suppressor protein P19 in the B6 cell line (Figure 5.2). Concluding from our 
results, we speculate that p19 expression in the cytoplasm is strongly decreased due to the 
shut down of the host RNA turnover initiated by adenovirus replication as we also observed 
significant decreased p19 mRNA levels during the time course of infection (Figure 5.2B) 
(Curiel and Douglas 2002). Different groups already demonstrated that the dose of P19 in 
the cell is a crucial factor regarding its functional activities (Qiu et al., 2002; Szittya et al., 
2002; Scholthof 2006). In the study by de Vries this point was not considered but instead it 
was discussed, that the inappropriate intracellular localization of P19 may have caused the 
5 Adenovirus 5 replication is enhanced by RNAi knockdown 
 
 
98 
failure. In a recent dissertation from R. Rawlings, however, the strong interaction of P19 with 
ds-siRNAs was shown because an over 20-fold bias towards p19-siRNA complexes in 
comparison to Dicer-siRNA interactions was detected. Unexpectedly, P19 was also able to 
destroy siRNA-RISC complexes (Rawlings 2010). Furthermore, Renata Rawling disproved 
the existing model of a 1:1 stoichiometric binding of P19 to the siRNA (Scholthof 2006) and 
revealed that the binding follows a sub-stoichiometric process consisting of fast association 
and dissociation (Rawlings 2010). Although these facts would suggest independency of the 
P19 dose, the amount of protein still plays a critical role. Thus, we believe that it is more 
likely that the amount of P19, rather than the cellular localization causes the defect of the 
P19 protein to increase adenovirus replication.  
In our experimental set-up we investigated two different strategies to express p19 in 
HEK293 cells resulting into moderate and strong effects on upregulation of adenovirus 
genome replication. On the one hand, p19 was stably expressed in a cell line comparable to 
the approach by de Vries and colleagues, which mediates a continuous but low-level p19 
expression (Figure 5.2B) (de Vries et al., 2008). On the other hand P19 was inserted into 
the adenoviral genome under the control of the MLP promoter (Bwtp19ΔE3) resulting in high 
amounts of the RNAi suppressor protein at later time points after infection because p19 
expression is directly coupled to adenovirus genome replication (Figure 5.3C). Due to the 
higher P19 dose, adenovirus replication was significantly increased with up to 100-fold more 
genome copy numbers in the viral context (Figure 5.4 B). With respect to the B6 cell line 
with less pronounce effects on adenovirus replication, there is evidence that infection of cells 
with an adenoviral vector blocks the host mRNA transport and transcription by several viral 
proteins encoded by the E1B and E4 transcription units (Curiel and Douglas 2002). 
Therefore, besides influencing the host mRNA metabolism the transcription of p19 in our 
stable cell line B6 was also affected resulting in 80% decreased p19 mRNA levels during 
infection compared to basic p19 levels in uninfected cells (Figure 5.2B). We believe that this 
could be the reason for the less pronounced upregulation of viral genome replication in 
stably p19 expressing cells.  
The highest P19 protein level was observed 24 hours after Bwtp19ΔE3 infection, which 
reflects the expression profile of the fiber protein (Figure 5.3C). Transcription of the late 
transcription unit starts round 5 hrs post infection and shows the highest expression level 
approximately at this time point as concluded from the qRT-PCR data (Figure 5.6, fiber). 
Consequently, Bwtp19ΔE3 replication was strongly increased at this particular time point 
with a 100-fold more copy numbers and 8-fold higher titers in comparison to the control virus 
AdΔfiberIL (Figure 5.4B and C). Notably, Bwtp19ΔE3 titers were increased 10-fold after 
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48 hrs, thus, the enhanced number of adenovirus DNA molecules was maintained in the 
cells. 
In order to ascertain the mechanism of up regulation of adenoviral replication, we analyzed 
expression levels of adenoviral proteins, which are important during adenoviral life cycle and 
may initiate a faster and more productive virus replication. In general, the adenovirus 
replication and virus production cycle is divided into two phases, the early transcription of 
predominantly regulatory proteins, responsible for transcription and replication and the 
expression of the late transcription unit, mainly encoding for structural proteins like the major 
capsid components hexon, fiber and penton (Curiel and Douglas 2002).  
In the present study, proteins of the early transcription unit, in particular proteins E1B55K 
and E4Orf6 displayed an increased expression level in the presence of P19 in the B6 cell 
line (Figure 5.5A). The distinct regulatory functions of the E1B55K and E4Orf6 proteins 
during the adenovirus life cycle may thereby play a decisive role. A complex consisting of 
both proteins is required to bind p53 and initiate its proteasom-dependent degradation to 
prevent cell cycle arrest (Curiel and Douglas 2002). Furthermore, each protein alone is 
necessary to produce a cellular environment in favour of virus replication, for instance the 
E4Orf6 protein shuts down the host cell translation machinery but selectively stabilizes and 
transports viral mRNAs (Curiel and Douglas 2002). Thus, the accumulation of both proteins 
under RNAi knockdown conditions may prolong the production period of virus particles 
because E4Orf6 and E1B55K may stabilize selectively the adenovirus RNA turnover and 
lead to an effective down regulation of apoptosis induction.  
We observed a different expression profile of viral proteins when we compared different 
sources of p19 expression. As mentioned before p19 expression was based on somatic 
integration of a p19 expression cassette into the host genome or it was transduced into the 
cells utilizing a replicating adenovirus carrying a p19 transcription unit. We speculate that 
this difference in viral protein expression is caused by the unequal time course and levels of 
p19 expression (Figures 5.3C). P19 protein levels are clearly dependent on the 
experimental set-up and the varying virus loads used in the experiments. Furthermore, in 
case of the B6 cell line, the P19 may modulate the miRNA profile of the cell in advance of 
viral replication and therefore promote especially immediate early genes like E1B55K 
(Figure 5.4). In contrast, after Bwtp19ΔE3 infection P19 proteins are present at the earliest 
3 hrs post infection. Thus, proteins, which were expressed later like the E4Orf6 and the DBP 
are affected to a greater extend (Figure 5.5). 
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Notably, E4Orf6 expression is significantly increased in both setups. However, the low 
infectious titer of only 0.05 transducing units used in the stable expressing cell line B6, led to 
low E4Orf6 levels even 48 hours post infection (Figure 5.5, E4Orf6). In contrast, in the viral 
context (Bwtp19ΔE3) we infected with an MOI of 3 leading to high E4Orf6 expression levels 
already 10 hours post infection. We speculate that the increased E4Orf6 protein levels 
enforce viral mRNA transport and stabilize the mRNA in the cytoplasm even at early time 
points. This hypothesis is supported by the strong increased viral mRNA levels observed 
after Bwtp19ΔE3 infection (Figure 5.6). In agreement to that, we also observed increased 
DBP protein amounts and RNA levels from Bwtp19ΔE3 infected cells another important 
protein for the initiation of adenovirus replication (Figure 5.5B, DBP).  
The expression levels of the structural proteins, which would potentially indicate increased 
production of viral particles, remain almost unaltered. In the viral context, however, as shown 
in Figure 5.6 we detected increased mRNA levels of hexon and fiber but protein levels 
appear unaltered. This is also in concert with the findings from the E1B55K protein and 
supports the notion that the increased E4Orf6 levels may enforce viral mRNA transport but 
coincidentally saturation of the translational machinery takes place, finally leading to an 
accumulation of viral mRNAs. This hypothesis is in agreement with observations of Renata 
Rawlings, as she detected increased mRNA levels after infection of plant cells with the p19 
expressing tomato bushy stunt virus (Rawlings 2010). Nevertheless, the increased viral titer 
of Bwtp19ΔE3 (Figure 5.4C) strengthens the suggestion that viral structural proteins are 
produced in excess as more infectious viral particles were produced from nearly the same 
amount of major capsid proteins present in the cell (Figure 5.4). We see this overproduction 
also in normal adenovirus production procedures, when we purify the virus by cesium 
chloride centrifugation (Figure 2.2). In the second, continuous centrifugation step, empty 
particles can be obtained, which separate from the complete particles due to the different 
density. 
As already mentioned we observed that the potency of the P19-effect on adenovirus 
replication strongly depends on the time course and strength of p19 expression. In our p19 
expressing virus Bwtp19ΔE3 we expressed p19 under the control of a major late viral 
promoter. Therefore, it would be of great interest to analyze the replication profile of an 
adenovirus expressing p19 under the control of an early viral promoter, for instance from the 
E1 region. With that strategy the time course and onset of p19 expression and potentially the 
expression levels could be varied. However, the group of Dirk Nettelbeck already 
characterized reporter fusion proteins in the early viral coding regions. These adenoviral 
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vectors were attenuated in viral growth and particle production, which may be due to instable 
viral genomes or improper transcription efficiencies (Rivera et al., 2004).  
To further shed light on the mechanism involved in the advanced replication, either if its 
cellular or viral based, we investigated the only currently known products of adenovirus that 
interacts with the RNAi pathway, the virus associated RNAs I and II (VAI-RNA and VAII-
RNA) and their processing products the small virus-associated RNAs (svaRNAs) 
(Andersson et al., 2005; Aparicio et al., 2006; Sano et al., 2006; Xu et al., 2007; Aparicio et 
al., 2010). Renata Rawlings demonstrated that P19 acts in a complex consisting of Dicer, 
P19 and the ds-siRNA, therefore it is speculated that the loading of P19 is very efficient 
(Rawlings 2010). As svaRNAs share structural features with cellular miRNAs and are 
generated from Dicer (Aparicio et al., 2006; Sano et al., 2006) we indeed detected sva-
RNAs originated from VAI-RNA and VAII-RNAs in the P19 fraction from B6 cells, but not 
control cells (Figure 5.7, middel panel). These svaRNAs are sequestered and degraded as 
detected by Northern Blot (Figure 5.7, lower panel). Notably, in our assay we detected VAI-
RNA derived svaRNAs and their degradation fragments much earlier at 15 hrs post infection, 
whereas small products from VAII-RNA appear not until 42 hours after infection (Figure 5.7). 
This finding was supported by the investigation of a VAII-RNA deleted adenovirus. Up to 24 
hrs post infection there was no impact on VAII-RNA-deleted adenovirus replication. 
However, 24 hrs post infection replication was stopped and converged to normal adenovirus 
copy numbers (Figure 5.8). Although VAI-RNAs are expressed at about 20-fold higher 
levels, around 2-fold more svaRNAs from VAII-RNA origin were detected within RISC 
complexes by Xu and colleagues (Xu et al., 2007). Thus, Dicer exhibits a 40-fold higher 
substrate performance for VAII-RNA in comparison to VAI-RNA (Xu et al., 2007). In addition, 
it was shown that RISC complexes are occupied at levels of up to 60% with sva-RNAs from 
VAII-RNA origin at late time points post infection. In conclusion, one can speculate that the 
tight binding of the VAII-RNA to Dicer, Dicer processing and loading of the RISC complex 
are highly efficient and svaRNAs are not as accessible to the P19 protein as svaRNAs from 
VAI-RNA. (Figure 5.6) (Xu et al., 2007).  
It is estimated that the generation of svaRNAs and subsequently silencing of complement 
mRNAs predominantly occurs during early times of infection, whereas the inhibition of RNAi 
is a relatively late event to prevent degradation of their own RNAs. However, one has to take 
into account, that cellular miRNAs have a relatively long half-life of 24 hrs, which therefore 
exceeds the adenovirus life cycle and may not be influenced by inhibition of the exportin 
pathway and Dicer. Solely the saturation of RISC complex by sva-RNAs could compete with 
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pre-existing cellular miRNAs, as it was demonstrated that 80% of RISC is occupied with 
svaRNAs at late infection phases (Xu et al., 2007).  
Assuming that svaRNAs play a role, several models on how P19 may influence viral 
replication at early and late time points of infection are possible. Starting with early time 
points (in particulare about 6 hours post infection) one could hypothesize that P19 binds to 
svaRNAs and other cellular or viral miRNAs. This lead to the increased production of 
E1B55K and E4Orf6 (Figure 5.5), which in turn stabilizes viral mRNAs in the cytoplasm and 
further boosts viral replication. However, during late phases of infection VA-RNAs are 
predominantly produced to inhibit the RNAi pathway to prevent down regulation of their own 
genes (Xu et al., 2007). Although no further adenoviral miRNAs have been identified so far, 
the genome composition with convergent transcriptional units spread on both strands of the 
viral genome could lead to dsRNAs intermediates. These dsRNA molecules could be able to 
inhibit viral proteins. Besides this, also cellular miRNAs may inhibit viral proteins. Thus high 
P19 levels, present in late phase of infection in the case of Bwtp19ΔE3 may contribute to 
downregulate and sequester pre-existing cellular and viral miRNAs. This is in agreement 
with the lower replication of the VAII-deleted adenovirus dl705 at later time points of infection 
(Figure 5.8). As it was shown that svaRNAs from VAII-RNA origin occupy 60% of RISC it is 
assumed that the lack of these svaRNAs reduce the inhibition of the RNAi pathway 
significantly (Xu et al., 2007). In contrast, in the stable cell line B6, p19 is diminished by the 
shut down of the host mRNA transport (Figure 5.2), therefore P19 proteins produced before 
infection may be already saturated and therefore inactive.  
As we detected higher titers from an E3-deleted adenovirus we investigated whether this 
system can also be subjected to HC-AdV production. In fact, we detected increased 
luciferase expression levels from the helper virus BHVp19 expressing p19 under the major 
late promoter (MLP), in comparison to the standard helper virus AdNG163R-2 (Figure 5.9). 
Importantly, helper virus contamination was similar in both virus preparations as measured 
by qRT-PCR (data not shown). To reach gene therapy relevant levels, however, we have to 
demonstrate increased HC-AdV titers also in large-scale production using the spinner flask 
system (compare to chapter 2). Furthermore the actual infectious titer has to be verified by 
qRT-PCR. 
However, in order to unravel the whole mechanism and the real influence of svaRNAs on the 
enhanced replication in the p19 expressing cell line one has to use an VAI- and VAII-RNA 
deleted virus. Furthermore RISC pulldowns to identify miRNAs that appear in P19 or in the 
argonaut complex in normal and in adenovirus infected cells are suggestable. Future 
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experiments should also include the analysis of cellular proteins involved in Ad replication, 
like the Oct1 protein or nuclear factor II (Curiel and Douglas 2002).  
In conclusion, in the present study we generated a new system to improve adenovirus 
replication and the production of HC-AdV. Along this line, the significantly increased virus 
replication of the p19 expressing adenovirus Bwtp19ΔE3 may be advantageous for the 
performance of oncolytic adenoviruses. Faster replication comes along with more efficient 
viral spread, better tumor penetration and consequently improved tumor regression. 
Furthermore, we started to investigate the complex interaction of the RNAi pathway with the 
adenovirus life cycle. However, more detailed information is required to understand the real 
importance of the silencing mechanism. Therefore, micro arrays to analyse the miRNA 
profile before and during infection as well as the identification of P19 and argonaute bound 
miRNAs may further uncover miRNAs that regulate adenovirus infection.  
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6 Discussion 
To date, recombinant adenoviruses are amongst the most prominent viral vectors used in 
gene therapy (Figure 1.1). Their genomic and capsid composition and the life cycle offers 
great potential to a broad range of applications, including replication-deficient recombinant 
adenoviruses for the treatment of genetic diseases and replication-competent oncolytic 
viruses for the treatment of neoplastic diseases. Each indication has individual demands on 
the vector properties and faces predominantly the cellular response and defense 
mechanisms in the infected cell. 
Monogenetic diseases are the third most frequently treated indication in gene therapy as 
demonstrated by a statistical analysis from “Gene Therapy Clinical Trials World Wide” 
(Figure 1.4) (Wiley 2010). These diseases are based on a defect of only a single gene, 
which is mainly due to mutations or deletions in the DNA sequence of the defective gene. 
Thus, the sufficient introduction of healthy copies of the affected gene by a viral vehicle to 
restore physiological protein production is a suitable method for the treatment of 
monogenetic diseases. Moreover, the vector system of choice should mediate lifelong 
transgene expression ultimately aiming at ameliorating the patient’s clinical symptoms or 
completely rescuing the phenotype.  
The treatment of monogenetic disease utilizing viral gene transfer vehicles is intended to be 
applied to human beings. Therefore, in comparison to initial in vivo experiments in mice and 
dogs either a 3500-fold or a 3.5-fold increase in body mass has to be considered for viral 
vector preparation. Thus, a prerequisite for performing small and large animal studies and 
finally clinical trials is the ability to up-scale viral vector production for production of clinical 
grade vector stocks preferentially with low costs. Using the advanced protocol for large-scale 
production of HC-AdV presented within this study (chapter 2) it is possible to produce up to 
1*1013 viral particles with less than 1% helper virus contamination using 3 liters of producer 
cells grown in suspension in spinner flasks (Figure 2.2). In addition, since there are 5-point 
magnetic stirrers available to amplify producer cells in 5 spinner flasks at the same time, it is 
estimated that within one round of amplification the production up to 5*1013 particles is 
possible within two weeks. In comparison to other viral vectors currently used for the 
treatment of monogenetic diseases, for instance lentiviral and adeno-associated viral vectors 
this means a 100000- and 100- fold increased vector yield from one amplification round 
(Aucoin et al., 2006; Tiscornia et al., 2006; Smith et al., 2009), respectively. Furthermore, for 
in vivo experiments the exact quantification of transducing units and the detailed 
characterization of the final viral vector stocks are required. In the case of HC-AdV the 
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simplified Real-Time PCR protocol provided within this study (chapter 2) offers the 
possibility to titrate different HC-AdV preparation independently of the introduced transgene 
expression cassette using only one primer pair. Thus, various vector preparations can be 
titrated comparably and the results obtained from experiments with these vectors are 
reliable.  
Nearly all HC-AdVs available so far are based on the adenovirus serotype 5 (Ad5). It was 
shown by Waddington and colleagues that the Ad5 hexon could be efficiently recognized by 
the coagulation factor X in the blood stream. This mediates the liver tropism independently 
of the naturally interaction of the cellular coxsackie and adenovirus receptor (CAR) with the 
fiber protein (Waddington et al., 2008). Therefore, AdVs were mainly used to treat liver 
associated diseases as this serotype has a strong tropism towards this organ. Within this 
work we demonstrated (chapter 2) that besides liver-derived monogenetic diseases such as 
hemophilia also liver-associated hepatitis B virus infection can be efficiently treated using 
HC-AdV vectors delivering shRNA sequences (Figure 2.4 and 2.5). Uprichard et al. already 
demonstrated the successful transfer of a shRNA incorporated into a first-generation 
adenoviral vector and detected down regulation of hepatitis B virus specific RNAs in a 
transgenic mouse model (Uprichard et al., 2005). However, when using first generation 
adenovirus based vectors to deliver shRNAs, it is important to consider the strong 
expression of virus-associated RNAs. These double-stranded RNA molecules are produced 
in enormous amounts of around 108 molecules during infection and may compete with the 
introduced shRNAs for the RNAi enzymes (Akusjarvi et al., 1987; Andersson et al., 2005; 
Aparicio et al., 2006; Xu et al., 2007). Thus, taking advantage of the special features of 
adenoviral vectors, the use of HC-AdVs to deliver shRNA sequences into cells is superior 
because of the improved toxicity profile and the lack of VA-RNA expression. 
Although Ad5 based vectors demonstrated efficacy for the treatment of liver associated 
diseases, there are several limitations when using this vector system for gene transfer. First 
of all, Ad5 displays a high serum prevalence in the human population and therefore also a 
high incidence of anti-adenovirus neutralizing antibodies, which in turn can mediate the 
clearance of the virus, just before reaching the target organ (Xu et al., 2008; Arnberg 2009). 
Furthermore, the treatment of organs besides the liver is very inefficient and specific 
methods have to be used, for instance a tracheal catheter to target lung cells (Koehler et al., 
2005). In addition, HC-AdV harbours the inverted terminal repeats originated from Ad5, 
which are essential for proper replication. As shown in chapter 3 of this work these ITRs 
however, displayed strong transcriptional activity in a plasmid-based assay (Figure 3.2). 
Transcriptional activity derived from the ITRs could either activate transgene expression in 
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an undesired tissue or could lead to changes in the promoter activity profile. Thus, serotypes 
other than Ad5 became of increasing interest in the research community. Regarding 
neutralizing antibodies, serotypes from subgroup B and D were advantageous as they only 
showed low serum prevalence (around 1-3% in subgroup B2 and 3-44% in subgroup D) in 
the Caucasian population (Arnberg 2009). In addition subgroup B adenoviruses and in 
particular serotypes 11 and 35 use mainly CD46 for cellular entry. Thus, on the one hand 
they can infect hematopoietic stem cells, escape from neutralizing antibodies and on the 
other hand they are not recognized by the clotting factor X, thereby omitting liver tropism 
(Waddington et al., 2008; Arnberg 2009). Unfortunately, for ITRs derived from this preferred 
subgroup we detected high transcriptional activity and also strong inhibition of the 
ubiquitously expressed PGK promoter (Figure 3.2 and 3.3). Nevertheless, serotype 7 from 
the subgroup B1, which showed a moderate serum prevalence of around 35-70% and share 
most features with subgroup B2 Ads did neither alter transgene expression significantly nor 
influenced promoter activity (Figure 3.2 and 3.3). Therefore ITR 7 could  be a model 
candidate for improved HC-AdVs (Arnberg 2009).  
Our plasmid-based assay provides some hints about the performance of the ITRs, but 
expression from a viral vector is influenced by several other viral and cellular factors, too. 
Along this line it is estimated, that for instance the terminal protein, covalently bound to the 
ITRs of the adenoviral genome, recruits transcription factors that can bind to motifs located 
in the ITRs (Curiel and Douglas 2002; Yamamoto et al., 2003). In concordance with these 
findings, Yamamoto et al. identified transcriptional start sites at the beginning of the ITRs at 
positions 15 and 25, located in close proximity to a TATA box (Yamamoto et al., 2003). Also 
other motifs, like Oct-1 or NFIII binding sites were predicted for all serotypes, using the 
TESS program (Figure 3.1) (Schug 2008). The TATA box is conserved throughout all 
serotypes (Figure 3.1) and therefore one may speculate that the analyzed ITRs in our study 
can induce transcription in an adenoviral context, although we did not detect any activity in 
our plasmid based assays. In accordance with that finding, when we introduced a luciferase 
expression cassette under the control of the strong viral SV40 promoter in close proximity of 
the right ITR of an HC-AdV, transgene expression was normal after plasmid transfection. 
However, upon infection with the respective HC-AdV luciferase expression was completely 
abrogated (data not shown). Thus, the investigation of the ITR 7 within a viral context is 
required to demonstrate real improvements. 
Although the construction of other than Ad5 serotype recombinant adenoviruses (rAdVs) 
including HC-AdV is recommended, the practical performance is still sophisticated. To date, 
the construction of rAdV is dependent on homologous recombination in eukaryotic producer 
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cells or bacteria, which is inefficient. Moreover, subcloned adenovirus genomes of the 
various serotypes for easy genetic manipulation are not available to many laboratories at the 
time (He et al., 1998; Luo et al., 2007). Up to now, most approaches aimed at exchanging 
one capsid element like the major capsid protein hexon, which is the main target for the 
neutralizing antibodies and clotting factor X (Waddington et al., 2008; Xu et al., 2008; Alba et 
al., 2009; Seregin and Amalfitano 2009). But still, cloning of these vectors and virus 
reconstitution are inefficient because of instability of the capsid structure. Although Ad5/48, a 
chimeric adenoviral vector based on Ad5 carrying hexon regions from Ad48, could 
circumvent Ad5 based immunity, a complete exchange of the serotype may be more 
favourable in terms of immunity, tropism and transgene expression, as also other capsid 
components play a crucial role (Roberts et al., 2006; Waddington et al., 2008). Of note, there 
are upcoming strategies for subcloning and genetic manipulation of adenovirus genomes 
based on bacterial artificial chromosomes (BAC), which simplifies the cloning procedure 
extensively. This allows subcloning of any adenovirus genome and the introduction of 
arbitrary genetic manipulations (Hausl et al., unpublished). Within the next few years a whole 
library of different rAdV could be available based on the complete biological reservoir of 
human adenoviruses. Thus, it would be possible to use vectors due to the specific demand 
of the specific therapeutic approach, for instance the serotype 7 we mentioned before, was 
shown recently to be advantageous for treatment of cancer cells (Wang et al., 2010).  
The treatment of monogenetic diseases and persistent chronic infections such as HBV 
requires a lifelong expression of the therapeutic DNA from the introduced vector. However, 
our group showed that HC-AdVs mainly persist as episomal linear double-stranded DNA 
molecules in the nucleus (Jager and Ehrhardt 2009) and thus, transgene expression 
diminishes over time in rapidly dividing tissues or upon induction of cell cycling due to 
natural degradation processes (Rauschhuber et al., 2011). Consequently, in order to 
achieve long-term transgene expression, hybrid vector systems have been explored, which 
were designed to combine the high transduction efficiency of adenoviral vectors with 
integration systems that mediate the integration of the transgene into the chromosomal 
DNA. The most prominent non-viral integration system used in gene therapy is represented 
by the Sleeping Beauty (SB) transposase system, a DNA transposon from the Tc1/mariner 
group (Ivics et al., 1997).  
DNA transposons and other mobile genetic elements, such as retrotransposons are ancient 
remainings, which are estimated to account for around 40% of DNA sequences in the 
human genome (Lander et al., 2001). The long interspersed element-1 (LINE-1) for example 
is a highly aboundant retrotransposon, which covers approximately 18% of the human 
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genome. Although most of the LINE-1s are inactive with respect to retrotransposition, 80-
100 full length, replication-competent LINE-1s exist and their activation can be associated 
with several diseases including cancer (Kazazian et al., 1988; Schwahn et al., 1998; Brouha 
et al., 2002; Cordaux and Batzer 2009). Since LINE-1s and DNA transposons encode for 
their own transposase protein, functional mobile elements are dependent on transcription 
from internal promoters to drive retro-transposition or transposition, respectively (Ostertag 
and Kazazian 2001). The transcription derived from two convergent promoters, however, 
can lead to formation of dsRNAs, which could present substrates for the RNAi machinery 
and subsequently target and inhibit protein expression required for transposition. Previously, 
this silencing mechanism was confirmed for the LINE-1 retrotransposons in human cells 
(Soifer et al., 2005) and for the Tc1 element, another member of the Tc1/mariner group in 
the germ line of Caenorhabditis elegans (Sijen and Plasterk 2003). Notably, in the case of 
the Tc1 element dsRNAs derive from random external read-through from flanking genomic 
sequences as no transcriptional activity from the Tc1 inverted repeats were detected (Sijen 
and Plasterk 2003). In the present work we confirmed the influence of the RNAi pathway on 
SB transposition and in particular on transgene expression (chapter 4). DsRNAs derived 
from convergent transcription of the SB inverted repeats are thereby the effectors within the 
RNAi pathway (Moldt et al., 2007). Importantly, in contrast to the original DNA transposon, in 
which the transposase was embedded between the IRs in one DNA fragment, the current 
SB system consists of two components (Figure 1.8). In this two vector system the transgene 
cassette is flanked by the IRs, whereas the transposase is expressed from an independent 
vector. Thus, RNAi mediates silencing of the transgene and transposition itself remains 
unaltered.  
Therefore, our finding strengthens the hypothesis that the RNA interference system is an 
evolutionary important mechanism that evolved to prevent the mobilization of transposable 
elements and consequently the damage of the chromosomal DNA (Gilbert et al., 2002; 
Symer et al., 2002). However, the Frog Prince transposable element, which belongs to the 
same group of transposable elements, did not show any inward transcriptional activity and 
therefore also no influence of the RNAi pathway could be detected (Figure 4.4B and C) 
(Moldt et al., 2007; Walisko et al., 2008). It is believed that during the reconstitution of the 
transposable elements, defects in the flanking sequences occurred, which now make the 
Frog Prince system less accessible to the RNAi mechanism (Moldt et al., 2007). 
The identification of transgene specific dsRNAs, derived from the transposon donor, 
mediating the silencing process may ultimately clarify the contribution of the RNAi pathway 
to transposition. However, this could be a difficult task, as transcriptional activties are quite 
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low in comparison to viral derived promoters (Moldt et al., 2007). Furthermore it remains to 
be elucidated, how RNAi-mediated gene silencing upon transposition occurs. There are 
three possible mechanisms concievable. The DsRNAs generated by inward transcriptional 
activity could either result into degradation or translational inhibition of the complementary 
mRNA or gene expression may be inhibited on a transcriptional level by cystein methylation 
(Kawasaki and Taira 2004a). Methylation of cystein residues initiated by the RNAi pathway 
was already demonstrated to occur in mammalian cells by Kawasaki and Taira (Kawasaki 
and Taira 2004a). Notably, the transcriptional silencing mediated by methylation is also 
supported by a study of Garrison et al., in which the administration of a methyltransferase 
inhibitor could revert gene silencing upon SB transposition (Garrison et al., 2007).  
Moreover, we also identified an influence of the RNAi pathway on PhiC31 integrase (Figure 
4.3C and D), but at the time the mechanism remains to be elucidated. Potentially, this 
phenomenon is a position dependent effect arising from the transgene promoter and a 
convergent promoter in the chromosomal DNA after somatic integration. Anyhow, PhiC31 is 
interesting as it mediates a unidirectional site-directed integration and there are already 
studies, in which targeted insertion of the transgene is performed by PhiC31-zinc-finger 
fusion proteins (Groth et al., 2000) (Nadja Noske, unpublished results). Nevertheless, in 
contrast to the Sleeping Beauty system, for which already 100-fold improved versions 
(Mates et al., 2009) are available the activity of PhiC31 could be increased up to 5-fold 
(Liesner et al., 2010).  
In conclusion, transposable systems and potentially the PhiC31 integrase system seem to 
have an effective counter defense mechanism in mammalian cells. These mechanisms need 
to be carefully characterized for proper function and further improvements.  
The database of “Clinical Trials World Wide” outlined the great potential of recombinant 
adenoviral vectors for a large variety of indications (Figure 1.5) (Wiley 2010). Herein, the 
majority of clinical trials face the treatment of cancer diseases. Thereby, the replication-
competent adenoviral vectors seem to be superior to the replication defective ones as they 
showed an improved tumor penetration and regression (Hemminki and Alvarez 2002; 
Lichtenstein and Wold 2004). Replication-competent or oncolytic adenoviruses are based on  
deletions in either the E1A or E1B gene, in order to restrict virus replication specifically to 
tumor cells, which mostly lack the retinoblastoma protein or p53 mediated cell cycle control 
(Bischoff et al., 1996; Fueyo et al., 2000). Normal tissues, however, can inhibit virus 
replication due to an intact cell cycle control. But still the low replication rate of most 
oncolytic adenoviruses and the specific targeting of the aberrant tissues are major 
limitations. Within the present study (see also chapter 5) we demonstrated that an E3-
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deleted adenovirus expressing the RNAi suppressor protein P19 under the control of the 
major late promoter (MLP), replicates 100-fold faster and produces 10-fold more infectious 
particles compared to the oncolytic adenovirus AdΔfiberIL virus in HEK293 cells (Figure 5.4) 
(Fueyo et al., 2000). AdΔfiberIL has a 24 bp deletion in the E1A gene and usually shows a 
growth advantage in immortalized cell lines (Nettelbeck et al., 2002; Gomez-Manzano et al., 
2004). Thus, the introduction of the P19 protein into an oncolytic adenovirus background 
may provide a faster replicating virus, which in turn may initiate a more efficient virus spread 
and tumor penetration. This subsequently can result into a faster tumor regression. 
Moreover, we demonstrated increased amounts of the viral E4Orf6 protein in Bwtp19ΔE3 
infected cells in comparison to AdΔfiberIL (Figure 5.5B). Sufficient expression of E4Orf6 in 
combination with radiotherapy was shown very recently to improve the treatment of cancer 
cells significantly (Liikanen et al., 2010). In addition, there were already efforts to improve 
oncolytic viruses by arming them with anti-tumoral genes. For instance the antiangiogenic 
vascular endothelial growth factor (VEGF) receptor can contribute to the inhibition of tumor 
growth (Zhang et al., 2005; Guse et al., 2009). Furthermore, it was already demonstrated, 
that in the human B cell lymphoma, oncogenic miRNAs are overexpressed (Cullen 2010). 
Thus, arming oncolytic Ads with p19 may increase virus replication with additive effects on 
the downregulation of oncogenic miRNAs.  
As mentioned above, there are E1B-deleted adenoviruses, like the well-established oncolytic 
virus Onyx-015 already used in many phase I and II clinical trials (Bischoff et al., 1996; 
Heise et al., 2000; Ries and Brandts 2004; Pesonen et al., 2010). Thus, it would be 
interesting to analyse whether P19 can improve the productive virus replication of Onyx-015. 
This is of special interest, because the lack of the E1B55K protein impaired virus replication 
significantly due to the defective late virus mRNA transport (Pesonen et al., 2010). Thus, 
P19 may provide a more stable environment for adenoviral mRNAs and therefore force virus 
replication. Moreover, it has to be elucidated if an adenovirus expressing P19 under an early 
promoter might further increase the virus particel production because of expected higher 
P19 amounts at early time points after infection. 
Regarding the treatment of cancer it is also worth considering to introduce a p19 expression 
cassette into an oncolytic adenovirus based on a serotype other than Ad5. Ad5 uses the 
CAR receptor for cellular entry, however on many malignant cell lines CAR is 
underrepresented and therefore resistant to Ad5 treatment (Hemmi et al., 1998; Miller et al., 
1998; Cripe et al., 2001; Breidenbach et al., 2004; Rein et al., 2004). Thus, it was 
demonstrated that chimeric viruses harbouring either fiber or hexon of the human 
adenovirus serotype 3 (Ad3), a member of subgroup B1, is superior when targeting cancer 
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cells (Krasnykh et al., 1996; Short et al., 2010). As mentioned before, most subgroup B 
adenoviruses use the CD46 receptor for cellular entry, a receptor that is present on many 
tumor cells (Krasnykh et al., 1996). In addition, very recently the Desmoglein 2 receptor was 
identified to play a crucial role in internalization of Ad3 (Wang et al., 2010). Desmoglein 2 is 
an epithelia tumor marker and would therefore be beneficial for the treatment of epithelia 
associated cancers. Ad3 displays only 30% serum prevalence in the human population and 
is not recognized by blood coagulation factor X, which diminishes the sequesteration of viral 
particles in the liver (Waddington et al., 2008). Thus, considering the instability of capsid 
modified adenoviruses and the inefficient generation of theses viruses, a complete serotype 
switch to the Ad3 would be preferable for the treatment of different cancer variants.  
It was already shown in the past by Lecellier and colleagues that virus replication such as 
the primate foamy virus can be enhanced in the presence of the RNAi suppressor protein 
P19 in a stable cell line (Lecellier et al., 2005). Using the bacterial artificial chromosome 
(BAC) cloning procedure we therefore generated a functional P19 expressing helper virus 
and showed 6-fold increased HC-AdV production in comparison to the standard helper virus 
from Philip Ng (AdNG163R-2) in a small-scale experiment (Figure 5.9) (Ng et al., 2001). 
This clearly indicated that the findings of this study can be used to improve virus production. 
All RNA interference experiments within the present study were based on the RNAi 
suppressor protein P19, however, there are also other considerable systems available. 
Since the complete deletion of Dicer, the cytoplasmic endonuclease generating the miRNAs, 
is lethal in mouse embryogenesis, only Dicer knockdown cells (Dicer-/-) are available 
(Kanellopoulou et al., 2005). However, most of these Dicer-/- cells are based on siRNA-
mediated knockdown of the Dicer protein. Although this system is highly efficient and can be 
used to analyze miRNA expression profiles, we could not adjust this system to our long-term 
experiments in the colony forming assay or the infection with adenovirus. For instance 
colony forming assays last for 2 weeks and would exceed the activity span of the introduced 
siRNA, which is approximately maintained for one week within a cell (Bartlett and Davis 
2006). In addition, Cummins et al. generated Dicer-/- cell lines by AAV mediated insertions 
into the Dicer gene, thereby disrupting the helicase function of Dicer (Cummins et al., 2006). 
But within their study they still observed around 50% of normal miRNA expression levels, 
thus it is hypothesized that other mechanisms evolve upon Dicer knockdown, which 
compensate the defect.  
Besides P19, there are several other RNAi suppressor proteins available targeting different 
steps of the RNAi pathway. The vaccinia virus-derived protein E3L or the Ebola virus VP35 
protein are both RNA binding proteins with a known interferon antagonistic function (Li et al., 
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2004; Haasnoot et al., 2007). Therefore, they influence the innate immune response, which 
is potentially mediated by the miRNA arm of the RNAi pathway (Pedersen et al., 2007). 
Previously, it was shown that both viral proteins (E3L and VP35) expressed in a stable cell 
line increased lentiviral titers (de Vries et al., 2008). In addition, there is evidence that RNA 
viruses and their virus-derived RNA intermediates, which occur during viral replication, may 
be recognized by helicases or intracellular receptors and activate the immune response 
(Baum and Garcia-Sastre 2010). Thus, it was concluded that both RNAi suppressor proteins 
are sufficient to increase lentivirus replication by disabling the immune response (de Vries et 
al., 2008). Since we were predominantly interested in the influence of the classical RNAi 
pathway in particular the influence of miRNAs on transgene expression and adenovirus 
performance, we have chosen the tomato bushy stunt virus P19 protein (Scholthof 2006). 
P19, as a miRNA inhibitory protein was already used to improve replication of the primate 
foamy virus (Lecellier et al., 2005). However, a crucial factor within the experiments was the 
amount of the RNAi suppressor protein (Qiu et al., 2002; Szittya et al., 2002). Thus, with 
respect to P19 it is recommended to use highly efficient expression systems like strong viral 
promoters or in our case the expression of the protein in the viral context under the major 
late promoter linking p19 expression to virus replication. Anyhow, it strongly depends on the 
experimental set up, which RNAi inhibitory system is most suitable. As shown by de Vries et 
al., the use of interferon antagonists may be very potent in terms of up-regulation of viral 
particle production, thus, it would be of great interest to introduce the VP35 protein into the 
adenoviral genome to further increase its replication (de Vries et al., 2008).  
Last but not least it is important to emphasize that the P19 system presented within this 
study can be also used to analyze the influence of the RNAi pathway on other viruses, like 
herpesviruses, for which most miRNAs have been identified so far (Skalsky and Cullen 
2010). It could also help to identify to date unknown contributions of the RNAi pathway to 
viral life cycles, including many RNA viruses for which an interaction with the RNAi pathway 
was already demonstrated (Lecellier et al., 2005; Cullen 2010). In general, the P19 system is 
suitable to investigate different cellular processes under RNAi knockdown conditions in vitro 
and, for instance by introducing the p19 expression cassette into an HC-AdV, also in vivo 
analyses are imaginable. 
In conclusion, this work outlined the great perspectives of recombinant adenoviral vectors in 
gene therapy. Since the death of Jessie Gelsinger, adenoviral vectors were considered with 
scepticism; however, modifications and improvements of these vehicles during the past 
decade make them an attractive tool for different applications with a broad diversification 
potential. This trend is also reflected by newest publications, in which novel adenoviral 
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receptors were identified and the crystall structure of adenovirus solved at high resolution 
(Nilsson et al., 2010; Reddy et al., 2010; Wang et al., 2010). In concert with upcoming 
advanced cloning strategies, adenoviral vectors will gain increasing attractivity for gene 
therapeutic applications. The results from this thesis add to the great potential of these 
viruses and provide novel insights into the complex interaction between adenovirus and the 
host cell.  
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7 Appendix 
7.1 Abbrevations 
°C degree celsius 
Amp ampicillin 
ATTC American Tissue Culture Company 
bp basepair 
cDNA complementary DNA 
CIP calf intestinal phosphatase 
CRE Cre-recombinase 
CsCl cesium chloride 
DGCR-8 DiGeorge critical region 8 
DNA desoxy ribonucleic acid  
EDTA Ethylene diamine tetra acedic acid 
Fg first generation 
FIX coagulation factor 9 
FITC Fluoresceinisothiocyanat 
FP Frog Prince 
FX coagulation factor 10 
GAPDH glycerinaldehyd3-phophat dehydrogenase 
GFP green fluorescent protein 
HA hemaglutinin 
hAAT human alpha-1-antitrypsin 
HBV hepatitis B virus 
HC-AdV high-capacity adenoviral vector 
HCl hydrogenchloride 
HCR hepatic control region 
HEK human embryonal kidney 
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His histidin 
Hox homeobox 
hrs hours 
IR inverted repeat 
ITR inverted terminal repeat 
LTR long terminal repeat 
Luc firefly luciferase 
MCS  multiple cloning site 
miRNA micro RNA 
mg milligram 
ml milliliter 
MLP major late promoter 
mg microgram 
ml microliter 
moi multiplicity of infection 
mRNA messenger RNA 
Neo neomycin 
ng nanogram 
nM nanomolar 
nt nucleotide 
OD optical density 
OPU optical particle units 
ORF open reading frame 
PCR polymerase chain reaction 
PBS phosphate buffered saline 
PGK phophoglycerinkinase promoter 
polyA polyadenylation signal 
pRB retino blastoma tumor suppressor protein 
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P/S penicillin/streptomycin 
qRT-PCR quantitative Real-Time PCR 
RISC RNA induced silencing complex 
RL renilla luciferase 
RNA ribonucleicacid 
RNAi RNA interference 
rpm rounds per minute 
RT reverse transcription 
SB    Sleeping Beauty 
SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
SSC side scatter 
SV40 simian virus 40 
sva-RNA  small virus-associated RNA 
TA tyrosin and adenosin dinucleotide 
TAE tris-acetat-EDTA buffer 
TBE tris-borat-EDTA buffer 
TESS transcriptional element search system 
Tris tris-hydroymethyl ammonium methane 
TSS transcriptional start sites 
TU transducing units 
VA-RNA virus-associated RNA 
wtAd5 wildtype adenovirus serotype 5 
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inverted terminal repeats of various human adenovirus serotypes. Journal of General 
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and Anja Ehrhardt (2011). Development of adenoviral hybrid vectors for Sleeping Beauty 
transposition in large mammals. Review. Current Gene Therapy. (submitted).  
Christina Rauschhuber and Anja Ehrhardt. Sleeping Beauty mediated transposition in 
human cells is enhanced in RNA interference knockdown cells (Manuscript ready for 
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Christina Rauschhuber, Martin Hausl, Matthew Weitzman, Dirk Nettelbeck and Anja 
Ehrhardt. Adenovirus Serotype 5 replication is enhanced in the presence of the RNA 
interference suppressor protein P19. (Manuscript in preparation). 
 
7.2.2 Oral presentations 
Christina Rauschhuber and Anja Ehrhardt (2008). Adenovirus uptake and replication are 
enhanced in micro RNA knock-out cells. SFB 455 Junior Faculty Meeting.  
Christina Rauschhuber and Anja Ehrhardt (2009). The micro RNA Machinery plays a 
prominent role in Adenovirus replication. American Society of Gene Therapy Meeting, San 
Diego. 
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